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ABSTRACT 
Structural and Functional Studies of TRPML1 and TRPP2 
Nicole Marie Benvin 
       
      In recent years, the determination of several high-resolution structures of transient receptor 
potential (TRP) channels has led to significant progress within this field. The primary focus of 
this dissertation is to elucidate the structural characterization of TRPML1 and TRPP2. 
      Mutations in TRPML1 cause mucolipidosis type IV (MLIV), a rare neurodegenerative 
lysosomal storage disorder. We determined the first high-resolution crystal structures of the 
human TRPML1 I-II linker domain using X-ray crystallography at pH 4.5, pH 6.0, and pH 7.5. 
These structures revealed a tetramer with a highly electronegative central pore which plays a role 
in the dual Ca2+/pH regulation of TRPML1. Notably, these physiologically relevant structures of 
the I-II linker domain harbor three MLIV-causing mutations. Our findings suggest that these 
pathogenic mutations destabilize not only the tetrameric structure of the I-II linker, but also the 
overall architecture of full-length TRPML1. In addition, TRPML1 proteins containing MLIV-
causing mutations mislocalized in the cell when imaged by confocal fluorescence microscopy.  
      Mutations in TRPP2 cause autosomal dominant polycystic kidney disease (ADPKD). Since 
novel technological advances in single-particle cryo-electron microscopy have now enabled the 
determination of high-resolution membrane protein structures, we set out to solve the structure of 
TRPP2 using this technique. Our investigations offer valuable insight into the optimization of 
TRPP2 protein purification and sample preparation procedures necessary for structural analysis.  
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Introduction to TRPML1 and TRPP2 
 
1.1 Transient receptor potential (TRP) channel family 
      Transient receptor potential (TRP) channels are a multifunctional superfamily of cation 
channels which consists of seven subfamilies: TRPC, TRPM, TRPA, TRPN, TRPV, TRPML, and 
TRPP (Figure 1) (1, 2). These subfamilies are categorized on the basis of their amino acid sequence 
homology and function (1, 3, 4). Interestingly, TRPN channels are not present within mammalian 









Figure 1. TRP channel subfamilies. Schematic diagram of TRP channel subfamilies illustrating 
the transmembrane topology. Domains or motifs at the N- and C-termini of the channels are 
depicted. Figure adapted from (6).      
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      TRP channels are readily influenced by their environments, and thus play an essential role in 
cellular sensory perception (1). Notably, they are able to be activated by varying signals such as 
temperature, mechanical stimuli, and ligands (2, 5). TRP channels differ largely in their 
physiological functions and mechanism of actions, and are regulated by diverse intracellular 
signals, including calcium, lipid metabolites, and phosphoinositides (4). 
      TRP channels are cation channels that each contain six-transmembrane polypeptide subunits 
(S1-S6)  and assemble as tetramers (Figure 2) (1, 5). Additionally, a pore-forming loop is present 
between S5 and S6. The N- and C-termini of TRP channels reside intracellularly and differ 
substantially between subfamilies with regard to their amino acid sequences, lengths, respective 
motifs, and domains (Figure 1) (1, 5). Moreover, the seven TRP subfamilies have been further 
divided into two subgroups based on their differences in topology and amino acid sequences (5). 
Group 1 TRP channels include TRPC, TRPV, TRPA, TRPM, and TRPN, while group 2 
encompasses the TRPML and TRPP subfamilies (5). 
      The aim of this thesis is to illustrate our structural studies pertaining to TRPML1 and TRPP2, 
founding members of the mucolipin and polycystin TRP subfamilies (1, 5), respectively. As part 
of the group 2 subfamily, both TRPML1 and TRPP2 exhibit a prominent linker between their first 
two transmembrane segments (S1-S2) (5). The structural significance of this domain in these two 
proteins will be further described in Chapters II and IV. In addition, the functional characterization 










Figure 2. Schematic representation of a TRP channel. (A) Illustration of a transient receptor 
potential protein present in the plasma membrane. The six transmembrane domains are indicated 
(S1-S6) and the pore loop (P) is situated between S5 and S6. (B) Tetrameric assembly of TRP 
channels consisting of four monomers (large circles). Of note, the pore loops of each monomer 
collectively form the central functional pore. Figure adapted from (7).     
 
1.2  Introduction to the TRPML1 protein 
      The human TRPML1 protein is 580 amino acids in length and has a molecular mass of 65 kDa 
(8). Like other TRP channels, TRPML1 is comprised of six transmembrane segments (S1-S6) and 
its N- and C-termini face the cytoplasm (4). As aforementioned, the I-II linker between the first 
two transmembrane segments forms a pronounced domain. Published results from our laboratory 
indicate that the TRPML1 I-II linker forms a tetrameric structure (9), which will be described in 








1.2.1  TRPML1 and its role in mucolipidosis type IV (MLIV) 
      Mutations in the gene MCOLN1 lead to mucolipidosis type IV (MLIV) (OMIM #252650), a 
rare autosomal recessive lysosomal storage disorder (10, 11). MCOLN1 encodes TRPML1 (or 
mucolipin-1), the founding member of the TRPML channel subfamily (10). Notably, greater than 
20 MLIV mutations have been identified in the TRPML1 gene (12, 13). The disease incidence of 
MLIV is approximately 1 in 40,000 individuals and 70-80% of patients diagnosed with MLIV are 
of Ashkenazi Jewish ancestry (8, 11, 13). Most commonly, MLIV becomes apparent during 
infancy, clinically characterized by symptoms including visual complications (corneal clouding, 
optic atrophy, and retinal degeneration), severe psychomotor impairments, and achlorydria (11, 
14, 15). After diagnosis, the patients remain stable and little disease progression occurs for two to 
three decades (13, 16). 
      Proper diagnosis of MLIV remains challenging due to its similarity in symptoms to other 
neurodegenerative diseases (13). As a result, patients with MLIV have been misdiagnosed as 
having spastic paraplegia and cerebral palsy, among other disorders (17). Additionally, patients 
with milder MLIV mutations can go undiagnosed, which raises the question of the overall rarity 
of this disease (13, 18).  
 
1.2.2.  Subcellular localization and channel regulation of TRPML1 
      Regulation of TRPML1 activity is dependent upon luminal and extracellular Ca2+ and H+ (12, 
19–21). TRPML1 primarily localizes to lysosomes, yet upon phagosomal biogenesis and 
lysosomal exocytosis it can be found in late endosomes and the plasma membrane, respectively 
(Figure 3) (21–24). Therefore, TRPML1 is exposed to a wide range of Ca2+ and pH levels, 
depending upon where it localizes in the cell. Notably, since TRPML1 is predominantly present 
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within lysosomes, it is exposed to an acidic environment of pH 4.5-5 with a Ca2+ concentration of 
0.5-0.6 mM (21, 25, 26). In late endosomes, it is in contact with surroundings of pH 5.0–6.0 and 
0.5 mM Ca2+, while at the plasma membrane TRPML1 exists in an environment containing a pH 
of 7.2–7.4 with Ca2+ levels of 1.8–2 mM (21, 25, 26). Hence, dual regulation of TRPML1 by Ca2+ 
and pH has been shown to vary. Of importance, the I-II linker in TRPML1 faces the lumen in 
lysosomes and the extracellular space when present on the plasma membrane. The regulatory 
mechanism involving the dual regulation of Ca2+ and pH of TRPML1 will be further elucidated in 





Figure 3. Subcellular localization of TRPML1. TRPML1 mainly localizes to late endosomes 
and lysosomes, yet can also be present at the plasma membrane upon lysosomal exocytosis. The 
lysosomal membrane trafficking pathway is illustrated.  
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    Furthermore, TRPML1 is also regulated by phosphoinositides in subcellular compartments (27, 
28). TRPML1 has been shown to be activated by (PI(3,5)P2) in the membranes of endosomes and 
lysosomes (27). Conversely, TRPML1 is inhibited by PI(4,5)P2 at the plasma membrane (28). 
Taken together, regulation by pH, Ca2+, and phosphoinositides ensures that TRPML1 activity is 
high within lysosomes and low at the plasma membrane.  
 
1.2.3  Trafficking of TRPML1  
      The loss of TRPML1 due to MLIV mutations leads to the buildup of undigested lipid 
components and additional biomaterial in enlarged late endosomal/lysosomal compartments, as 
seen in other lysosomal storage disorders (23, 29). However, the agglomeration of lipid products 
are more heterogeneous than in other storage disorders. These lipids include cholesterol, acidic 
mucopolysaccharides, sphingolipids, phospholipids, and gangliosides (30–32). 
      Although most lysosomal storage disorders exhibit abnormalities in lysosomal hydrolases 
associated with the processing of lipids (33), the hydrolase activity within cells of MLIV patients 
is reported to be fairly normal (34). Rather, abnormalities that are manifested may presumably be 
due to a defect in the sorting and trafficking within the late endocytic pathway (34). In particular, 
the departure of lipids from the late endosome and lysosome to the trans-Golgi network is 
abnormal in ML4 cells (34, 35). Hence, TRPML1 is presumed to play an essential role in the 
formation of transport vesicles that traffic materials between these subcellular compartments. 
Additionally, it has been reported that the expression of TRPML1 increases after the induction of 
lysosome biogenesis (36). Thus, TRPML1 may be associated with reconfiguring lysosomes 






1.2.4  The TRPML subfamily 
 
Structural similarities 
      The TRPML subfamily consists of three proteins, namely TRPML1-3, that exist in mammals 
(26) and exhibit 60% amino acid sequence homology to one another (16). Our research group 
determined the I-II linker structure of TRPML1 (9), which will be described further in Chapter II. 
Due to the high sequence homology among TRPML channels, TRPML2 and TRPML3 likely 
display similar I-II linker structures to that of TRPML1. Notably, TRPML1 is able to homo- or 
heteromultimerize with TRPML2 and TRPML3 (39).  
 
Expression pattern of TRPML1-3 in tissue  
 
      TRPML1 expression exists in every tissue in mammals, yet highest expression levels occur in 
the kidney, brain, liver, spleen, and heart (10). Contrarily, the expression of TRPML2 and 
TRPML3 is limited to several organs. TRPML2 is primarily expressed in the mouse liver, heart, 
thymus, spleen, and kidney (40). In addition, TRPML3 is present in the kidney, lung, thymus, eye, 
spleen (40, 41), epithelial cells in the cochlea (42), and hair cells (42, 43). Interestingly, TRPML1-
3 are all present within the kidney.  
 
1.2.5  Electrophysiological properties of TRPML channels 
      Overexpressed TRPML3 has been found to exist at the plasma membrane (44). Through the 
whole-cell patch clamp method, TRPML3 was identified as an inwardly rectifying Ca2+ permeable 
channel (41, 43, 45). However, since overexpressed TRPML1 and TRPML2 primarily localize to 
late endosomes and lysosomes (26), it has be challenging to characterize their electrophysiological 
properties. A gain-of-function mutation (A419P) in mouse TRPML3 renders the channel 
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constitutively active and causes the varitint-waddler (Va) phenotype, characterized by 
pigmentation and deafness in mice (43, 45–47).  
      Notably, the introduction of the analogous gain-of-function (GOF) V432P mutation in 
TRPML1 and A396P mutation in TRPML2 results in constitutively active channels at the plasma 
and endolysosomal membranes (43, 48, 49). In TRPML1, the V432P mutation is situated in the 
lower region of S5 by the channel gate, which presumably secures the channel in an open state 
(27, 43). Thus, the TRPML1 V432P (TRPML1VP) mutation heightened the ability of the channel 
to localize to the plasma membrane, compared to that of wild-type TRPML1. Hence, this GOF 
mutation has essentially enabled functional characterization of the TRPML1 and TRPML2 
channels through electrophysiological approaches (40, 43, 48, 49). Our findings pertaining to 


















1.3  Introduction to the TRPP2 protein and ADPKD 
      TRPP2 (also referred to as polycystin-2, PC2, or PKD2) is a 968 amino acid 110 kDa 
membrane protein encoded by the PKD2 gene, and is part of the TRP channel superfamily (5, 50). 
Like other TRP channels, it contains six transmembrane segments, intracellular N- and C-termini, 
and a pore-forming loop between S5 and S6 (Figure 4) (1, 5, 50). TRPP2 is considered to be a non-
selective calcium channel that regulates intracellular calcium levels (51–53). Of note, the C-
terminal EF-hand domain binds to calcium and may aid in calcium regulation (54). Additionally, 
a domain distal to the EF-hand is the coiled-coil domain, which plays a role in the assembly of 
complexes (55, 56). The structures of the EF-hand domain and the coiled-coil domain have been 
solved by NMR (54, 57, 58) and X-ray crystallography (59), respectively. As aforementioned, a I-
II linker exists between the first two transmembrane segments of TRPP2, which is likewise 
exhibited in TRPML1. The structural features of TRPP2 will be elucidated in detail in Chapter IV.  
    Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
monogenetic disorders in humans and is characterized by the bilateral development of fluid-filled 
cysts in the kidneys (60–62). Notably, mutations in TRPP2 cause approximately 15% of all 
ADPKD cases (50). Moreover, mutations in PKD1, a 4,302 amino acid integral membrane protein 
with eleven transmembrane segments (63, 64), cause 85% of the other ADPKD cases (Figure 4) 
(60–62). PKD1 also contains a TRP channel sequence homology domain in transmembrane 
segments 6-11 (Figure 4) (65). The N-terminal region of PKD1 spans ~3000 amino acids and 
includes several motifs and domains, while the C-terminus comprises ~ 220 amino acids (Figure 
4) (64). As indicated in Figure 4, it has been reported that TRPP2 and PKD1 form a complex 
through the association of their coiled-coil domains (61, 66). The PKD1/TRPP2 complex has been 
shown to be involved in various cellular processes such as mechanosensation, cell proliferation, 
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cell polarity, and apoptosis (61, 67–71). The role that this complex plays in mechanosensation will 














Figure 4. Schematic representation of the PKD1/TRPP2 complex. Structural motifs and 
domains in PKD1 and TRPP2 are indicated. Of note, PKD1 and TRPP2 interact through their 
coiled-coil domains. The ion permeation pathway of TRPP2 is shown between the 5th and 6th 
transmembrane segments. Figure adapted from (65). 
 
1.3.1  Clinical manifestations of ADPKD 
      ADPKD generally affects between 1:400 and 1:1000 individuals worldwide (72). In many 
cases, ADPKD can lead to the development of end-stage renal disease (ESRD) (73). The first 
noticeable signs of ADPKD include hypertension (74) and abdominal masses (72). Pain is 
reportedly the most common symptom among ADPKD patients, particularly in the abdominal 
regions and the lower back (75, 76). ADPKD is a late onset disorder and patients will generally 
experience symptoms within the third and fourth decade of life (72). Patients who have mutations 
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in TRPP2 exhibit a milder form of ADPKD by experiencing later onset of the disease and reach 
end stage renal failure more than ten years later than patients who have mutations in PKD1 (77). 
Hence, individuals that have mutations in PKD1 reportedly have a shorter life expectancy than 
those with mutations in TRPP2 (77). Moreover, effective treatments for ADPKD are yet to be 
determined. 
 
1.3.2  Pathogenesis of ADPKD 
      The “two hit” proposed mechanism in ADPKD is believed to initiate the development of cyst 
formation in patients (78). According to this hypothesis, both copies of a PKD gene (PKD1 or 
TRPP2) need to be inactivated in order for cyst formation to occur. Thus, the inherited germ line 
mutation signifies the “first hit” and an additional somatic mutation that arises denotes the “second 
hit” (78). Therefore, the ensuing homozygous inactivation of a PKD gene is purportedly essential 
for the pathogenicity of ADPKD, culminating in the expansion of cysts (79). Despite evidence 
supporting this “two-hit” hypothesis, it remains controversial. In theory, if indeed a somatic 
mutation triggers the development of cysts, then all cyst cells would harbor this mutation, yet it 
has been shown that this phenomena occurs in only a subset of isolated cysts (80). These findings 
indicate that factors other than somatic mutations have been implicated in cyst development. 
Alternatively, it has been proposed that haploinsufficiency necessitates the formation of cysts, in 
which mutations in one allele may lead to cyst generation through a genedosage-dependent 
mechanism (81). Purportedly, if the expression level of PKD1 or TRPP2 is below a critical 
threshold in tissues, resulting from genetic, environmental, and stochastic factors, it could incline 




1.3.3  Cellular and subcellular localization of TRPP2 
      TRPP2 is primarily expressed in the kidney, yet expression levels have been found in other 
tissues including the heart, intestine, pancreas, bile ducts, ovary, testis, vascular smooth muscle, 
and placenta (50, 82, 83). Within the kidney, TRPP2 has been shown to exist in all regions of the 
nephron, except the glomeruli (72, 73). The intracellular localization of TRPP2 is a complex 
system that is highly regulated and is dependent on cell type (84). TRPP2 primarily localizes to 
various subcellular compartments including the endoplasmic reticulum (ER), the plasma 
membrane, and the primary cilium of renal epithelial cells (51, 85–87). In cells undergoing cell 
division, TRPP2 localizes to centrosomes and mitotic spindle poles where it is believed to regulate 
intracellular Ca2+ during or after mitosis (88, 89). Notably, several sequence motifs and binding 
domains within TRPP2 aid in the regulation of its trafficking between compartments (90, 91). 
 
ER localization   
      Studies have indicated that native and heterologously overexpressed TRPP2 localizes to the 
ER membrane of tissues (51) and cultured cells (55, 86, 92). TRPP2 aids in the regulation of Ca2+ 
release and Ca2+ homeostasis in the ER (51, 71, 93). For instance, TRPP2 functions as a Ca2+ 
release channel in conjunction with IP3 receptors (93–95). Additionally, it has been proposed that 
TRPP2 is involved  in apoptosis and Ca2+ storage (71). TRPP2 contains an endoplasmic reticulum 
(ER) retention motif (Glu787–Ser820) whereby phosphorylation at Ser812 by casein kinase 2 
(CK2) occurs (90). Upon CK2 phosphorylation, phosphofurin acidic cluster sorting protein 1 and 
2 (PACS-1 and PACS-2) subsequently associate with TRPP2, which is fundamental for the 




Plasma membrane localization    
      Although it is generally accepted that TRPP2 localizes to the ER and primary cilia, the 
localization of TRPP2 to the plasma membrane has been an area of controversy (97). It has been 
shown that native TRPP2 exists on the plasma membrane, but not when TRPP2 is heterologously 
overexpressed (52, 98). Studies reveal that the formation of the PKD1/TRPP2 complex is 
necessary for the targeting and retention of TRPP2 to the plasma membrane (55). Thereupon, this 
complex gives rise to calcium permeable non-selective cation currents (55).  
 
Primary cilia localization 
      Studies have shown that TRPP2 localizes to the primary cilia of kidney tissues as well as 
cultured epithelial cells (87, 99). A fifteen amino acid conserved RVxP motif at the N-terminus of 
TRPP2 is necessary for proper trafficking to the primary cilia (91). Interestingly, although TRPP2 
is dependent on PKD1 to traffic to the plasma membrane, TRPP2 has been shown to independently 
traffic to the cilia without the presence of PKD1 (91).  
 
1.3.4  Mechanotransduction model of the PKD1/TRPP2 complex  
      PKD1 and TRPP2 have been shown to form a protein complex in primary cilia of renal 
epithelial cells, where they act as mechanosensors in the renal tubule (100). It has been reported 
that luminal fluid flow prompts the bending of cilium, whereby the PKD1/TRPP2 complex detects 
this movement and generates an influx of Ca2+ (100). Thus, this response activates a signaling 
cascade, leading to increased intracellular Ca2+ levels (51) by Ca2+-induced Ca2+ release. This latter 
phenomena may occur from activation of TRPP2 in the ER (51) as well as by IP3 and ryanodine 
receptors (100). Additionally, TRPP2 may play a role in mechanotransduction due to its 
interactions with several cytoskeletal components including α-actinin, troponin I, and 
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tropomyosin-1 (101–103). Taken together, the PKD1/TRPP2 complex appears to regulate renal 
tubular morphology and function (55, 104). 
 
1.3.5  TRPP2 and its role in ADPKD 
      Aberrant calcium signaling presumably contributes to the pathogenesis of ADPKD by 
influencing significant signaling pathways. The loss of PKD1 or TRPP2 due to pathogenic 
mutations results in lower cytosolic calcium levels in cystic cells compared to normal cells (61, 
105). This attenuation of cytosolic calcium in part leads to increased levels of cAMP and mitogen-
activated protein kinase (MAPK), prompting the proliferation of cystic cells (104). Of note, in 
normal renal epithelial cells, cAMP stimulates anti-proliferative pathways (61). Vasopressin 
receptor V2 (VRV2) activation induces the release of cAMP within collecting ducts of the kidney 
(51), and a VRV2 antagonist tolvaptan has appeared to be beneficial in a number of patients with 
ADPKD, within a clinical trial (106).  
 
1.3.6  Stoichiometric assembly of the PKD1/TRPP2 complex 
      Several findings are not consistent with regard to the assembly of homomeric and heteromeric 
TRPP2. When TRPP2 was integrated into lipid bilayers, homomeric TRPP2 channels were 
reported to be tetramers (107). In agreement with these findings, several near full-length and full-
length structures of TRPP2 have been solved, which reveal that the channel assembles into 
tetramers (108–110). These TRPP2 structures will be characterized in Chapter IV. Additionally, 
dimerization motifs have been found at the N-terminus of TRPP2 (aa 199–207) in addition to a 
Cys632 within the third extracellular loop (104, 111, 112). These dimerization motifs are 
presumably involved in the tetramerization of the channel (104, 111, 112). 
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      However, previous studies conducted in our lab by a former member, Dr. Yong Yu, revealed 
several interesting findings regarding TRPP2 assembly. Firstly, upon being heterologously 
expressed in HEK293 cells and Xenopus oocytes, TRPP2 appeared to have formed homomeric 
trimers (59). Secondly, the crystal structure of the coiled-coil domain (aa839–873) within the C-
terminus of TRPP2 also formed a trimer. Thirdly, based on photobleaching experiments, it was 
proposed that trimeric TRPP2 and the PKD1 protein form a complex with 3:1 stoichiometry 
through their coiled-coil domains (59). Taken together, as seen in the structural studies involving 
full-length TRPP2, a homomeric tetramer exists when concentrated at high levels during protein 
purification (108–110). However, at lower concentrations, TRPP2 supposedly forms trimers (59). 
Therefore, how TRPP2 and PKD1 stoichiometrically form a complex at the structural level 
remains to be elucidated. The determination of the structure of the PKD1/TRPP2 complex will 
reveal important insights into biochemical interactions within this complex.    
 
1.3.7  TRPP2 agonist triptolide    
      The identification of chemically and naturally derived agonists that interact with TRPP2 has 
been lacking. However, triptolide, a diterpenoid epoxide, has been shown to presumably bind to 
TRPP2 and activate the opening of the channel (113). This finding resulted from a cell 
fractionation study in which TRPP2 appeared to be a [3H] triptolide-binding protein (113). 
Triptolide is a natural product derived from Tripterygium wilfordii (Thunder God Vine), which 
has been utilized in traditional Chinese medicine (114). Leuenroth et al. reported that triptolide 
can initiate the release of Ca2+ by a mechanism that is dependent upon TRPP2 (113). Additionally, 
it has been shown that triptolide can inhibit cell proliferation and decrease cyst formation in   
PKD1-/- embryonic mice (115). However, Leuenroth et al. mentioned that the agonistic effect on 
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TRPP2 by triptolide may be indirect (115). Moreover, a recent study reported that current 
activation by triptolide was not seen when TRPP2 was expressed in CHO or HEK293T cells (108). 
Therefore, how triptolide interacts with TRPP2 remains controversial in the field. 
 
1.3.8  Interaction between TRPP2 and additional channels  
      Several other channels, primarily in the TRP superfamily, have been identified to form 
heteromeric complexes with TRPP2, including TRPV4 (116), TRPC1 (107, 117), and TRPC4 
(104, 118). TRPP2 has been reported to associate with TRPC1 and TRPC4 in mesangial cells, 
giving rise to complexes that influence angiotensin II (118). Additionally, TRPP2 associates with 
TRPC1 at the primary cilia which can be activated by G-protein-coupled receptors (117). 
Furthermore, it has been shown that TRPP2 and TRPV4 form a functional channel within primary 
cilia (116). TRPP2 also forms a complex with the cardiac ryanodine receptor (RyR2), whereby 
TRPP2 can lead to the inhibition of RyR2 activity (119).   
 
 
1.3.9  Ion selectivity in TRPP2  
      Over the years, inconsistent findings regarding the biophysical properties of TRPP2 currents 
have been reported. As previously mentioned, overexpressed TRPP2 is retained in the ER (86). 
Therefore, functional characterization of TRPP2 at the plasma membrane has been challenging 
since channel activity cannot be readily measured (86). However, upon removal of the ER retention 
motif, TRPP2 is able to be studied at the plasma membrane (55, 86, 120). Additionally, it has been 
found that the purported F604P gain-of-function mutation in TRPP2 leads to the constitutive 
opening of the channel when heterologously expressed in Xenopus oocytes, producing an 
observable current (121). However, currents were not able to be reproduced in another study using 
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the transfected F604P construct in HEK293T and CHO cells (108). Therefore, TRPP2 containing 
the F604P mutation may display different trafficking patterns to the plasma membrane depending 
on the expression system utilized.  
      There is general agreement that TRPP2 is considered to be a Ca2+-permeable non-selective 
cation channel (51–53, 55). However, several findings are not consistent with regard to the specific 
selectivity properties of Ca2+ in TRPP2. Of note, the differences observed in channel properties of 
TRPP2 may be due in part to the number of biophysical systems utilized (51–53, 55, 73). It has 
been reported that TRPP2 has a slightly higher selectivity of Ca2+ compared to K+ and Na+ (120, 
122), whereas other studies suggested that TRPP2 has limited selectivity for Ca2+ (51, 53). In 
accordance with the latter findings, a recent study demonstrated that a TRPP2-TRPP3 chimera is 
more selective for K+ and Na+ than Ca2+, compared to native TRPP3 (108). Additionally, although 
most studies indicate that TRPP2 conducts Ca2+ (55), it has also been demonstrated to be blocked 
by Ca2+(90). Evidently, many discrepancies exist with regard to the channel activity of TRPP2.  
       
1.3.10  Additional members of the TRPP subfamily 
TRPP3 
      TRPP3, also regarded as PKD2L1, is a homologue of TRPP2 which is composed of 805 amino 
acids. TRPP3 contains residues that share 50% sequence identity to TRPP2 (123). These 
homologous regions are apparent in the six transmembrane segments and the I-II linker domain 
that is present between S1-S2 (123). Like TRPP2, TRPP3 harbors a putative Ca2+ binding EF-hand 
domain followed by a coiled-coil domain at its C-terminus (124). TRPP3 is primarily expressed in 
the kidney, testis, non-myocyte cardiac tissue, and neurons (70, 124–126). Since TRPP3 does not 
contain an ER retention motif at its C-terminus (96, 127) it is thereby functionally expressed at the 
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plasma membrane in heterologous systems, including Xenopus oocytes (128). Therefore, TRPP3 
can be investigated through electrophysiological methods where it has been shown to form a 
constitutively active Ca2+-permeable non-selective cation channel (123, 128).  
 
TRPP5 
      Another TRPP2 homologue is TRPP5, also referred to as PKD2L2. TRPP5 contains 624 amino 
acids and exhibits 71% sequence similarity with TRPP2, lacking homology at the N- and C-termini 
(127). Similar to TRPP3, TRPP5 does not harbor an ER retention motif at its C-terminus (127). 
TRPP5 has been shown to be expressed in mouse testis, mouse heart, and the developing mouse 
oocyte (126, 129, 130). Therefore, TRPP5 may physiologically function as a non-selective cation 
channel associated with Ca2+ signaling in germ line cells (70). 
 
1.4  Structural determination of TRP channels 
      Expressing and crystallizing domains of membrane proteins, known as the divide and conquer 
method, is a technique that has been utilized extensively over the past ten years to obtain structural 
information of significant portions of membrane proteins (131). Several TRP channel domains 
were able to be solved using this method, including the EF-hand (54, 57, 58) and coiled-coil 
domains (59) of TRPP2. However, these structures provided only pieces of the overall TRP 
channel puzzles, and further functional information was needed in order to discern how these 
structures fit into the overall context of the full-length channels. Yet, the ultimate goal in the field 
was to determine the structures of full-length TRP channels at atomic resolution. 
      Notably, over the past few years great advancements were made in the field of single-particle 
cryo-electron microscopy (cryo-EM), primarily by the development of new direct electron 
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detectors and software algorithms (132, 133). These technological improvements prompted the 
‘resolution revolution,’ which enabled the determination of membrane protein structures at near-
atomic resolution (133). Remarkably, for the first time small ion channels could be solved at high-
resolution using the cryo-EM technique, pioneered by the determination of the TRPV1 structure 
in 2013 (134, 135). Consequently, this groundbreaking study sent ripples not only throughout the 
TRP channel space, but throughout the entire field of structural biology. Of note, before the 
‘resolution revolution’ X-ray crystallography was the primary method to solve protein structures 
at high-resolution. However, many crystallographers began to shift gears and transition to using 
the cryo-EM technique as well. Intriguingly, the number of cryo-EM publications have 
dramatically increased and led to the determination of several other high-resolution TRP channel 















1.5  Conclusion and thesis overview  
      It has certainly been fascinating to witness the recent ‘resolution revolution’ occurring in the 
cryo-EM field during the duration of my PhD experience. It is amazing that within a few years the 
TRP channel structural field has made significant strides from determining isolated domains of 
TRP channels using X-ray crystallography and NMR to solving full-length structures of these 
channels, primarily by cryo-EM. I initially started off my PhD being trained in X-ray 
crystallography, only to see firsthand several years later that high-resolution membrane protein 
structures can be obtained with cryo-EM as well. Therefore, this thesis primarily serves to 
elucidate the structural investigations of TRPML1 and TRPP2 using both X-crystallography and 
cryo-EM methods. Functional studies of TRPML1 were performed to further support and 
characterize our findings.   
      My initial studies pertained to the structural determination of the TRPML1 I-II linker domain 
at two physiologically relevant pH conditions. During that time, the divide and conquer approach 
was being utilized extensively by many research groups to uncover structural information of TRP 
channels, and our rationale was to apply this method as well. Heretofore, structural knowledge of 
the TRPML1 channel has been lacking. Furthermore, the I-II linker structures provided a 
molecular basis from which to functionally assess the regulatory mechanisms of this domain. Of 
note, we demonstrated that these mechanisms involved the dual regulation of Ca2+ and pH of 
TRPML1. Additionally, these static structures along with functional investigations were able to 
provide insights into the dynamic pathogenic mechanisms of several MLIV-causing mutations. 
Therefore, a detailed description of our published results (9) pertaining to the TRPML1 I-II linker 
will be delineated in Chapter II. 
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      The second topic of investigation that I focused on was to determine a high-resolution cryo-
EM structure of TRPP2. This endeavor would provide a greater understanding of the TRPP 
subfamily, as well as insights into ADPKD. Since the first near-3.Å resolution cryo-EM structure 
of an ion channel was of a TRP channel, this major achievement significantly affected the nature 
of our research. Therefore, our mindset was shifted from utilizing X-ray crystallography to 
determine the structure of TRPP2, to using cryo-EM. Chapter III serves to elucidate the protein 
purification and sample preparation methods for TRPP2 structural analysis. In collaboration with 
the laboratory of Dr. Reza Khayat (City College of New York) and the laboratory of Dr. Xueming 
Li (Tsinghua University), we were able to test the purified TRPP2 protein samples by cryo-EM. 
We were mindful of the potential difficulties that would arise during this endeavor, as well as the 
competitive nature of the TRP channel structural biology field. Until recently, no structural 
information pertaining to full-length TRPP2 has been reported. However, several months ago, a 
number of groups published TRPP2 full-length or near full-length structures. A comprehensive 
analysis of methods utilized in these studies as well as my own will be described at length in 
Chapter III and the structural details of TRPP2 will be elucidated in Chapter IV.  
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Structural and Functional Studies of the TRPML1 I-II Linker 
 
2.1  Introduction 
      As described previously in Chapter I, TRPML1 contains a linker domain between its first two 
transmembrane segments, which we refer to as the I-II linker. TRPML1 has been extensively 
studied in our laboratory over the years. Dr. Minghui Li, a senior research associate in our 
laboratory initially conducted investigations of this channel and determined the first crystal 
structure of the human TRPML1 I-II linker at pH 6.0. Subsequently, I then set out to determine 
the crystal structures of this linker at two physiologically relevant pH conditions, pH 4.5 and pH 
7.5. The crystal structures of the TRPML1 I-II linker are the first high-resolution structures of a 
domain in the TRPML channel subfamily. Furthermore, I characterized several MLIV-causing 
mutations present in this domain by analyzing the subcellular localization patterns of mutant 
TRPML1 proteins using confocal fluorescence microscopy.  
      The TRPML1 I-II linker structures served as a foundation from which to investigate pH and 
divalent ion regulation of the channel. Dr. Wei Kevin Zhang, a former postdoctoral fellow in our 
lab, performed the majority of the electrophysiology experiments pertaining to this project. Taken 
together, our efforts culminated in a triple co-first author publication (see Appendix A) describing 
the studies in this chapter (1). Essentially, this chapter elucidates the structural and functional 
studies of the TRPML1 I-II linker, which provide insight into the Ca2+ and pH regulation of the 





2.2  Experimental procedures for structural studies 
2.2.1  Protein expression and purification of the TRPML1 I–II linker  
      A region of MCOLN1 encompassing the I–II linker (Gly84-Ser296) was obtained by PCR and 
sub-cloned into a modified pET26b(+) vector using BamHI/XhoI restriction sites. The construct 
utilized for structural studies was comprised of an N-terminal maltose-binding protein (MBP) tag 
followed by a thrombin-recognition site, the TRPML1 I–II linker, and a C-terminal hexahistidine 
tag (Figure 1A). This construct was transformed into Rosetta-gami 2 (DE3) cells to enable proper 
disulfide-bond formation within the I-II linker. The cells were cultured in LB medium at 37°C 
with 50 µg/ml kanamycin and 34 µg/ml chloramphenicol in an incubator shaker at 250 r.p.m. 
When the optical density at 600 nm (OD600) reached 0.8-1.0, the culture was cooled to 22°C, and 
the cells were induced for 12 hours with 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). 
       The cells were harvested by centrifugation at 3,000g for 15 min and were resuspended in a 
solution containing 300 mM NaCl, 50 mM sodium phosphate pH 8.0, and 2.5% (w/w) glycerol 
(solution A). Additionally, 0.5 mg/ml lysozyme, 25 µg/ml DNase, 2mM phenylmethylsulfonyl 
fluoride (PMSF), and 5 mM imidazole were added, which was followed by sonication and 
centrifugation at 17,000g for 30 min. The cell lysate was then incubated with Ni–NTA His-Bind 
resin (Novagen) for 1 hour at 4°C. Subsequently, the beads were spun down at 800g for 1 min and 
transferred to a disposable polyprep column. The resin was then washed with solution A containing 
5 mM imidazole and the protein was eluted from the resin with solution A containing 500 mM 
imidazole. The eluted I-II linker protein was subsequently incubated with amylose resin (NEB) at 
4°C for 2.5 hours, collected by centrifugation at 800g for 1 min, and washed with solution A in a 
polyprep column. Thereafter, the I-II linker protein was eluted with 20 mM maltose in solution A 
and thrombin (Sigma-Aldrich) was added at 4 units per milligram of protein in order to cleave the 
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MBP tag. Following incubation at 16°C overnight, the protein was concentrated and purified by 
gel filtration chromatography using a Superdex 200 column (GE Healthcare). The gel filtration 
buffer contained 150 mM NaCl and 10 mM HEPES pH 7.5. The peak fractions corresponding to 
the tetrameric I–II linker protein were collected (Figure 1B) and concentrated by ultrafiltration 
using the Amicon Centrifugal Filter Units (EMD Millipore) prior to crystallization. The expression 
and purification protocols for the TRPML1 I-II linkers at pH 4.5 and pH 7.5 were comparable to 
the methods described above for the I-II linker at pH 6.0 (1). 
 
 
Figure 1. Expression and purification of the TRPML1 I-II linker. (A) Schematic 
representation of the construct containing the TRPML1 I-II linker in a modified pET26b (+) vector. 
The N-terminal MBP tag was used to increase the purity of the protein during purification, yet was 
cleaved off by thrombin before loading onto the gel filtration column. (B) Representative gel 
filtration profile of the TRPML1 I-II linker. Peaks eluted from a Superdex 200 column correspond 
to the I-II linker and cleaved MBP, respectively. 
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2.2.2  Protein crystallization of the TRPML1 I-II linker 
Crystallization of the TRPML1 I-II linker at pH 6.0 
      Crystallization of the human TRPML1 I-II linker was conducted using the hanging drop vapor 
diffusion method at 16°C. The protein concentration was 4 mg/ml and the reservoir solution 
contained 1.38 M sodium phosphate monobasic monohydrate, 0.42 M potassium phosphate 
dibasic pH 6.0, and 5% pentaerythritol ethoxylate (3/4 EO/OH) (Hampton Research). The protein 
solution was mixed with the reservoir solution at a 1:1 ratio. For the preparation of heavy-atom- 
derivative crystals, crystals were soaked in a solution containing 1.53 M sodium phosphate 
monobasic monohydrate, 0.47 M potassium phosphate dibasic pH 6.0, and 1 mM K2Pt(CN)4 for 
24 hours. Crystals were cryoprotected with Paratone-N (Hampton Research).  
 
Crystallization of the TRPML1 I-II linker at pH 4.5 and pH 7.5 
      To facilitate crystallization of the human TRPML1 I-II linker at pH 4.5 and pH 7.5, a flexible 
region containing residues R200-E213 was removed by overlapping PCR from the Gly84-Ser296 
linker and all constructs were verified by sequencing. Of note, within the pH 6.0 structure, the 
flexible region containing Glu199-Lys219 was unresolved. Crystallization of the TRPML1 linker 
at pH 4.5 and pH 7.5 was carried out utilizing the hanging drop vapor diffusion method at 20°C. 
Crystals for the TRPML1 I-II linker at pH 4.5 were obtained at a protein concentration of 4 mg/ml 
and a reservoir solution containing 200 mM magnesium sulfate, 5.3% PEG 3350, and 100 mM 
acetate pH 4.5 (Figure 2A). Crystals at pH 7.5 were macroseeded at a protein concentration of 4 
mg/ml in a reservoir solution containing 100 mM magnesium sulfate, 4% PEG 3350, and 100 mM 
HEPES pH 7.5 (Figure 2B). For all conditions, the protein solution was mixed with reservoir 
solution at a 1:1 ratio. Crystals at pH 4.5 were cryoprotected with Paratone-N (Hampton Research) 
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and crystals at pH 7.5 were cryoprotected using 30% glycerol. All crystals were flash-frozen in 
liquid nitrogen for data collection at 100 K. 
Figure 2. Crystals of the TRPML1 I-II linker at pH 4.5 and pH 7.5. (A-B) Crystals of the 
TRPML1 I-II linker domain at pH 4.5 (A) and pH 7.5 (B). Crystallization conditions are specified 
in the experimental procedures. TRPML1 I-II linker crystals were obtained from a modified 
construct, omitting 14 amino acid residues that were previously unresolved in the pH 6.0 structure.  
 
2.2.3  Data collection and structure determination 
TRPML1 I-II linker at pH 6.0  
      X-ray diffraction data for native and heavy atom derivative K2Pt(CN)4 TRPML1 I-II linker 
crystals at pH 6.0 were collected at 100 K on a RAXIS-IV detector with Cu K radiation (λ = 1.5418 
Å) from a Rigaku RuH3R X-ray generator. Diffraction images were processed and scaled with the 
HKL package (2). The X-ray diffraction data set was collected at 2.3 Å and 2.6 Å resolution, for 
the I-II linker and the heavy atom derivative K2Pt(CN)4 I-II linker, respectively. The crystal 
belonged to the I422 space group with cell parameters of a = b = 125.3 Å, c = 76.7 Å, α = β = γ = 
90.0°. The asymmetric unit contained a single monomeric subunit. The structure at pH 6.0 was 
determined with the single isomorphous replacement with anomalous scattering (SIRAS) method 
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using native and platinum-derivative data sets. Shake and Bake (3) was used to identify two 
platinum sites which were used in SOLVE (4) to determine the initial phases (1). 
      Additionally, density modification was carried out with RESOLVE (4) in order to ameliorate 
phase accuracy. The quality of the density map was reasonably sufficient to locate the majority of 
the residues and the initial atomic model of the I-II linker was built into the electron density map 
using COOT (5). Structural refinement with CNS (6) and manual rebuilding were carried out 
iteratively prior to deposition in the Protein Data Bank (accession code:PDB 5TJA). Since the 
density was missing for Glu199-Lys219, the final model contained amino acid residues 84-198 
and 220-293. Data collection and refinement statistics are summarized in Table 1. 
 
TRPML1 I-II linker at pH 4.5  
      X-ray diffraction data for the TRPML1 I-II linker at pH 4.5 were collected at 100 K on a 
RAXIS-IV detector with Cu K radiation (λ = 1.5418 Å) from a Rigaku RuH3R X-ray generator. 
All diffraction images were processed and scaled with the HKL package (2). The X-ray diffraction 
data set was collected at 2.4 Å resolution, and the crystal belonged to the P4212 space group with 
cell parameters of a = b = 94.4 Å, c = 50.7Å, α = β = γ = 90.0°. The structure of the I–II linker at 
pH 4.5 was solved by molecular replacement with the program PHASER (7) using the structure at 
pH 6.0 as the search model. The atomic model was built using COOT and structural refinement 
was carried out using CNS and deposited into the Protein Data Bank (accession code: 5TJB). 






TRPML1 I-II linker at pH 7.5  
      X-ray diffraction data at pH 7.5 were collected at the National Synchrotron Light Source 
(NSLS) beamline X29 at Brookhaven National Laboratory. Diffraction images were processed and 
scaled with the HKL package (2). The X-ray diffraction data set was collected at 2.4 Å resolution, 
and the crystal belonged to the F432 space group with cell parameters of a = b = c = 182.8 Å, α = 
β = γ = 90.0°. The structure of the I–II linker at pH 7.5 was also solved by molecular replacement 
with the program PHASER (7) using the structure at pH 6.0 as the search model. The atomic model 
was built using COOT and cycles of structural refinement were carried out using CNS and 
deposited into the Protein Data Bank (accession code:5TJC). Data collection and refinement 























2.3  Structural features of the TRPML1 I-II linker structures  
2.3.1  TRPML1 I-II linker structure at pH 6.0 
      We first determined the 2.3 Å X-ray crystal structure of the TRPML1 I-II linker (Gly84-
Ser296) at pH 6.0 (Figure 3 and Table 1), mimicking the pH of an endosome. As previously 
mentioned, residues Glu199–Lys219, comprising a region of the loop between β4 and β5 were 
unresolved, most likely due to its flexibility. A prominent feature of the TRPML1 linker structure 
is that a monomer exists in the asymmetric unit, which forms a tetramer through a four-fold 
rotational crystallographic symmetry axis (Figures 3A, B). The structure has a height of 30 Å and 
the diameter at the widest point is 90 Å (Figures 3A, B). 
 
Figure 3. Crystal structure of the TRPML1 I-II linker at pH 6.0. (A) Ribbon representation of 
the I-II linker structure. Monomeric subunits are highlighted with different colors. (B) Electrostatic 
potential surface representation of the tetrameric structure. (A-B) Upper panels illustrate views 
looking down the four-fold symmetry axis from the extracellular surface of the membrane. Lower 
panels indicate side views displayed parallel to the plane of the membrane. Published in (1). 
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      Each subunit contains 213 amino acids and is comprised of 2 long α-helices (α1 and α2), two 
short α-helices (α3 and α4), and eight β-strands (Figures 3A, 4A). In addition, three loops are 
present between α1 and α2, α3 and β1, and β4 and β5. The four α-helices are arranged in a compact 
manner against a central five-stranded antiparallel β-sheet consisting of β1, β4, β5, β6, and β7. The 
first 22 amino acids at the N-terminus of the I-II linker form α1 (Figure 3A), which presumably 
links to the first transmembrane segment in the full-length channel. In addition α2 constructs a 
level surface atop the domain (Figure 3A) (1). Of significance, an intrasubunit disulfide bond exists 
between Cys253 in β6 and Cys284 in the short loop between β7 and β8 (1). 
      Notably, domain-swapping is evident, as a 3-stranded beta-sheet is formed between β2 and β3 
(green) within one monomer and β8 from an adjacent monomer (Figure 4A). Similarly, β8 (purple) 
from one monomer forms another 3-stranded beta-sheet with β2 and β3 in another adjacent 
monomer (Figure 4A). The formation of this antiparallel three-stranded β-sheet between two 
adjacent subunits is also illustrated in Figure 3A. The overall architecture of the TRPML1 I-II 
linker is similar to that of the I-II linker in TRPP2, which likewise forms a tetrameric structure (8–
10). The structure of TRPP2, as well as the comparison between the linker domains in TRPP2 and 
TRPML1 will be elucidated in Chapter IV.  
 
2.3.2  Features of the central luminal pore 
      At the center of the tetramer exists a pore, which we refer to as the luminal pore. This region 
is 14Å at its narrowest point (Figure 3A), which would enable hydrated K+, Na+, and Ca2+ ions to 
translocate through the channel. Intriguingly, the central luminal pore has several distinctive 
features. Firstly, a 16–amino acid (L106–T121) luminal pore loop links α1 and α2 (Figures 4A, 
B). Secondly, 12 aspartates in the tetrameric structure (Asp111, Asp114, and Asp115 in each 
40 
 
subunit) are situated in the luminal pore loops (Figure 4B). Thirdly, at neutral pH, these aspartates 
generate a highly electronegative region (Figure 4C). The role that this luminal pore plays in the 
Ca2+/pH regulation of TRPML1 will be detailed in section 2.4.  
 
 
Figure 4. Features of the central luminal pore in the TRPML1 I-II linker. (A) Stereo view of 
the monomeric I-II linker. (B) Enlarged stereo side view representation of the 16 residue luminal 
pore loop (L106–T121). (C) View looking down the central pore of the I-II linker, illustrating the 




2.3.3  TRPML1 I-II linker structures at pH 4.5 and pH 7.5 
      After solving the I-II linker structure at pH 6.0, we then set out to ascertain whether TRPML1 
I-II linker structures at additional physiologically relevant pH values would differ from one 
another. Since TRPML1 channels primarily localize to lysosomes and the I-II linker faces the 
lysosomal lumen, we solved the crystal structure of the I-II linker at pH 4.5, mimicking its native 
physiological state. In addition, we determined the I-II linker crystal structure at pH 7.5, simulating 
the pH at the plasma membrane where TRPML1 can be present during exocytosis (11). At the 
plasma membrane, the I-II linker would be surrounded by the extracellular fluid.   
      Remarkably, despite the changes in pH, the structures at pH 4.5 and pH 7.5 were nearly 
identical to the original pH 6.0 structure when superimposed (Figure 5A). After closer analysis, 
we detected local minor conformational changes among the different pH structures near the 
periphery. Notably, the structure at pH 6.0 has the longest α-helix near the N-terminus, while the 
pH 4.5 structure has the shortest (Figure 5B). The first nine amino acids of α1 within the pH 4.5 
structure were therefore unresolved. Moreover β2, β3, and β8 were not able to be fully resolved in 
the pH 4.5 structure. We presume that these differences can be attributed to the distinct crystal 
packing at the various pH conditions. Intriguingly, even the orientation of the aspartate side chains 
within the luminal pore loop region (Figure 5C) were nearly identical. Taken together, the I–II 
linker appears to be in a highly stable state since significant conformational changes were not 











Figure 5. Comparison of the TRPML1 I–II linker structures. (A) Superposition of the I–II 
linker crystal structures obtained at pH 4.5 (magenta), pH 6.0 (yellow) and pH 7.5 (cyan). 
Orientation of the structures are illustrated as seen from the extracellular side of the membrane. 
(B) A close-up view indicating slight differences among the overlaid structures. (C) Enlarged view 





2.3.4  Verification of the tetrameric I-II linker 
      In order to determine whether the tetrameric structure of the TRPML1 I-II linker is indeed 
present within full-length TRPML1, our collaborators in the laboratory of Dr. Xueming Li 
(Tsinghua University) performed cryo-EM analysis of purified protein to visualize the linker. 
Thus, the cryo-EM density of full-length wild-type C. elegans TRPML1 was visible for the 
extracellular domain, however, the density was indeterminate for the transmembrane domains. A 
masking technique was then implemented to partition the densities of the extracellular and 
transmembrane domains. The identity of the densities of these regions were decipherable based on 
their dimension as well as the resemblance of the transmembrane domain of TRPML1 to that of 
TRPV1 (1). 
      Subsequently, a cryo-EM density map of the extracellular domain was obtained at an overall 
resolution of 5.28 Å with C4 symmetry (Figure 6A). Despite the low-resolution electron density 
map, approximately 79% of the density comprised the I-II linker. The extra density could be 
attributed to the E199-K219 loop and/or glycosylation. The overall density revealed a tetramer 
with a large central pore, hence verifying that the I-II linker is present as a tetramer both within 
the isolated domain as well as within the context of the overall full-length structure. Moreover, the 
TRPML1 I-II linker crystal structure fitted quite reasonably into the cryo-EM density map (Figure 
6B). Since we could not obtain an electron density that would yield a high-resolution structure, an 
atomic model was not built (1). 
 







Figure 6. Tetrameric structure of the I-II linker verified in full-length TRPML1. (A-B) Cryo-
EM reconstructions of the TRPML1 I-II linker present within full-length TRPML1. The gray 
envelopes signify cryo-EM reconstructions of the TRPML1 extracellular domain at 5.28 Å 
resolution (A) with the crystal structure of the I-II linker docked within the cryo-EM density (B). 
Upper panels indicate views looking down the four-fold rotational crystallographic symmetry axis 
as seen from the extracellular/luminal side of the membrane. Lower panels denote views parallel 





2.3.5  Role of the I-II linker in TRPML1 assembly 
      Next we wanted to investigate the role of the I-II linker structure in influencing the 
tetramerization of full-length TRPML1. We proceeded to simultaneously mutate two residues that 
are involved in intersubunit interactions, Leu144 and Arg146 (Figure 7A), to L144K and R146S 
in both the I-II linker structure as well as in the full-length TRPML1 channel. Dr. Minghui Li then 
assessed their oligomeric states by native gel electrophoresis. Upon examination of full-length 
TRPML1 with and without the L144K R146S mutation in a nondenaturing blue native gel, a band 
corresponding to a tetramer was present for full-length wild-type TRPML1 but not for the mutant 
channel. Instead, full-length TRPML1 with the L144K R146S mutation resulted in aggregated 
oligomers. Consistent with these findings, the I-II linker alone containing the L144K R146S 
mutation migrated at a low molecular weight in a nondenaturing gel, indicative of a monomer, 
while the wild-type I-II linker migrated as an apparent tetramer. Taken together, these results 
signify that the L144K R146S mutation appeared to have interfered with the tetrameric assembly 
of both the I-II linker domain as well as the full-length TRPML1 channel (1). 
 
Subcellular localization of TRPML1-LR 
      Consequently, I performed confocal fluorescence imaging in order to investigate whether the 
subcellular localization pattern of the full-length TRPML1-LR channel, containing the L144K 
R146S mutation, was altered compared to that of wild-type. Detailed methods for cell culture and 
live-cell confocal imaging are provided in section 2.5.2. Briefly, Hela cells were transfected with 
wild-type or mutant (L144K R146S) full-length TRPML1 tagged with EGFP on the N-terminus. 
To visualize the lysosomes, Hela cells were loaded with the lysosomal marker LysoTracker® Red 
DND-99 (Invitrogen). Consistent with previous imaging studies performed by other groups, wild-
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type TRPML1 localized to the lysosomes (12–14). Conversely, TRPML1-LR did not localize to 
lysosomes and instead was distributed throughout the cell (Figure 7B). These results further 
verified that the tetramerizaton of the I-II linker is essential for the association of the full-length 






Figure 7. Role of intersubunit interactions in TRPML1 assembly. (A) Intersubunit interactions 
within the TRPML1 I-II linker. Schematic representation of an intersubunit interface within the 
TRPML1 I-II linker, highlighting intersubunit interactions. Residues Leu144 and Arg146 are 
denoted in red boxes, alongside their interacting partners. (B) Confocal images of Hela cells 
expressing either GFP-tagged full-length wild-type TRPML1 (top panel) or full-length TRPML1 
containing the L144K R146S mutation (bottom panel). Red illustrates lysosomes loaded with 
LysoTracker Red DND-99 and yellow indicates colocalization of GFP-tagged TRPML1 and 
lysosomes. Only wild-type TRPML1 colocalized with the lysosomal marker. The indicated scale 




2.4  Structural basis of pH and Ca2+ regulation of TRPML1  
2.4.1  Dual regulation of TRPML1 activity by pH and Ca2+ 
      In order to measure human TRPML1 currents, a well-characterized constitutively active 
mutant channel, TRPML1VP, was utilized in HEK293T cells. As described in Chapter I, this 
mutation allows TRPML1 to traffic to the plasma membrane in order for electrophysiological 
studies to be carried out (15, 16). TRPML1VP containing an N-terminal EGFP tag produced a 
strong inward-rectifying current in a nominal divalent-ion-free (NDF) extracellular/luminal 
solution at pH 7.4 upon investigation with whole-cell patch-clamp recordings. The current was 
inhibited in a dose-dependent manner upon addition of Ca2+ to the extracellular/luminal solution. 
Furthermore, a dose–response curve exhibited an IC50 (calcium concentration producing half 
maximal inhibition) of 0.27 mM, with a Hill coefficient of 1 (Figure 8A). Thus, these results 
indicate a one-to-one Ca2+ blocking mechanism (1). 
      Moreover, Ca2+ blockage of the TRPML1 channel was greatly dependent on the extracellular 
or lysosomal luminal pH (7.4 and 4.6, respectively), and decreased upon reduction of pH from 7.4 
to 4.6. As illustrated by Figure 8A, at pH 4.6 the dose–response curve was shifted to the right, 
increasing the apparent IC50 by 14-fold, from .27 mM to 3.8 mM. Notably, the shape of the dose–
response curve was altered and the Hill coefficient was changed from 1 to 0.5. These findings 
therefore alluded to the presence of negative cooperativity between extracellular/luminal Ca2+ and 
H+. Given that Ca2+ inhibition at pH 4.6 decreased, TRPML1VP currents increased when the 
extracellular/luminal pH was reduced from 7.4 to 4.6 (Figure 8B). Of note, since the V432P 
mutation was implemented in these studies, resulting in a constitutively open channel, the 
consequences of the dual regulation by luminal Ca2+ and pH on gating may not be detected. Dr. 




Figure 8. Regulation of TRPML1 by Ca2+ and pH. (A) Dose-response curves indicating Ca2+ 
inhibition of TRPML1VP at pH 7.4 and pH 4.6. Error bars represent the standard error of the mean 
(SEM). The number of recordings are displayed in parentheses. Curves are fits to the Hill equation. 
(B) Time course of TRPML1VP currents at pH 7.4 and pH 4.6 with 1 mM Ca2+ and either Na+ or 
NMDG+ as the charge carrier. Published in (1). 
 
 
2.4.2  The central pore is essential for pH and Ca2+ regulation 
      As previously mentioned, the central pore of TRPML1 is highly electronegative, which likely 
intensifies Ca2+ conduction by attracting and concentrating Ca2+ through an intricate and pH 
dependent process. Additionally, upon Ca2+ binding, the central pore in the I-II linker can be 
obstructed, resulting in reduced Ca2+conduction. A model for pH and Ca2+ regulation will be 
detailed in section 2.4.3.  
      In order to further investigate what function the 12 aspartate residues have in the central pore, 
we mutated all of them concurrently to glutamine within the TRPML1VP construct, hence creating 
the TRPML1VP-3DQ channel. At pH 7.4, upon addition of Ca2+, the dose-response curve for 
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TRPML1VP exhibited an IC50 of .27 mM (Figure 9A). However, upon examination of TRPML1
VP-
3DQ, the dose-response curve shifted to the right, significantly increasing the apparent IC50 by 20-
fold to 5.5 mM, maintaining the Hill coefficient at 1 (Figure 9A). Therefore, TRPML1VP-3DQ 
greatly led to the reduction in Ca2+ inhibition at pH 7.4. As described earlier, Ca2+ inhibition of 
TRPML1VP (Figures 8A, B) was reduced when the pH was lowered from 7.4 to 4.6. Interestingly, 
the TRPML1VP-3DQ channel led to additional reduction of Ca2+ inhibition at pH 4.6, thus 
increasing the apparent IC50 from 3.8 mM to >10 mM (Figure 9B). Taken together, these results 
suggest that the 12 aspartate residues in the central luminal pore are essential for Ca2+ and pH 




 Figure 9. Role of luminal pore aspartate mutations in Ca2+ regulation. (A-B) Dose-response 
curves of Ca2+ inhibition of TRPML1VP or TRPML1VP-3DQ at pH 7.4 (A) and pH 4.6 (B). 
Measurements were taken at a potential of -80 mV. Error bars indicate the standard error of the 
mean (SEM). The number of recordings are indicated in parentheses and the curves are fits to the 




      We further investigated Ca2+ conduction within the luminal pore by performing Ca2+ imaging 
to determine Ca2+ influx into HEK293T cells. These experiments were carried out by Deyuan Su 
at the Kunming Institute of Zoology. Upon cellular expression with TRPML1VP, the extracellular 
solution utilized was altered from 0 to 3 mM Ca2+, and an increase in concentration of intracellular 
Ca2+ was subsequently observed over time. Notably, the rise in intracellular Ca2+ levels occurred 
more rapidly at pH 4.6 than at pH 7.4. This finding likely signified quicker Ca2+ conduction at pH 
4.6 resulting from weakened Ca2+ blockage as well as reduced Ca2+ accretion at low pH.  
      Subsequently, TRPML1VP-3DQ was expressed and rise time in intracellular Ca2+concentration 
was comparable at pH 4.6 and pH 7.4. The increase in intracellular Ca2+ in TRPML1VP-3DQ was 
comparable to that of TRPML1VP at pH 7.4, leading to strong Ca2+ blockage. Conversely, at pH 
4.6, TRPML1VP-3DQ exhibited a slower increase in Ca2+ levels, possibly due to reduced Ca2+ 
accumulation at the pore. In summary, these findings indicate that the 12 aspartates present within 
the central luminal pore contribute to Ca2+ conduction within TRPML1 (1). 
 
2.4.3  Model of pH and Ca2+dual regulation of TRPML1  
      Based on our structural and functional findings, we suggested a model for the dual Ca2+ and 
pH regulation of TRPML1. At pH 7.4, the aspartates in the luminal-pore are generally negatively 
charged (Figure 10A). Hence, these negative charges through electrostatic interactions can attract, 
accumulate, and bind to extracellular/luminal Ca2+. Therefore, the Ca2+ ions can essentially block 
the luminal pore, resulting in decreased Ca2+ conduction (Figure 10A).  
      In contrast, at pH 4.6 protonation of the aspartates occur, thus reducing the number of negative 
charges within this region, leading to decreased Ca2+ block and increased Ca2+ conduction (Figure 
10B). Of note, protonation presumably occurs in acidic environments since pH 4.6 is similar to the 
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pKa of the aspartates. Yet, not all aspartates may become protonated at pH 4.6, which can then 
attract Ca2+ and still contribute to a low level of Ca2+ block. Our proposed model is further 
supported by the demonstration of negative cooperativity between Ca2+ and H+ at pH 4.6 (Figure 
8A). When the aspartates are mutated to glutamines, the negative charges in the luminal pore are 
eliminated, thus resulting in an even greater reduction of the Ca2+ block which subsequently leads 
to increased Ca2+ conduction (Figure 10C).  
      In summary, with regard to Ca2+ conductivity, the acidic environment within the lysosome 
facilitates Ca2+ conductance within this organelle by decreasing the inhibitory effect of luminal 
Ca2+ on TRPML1. Alternatively, at the plasma membrane the neutral extracellular pH results in 

























Figure 10. Schematic representation of Ca2+/pH dual regulation of TRPML1. Depiction of 
the I-II linker structure, looking down the four-fold symmetry axis. Negative charges are indicated 
by orange dashes and Ca2+ ions are signified by purple circles. (A) Illustration of the highly 
electronegative luminal pore at pH 7.4. Negative charges attract and obstruct the luminal pore upon 
accumulation of Ca2+, thereby decreasing Ca2+ conduction. (B) A reduction in pH induces 
decreased Ca2+ hindrance, leading to increased Ca2+ conduction. (C) All twelve aspartates are 
mutated to glutamines, hence eliminating negative charges in the luminal pore, resulting in 





2.5  Characterization of MLIV-causing mutations 
 
2.5.1  MLIV-causing mutations in the TRPML1 I-II linker 
      The elucidation of the TRPML1 I-II linker structures provided us with a framework from 
which to investigate and characterize MLIV-associated missense mutations. Interestingly, three 
missense mutations, namely, L106P, C166F, and T232P, have been identified in human MLIV 
patients  (17–21) and are located in the I-II linker domain (Figure 11). Wakabayashi et al. reported 
that these mutations manifest as milder symptoms compared to other MLIV truncation or frame-
shift mutations, which typically lead to the complete loss of the TRPML1 protein (17). However, 
based on other studies, it appears that the severity of the disease stemming from the same mutation 
may be distinctly different from one individual to another. For instance, the T232P mutation led 
to a severe MLIV phenotype in one patient (18) yet manifested milder MLIV symptoms in another 
patient (22). 
      Intriguingly, the L106P mutant is present not only in the putative serine lipase consensus motif 
(L104-A113) (20, 23) located in the luminal pore loop, but also at the intersection between the 
pore loop and α1 (Figures 11A,B). Furthermore, T232P resides within the central β-sheet on β5 
(Figures 11A, C) and C166F is located on β1 (Figures 11A, D). Cys166 forms an intrasubunit 
disulfide bond with Cys192 in β4. Notably, C166F disrupts this interaction and mutates a small 
amino acid to a substantially larger hydrophobic residue, while the other two MLIV mutations give 
rise to prolines (L106P and T232P). Additionally,  Dong et al. determined that TRPML1VP with 
the T232P MLIV-causing mutation inhibited the constitutive activity of TRPML1VP (16). Taken 
together, it was plausible that these mutations could be detrimental to the folding, localization, 





Figure 11. Locations of MLIV-causing missense mutations in the TRPML1 I-II linker. (A) 
Schematic ribbon representation of the I-II linker tetrameric structure highlighting the locations of 
the MLIV-causing missense mutations L106P, T232P, and C166F, indicated by colored spheres. 
(B-D) Monomeric structures of the I-II linker depicting the specific locations of the missense 
mutations L106P (B), T232P (C), and C166F (D), denoted by red spheres. Published in (1). 
 
 
2.5.2  Cell culture, transfection, and confocal live-cell imaging 
      Hela cells were maintained in DMEM (Gibco) containing 10% FBS (Atlanta Biologicals) and 
100 µg/mL of penicillin/streptomycin (Invitrogen) at 37°C in a 5% CO2 humid atmosphere. Hela 
cells were cultured and plated onto poly-D-lysine hydrobromide (Sigma) coated coverslips 18 to 
24 hours prior to transfection. The cells were grown on the coverslips in DMEM plus 10% FBS 
supplemented with 100 µg/mL of penicillin/streptomycin at 37°C until they became about 80% 
confluent.  Hela cells were then transfected with wild-type full-length TRPML1 as well as full-
length TRPML1 containing mutations L144K R146S (LR), T232P, L106P, or C166F linked to 
EGFP on the N-terminus. Cells were transfected with 1µg/ml of DNA using LipoD293 In Vitro 
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DNA Transfection Reagent Ver II. (SignaGen Laboratories) following the manufacturer’s 
instructions. After 17 hours post-transfection, Hela cells were loaded with 100 nM of the lysosomal 
marker LysoTracker® Red DND-99 (Invitrogen) for 50 minutes at 37°C to visualize lysosomes in 
the cells. Cells were then gently washed three times with PBS (Gibco) and live-cell images were 
acquired in PBS at 20°C (1). 
      Confocal images were acquired from random live cells in an unbiased manner. The microscope 
used was a Nikon Eclipse TE2000-S equipped with a 60x oil-immersion objective, a Hamamatsu 
C9100-13 back-thinned EM-CCD digital camera (Hamamatsu Photonics Ltd. Instruments 
Pentamax), and a spinning disc head (Yokogawa). Z-stacks were acquired at an optical slice 
thickness of 0.3 μm using a Piezo Focus Drive (Ludl) and data were analyzed using the Volocity 
software (PerkinElmer). All z-stacks were deconvolved utilizing the iterative restoration function 
in Volocity with the iteration limit set to 40 and the confidence limit set to 99%. All images 
illustrated are derived from deconvolved z planes (1). 
 
2.5.3  Confocal imaging of MLIV-causing mutations 
      Since MLIV is a lysosomal storage disorder, I investigated the subcellular localization of wild-
type TRPML1 and TRPML1 containing three MLIV-causing mutations (L106P, T232P, and 
C166F) using confocal fluorescence microscopy. Since full-length wild-type and mutant TRPML1 
constructs contained EGFP, their expression and locations in Hela cells could be readily visualized. 
Additionally, the use of LysoTracker® Red DND-99 clearly identified the lysosomes in the cells. 
Live-cell confocal imaging revealed a distinct difference in localization patterns between the cells 
transfected with wild-type and mutant TRPML1 constructs, as illustrated in Figure 12.  
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      The wild-type TRPML1 channels localized to the lysosomes (Figure 12), as expected based on 
previously reported studies (12, 13). However, as shown in the confocal images, all three of the 
disease-causing mutations did not localize to the lysosomes (Figure 12), yet rather appeared to 
have been retained in the ER (1). These results are consistent with formerly reported imaging 
results of TRPML1 mutant proteins (12, 14). Therefore, these mutations presumably cause MLIV 
since they are not targeted to the lysosomes and retention of these mutants in the endoplasmic 
reticulum is presumably due to incorrectly folded proteins (12, 13). This plausible explanation is 
supported by our circular dichroism findings and biochemical analysis of these mutants (detailed 
in 2.5.4). Hence, residues Leu106, Thr232, and Cys166 may play a role in the correct transport of 
TRPML1 through the biosynthetic pathway, and missense mutations resulting in misfolded 





















Figure 12. Subcellular localization of wild-type and MLIV-causing mutant TRPML1 
channels. Confocal images of live Hela cells expressing full-length GFP-tagged wild-type 
TRPML1 or full-length TRPML1 harboring pathogenic mutations L106P, T232P, and C166F. Red 
denotes lysosomes labeled with LysoTracker® Red DND-99 and yellow signifies colocalization 
of GFP-tagged TRPML1 and lysosomes. Only wild-type TRPML1 localized to the lysosomes. The 





2.5.4  Biochemical analysis and circular dichroism spectroscopy 
Experimental Procedures  
      TRPML1 I–II linkers containing wild-type or MLIV-causing mutations (L106P, T232P, and 
C166F) were expressed through viral infection in Hi5 insect cells (Trichoplusia ni) (Expression 
Systems) and subsequently purified by Dr. Minghui Li. Fluorescence-detection size-exclusion 
chromatography (FSEC) was performed with a spectrofluorometric detector RF-10AXL 
(Shimadzu) for fluorescence detection and for size-exclusion chromatography, a Superose 6 
10/300 column (GE Healthcare) was utilized. Detailed methods regarding insect cell expression, 
purification, and FSEC analysis will be provided in Chapter III.   
 
Circular dichroism spectroscopy 
      Circular dichroism spectroscopy, CD, was performed with a J-815 CD spectrometer (Jasco). 
TRPML1 I–II linker proteins at a concentration of 1 mg/ml were loaded into a quartz cuvette with 
a path length of 0.01 cm for measurement. A sample containing only buffer was used for 
subtraction of the baseline signal. Measurements were obtained from 185 to 250 nm with a 0.1-
nm interval, 1-nm bandwidth, and scanning speed of 50 nm/min. For each TRPML1 I–II linker 
protein, three samples were measured, and three accumulations were measured for each sample 
and averaged. The MRE (mean residue ellipticity) was computed from the raw CD signal, θ, using 
the equation [θ]MRE = θ/(10 × Cr × l), where Cr indicates the protein concentration (M × residue 






Analysis of the TRPML1 I-II linker mutant proteins 
      The cell lysates of three TRPML1 I-II linker proteins containing MLIV-causing mutations 
L106P, T232P, or C166F in addition to the wild-type TRPML1 I-II linker were subjected to FSEC. 
Upon analysis of these samples, it was evident that not only were these pathogenic channels 
expressed at a relatively low yield, but they also exhibited a fair amount of protein aggregation 
(Figure 13A). Therefore, we used circular dichroism to examine secondary structural changes 
caused by these mutations. Circular dichroism (CD) is a technique that rapidly determines protein 
characteristics including the folding and secondary structure of proteins (24). It is widely used to 
ascertain whether a purified protein is folded and if a particular mutation affects the stability or 
conformation of the protein (24).  
      CD analysis of these three purified mutant linker proteins demonstrated significant changes in 
their secondary structures compared to that of wild-type TRPML1 (Figure 13B). Additionally, 
full-length wild-type TRPML1 in a blue native gel migrated as a band consistent with that of a 
tetramer, while the full-length pathogenic proteins appeared to have migrated as aggregated 
oligomers. Moreover, in HEK293T cells, these pathogenic mutants in the TRPML1VP channel 
background produced little or no current. Consistent with the confocal imaging results, 
biochemical and structural analyses indicate that these mutations all appear to affect the structural 










Figure 13. Biochemical and structural analysis of the I-II linker pathogenic mutations. (A) 
Representative FSEC profiles of the wild-type and mutant TRPML1 I-II linker proteins tagged 
with GFP. Peaks correspond to the fluorescence of aggregated protein, TRPML1 tagged with GFP, 
and free GFP, respectively. (B) Illustrative CD spectra of TRPML1 wild-type and mutant I–II 
linker proteins. [θ]MRE denotes mean residue ellipticity. Published in (1). 
 
 
2.6  Conclusion 
      In summary, our studies of the TRPML1 I-II linker provided us with a greater understanding 
of the structure and function of this domain within the full-length TRPML1 channel. The crystal 
structures that we determined of the TRPML1 I-II linker are the first reported high-resolution 
structures of a TRPML channel domain. The structure demonstrates that the I-II linker forms a 
tetramer with four-fold rotational symmetry. Interestingly, the I–II linker structures at pH 4.5, 6.0, 
and 7.5 seem to exist in a highly stable state since significant conformational changes were not 
detected, despite changes in pH conditions. Ultimately, determining the full-length structure of 
TRPML1 will provide valuable information and is an area to explore in future research. 
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      To expand upon our structural findings, functional studies were performed, revealing that the 
central luminal pore plays a significant role in pH and Ca2+ regulation of TRPML1. Taken together, 
our studies indicate that the dual Ca2+/pH regulation involves the intricate interrelationship 
between the Ca2+ blockade of the luminal pore and the protonation of aspartates. This salient 
finding can further be supported by future NMR studies that ascertain protonation states at various 
pH conditions. 
      Importantly, our TRPML1 I-II linker structures served as a basis from which to analyze and 
thereby characterize several MLIV-causing mutations that reside in this domain, namely L106P, 
C166F, and T232P. The localization patterns of these MLIV-causing mutations in the cell were 
investigated using confocal fluorescence microscopy, demonstrating that mutations in TRPML1 
lead to the mislocalization of these proteins. In addition to our confocal imaging results, 
biochemical and CD studies support that the MLIV-causing mutations in the I-II linker can 
significantly influence the tetrameric assembly of the channel. In conclusion, our findings have 
revealed novel insights into the structure and function of TRPML1 as well as how disease-causing 
















2.7  References 
 
1.  M. Li, W. K. Zhang, N. M. Benvin et al., Structural basis of dual Ca2+/pH regulation of the 
endolysosomal TRPML1 channel. Nat Struct Mol Biol. 24, 205–213 (2017). 
2.  Z. Otwinowski, W. Minor, Processing of X-ray diffraction data collected in oscillation 
mode. Methods Enzymol. 276, 307–326 (1997). 
3.  C. M. Weeks, R. Miller, The design and implementation of SnB version 2.0. J. Appl. 
Crystallogr. 32, 120–124 (1999). 
4.  T. Terwilliger, SOLVE and RESOLVE: Automated structure solution, density 
modification, and model building. J. Synchrotron Radiat. 11, 49–52 (2004). 
5.  P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 60, 2126–2132 (2004). 
6.  A. T. Brunger et al., Crystallography & NMR System: A New Software Suite for 
Macromolecular Structure Determination. Acta Cryst. 54, 905–921 (1998). 
7.  A. J. McCoy et al., Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 
(2007). 
8.  P. S. Shen et al., The Structure of the Polycystic Kidney Disease Channel PKD2 in Lipid 
Nanodiscs. Cell. 167, 763–773 (2016). 
9.  M. Grieben et al., Structure of the polycystic kidney disease TRP channel Polycystin-2 
(PC2). Nat Struct Mol Biol. 24, 114–122 (2017). 
10.  M. Wilkes et al., Molecular insights into lipid-assisted Ca2+ regulation of the TRP channel 
Polycystin-2. Nat. Struct. Mol. Biol. 24, 123–130 (2017). 
11.  X. Zhang, X. Li, H. Xu, Phosphoinositide isoforms determine compartment-specific ion 
channel activity. Proc. Natl. Acad. Sci. U. S. A. 109, 11384–9 (2012). 
12.  M. Manzoni et al., Overexpression of wild-type and mutant mucolipin proteins in 
mammalian cells: effects on the late endocytic compartment organization. FEBS Lett. 567, 
219–224 (2004). 
13.  P. R. Pryor et al., Mucolipin-1 Is a Lysosomal Membrane Protein Required for Intracellular 
Lactosylceramide Traffic. Traffic. 7, 1388–1398 (2006). 
14.  K. Kiselyov et al., TRP-ML1 Is a Lysosomal Monovalent Cation Channel That Undergoes 
Proteolytic Cleavage. J. Biol. Chem. 280, 43218–43223 (2005). 
15.  H. Xu et al., Activating Mutation in a Mucolipin Transient Receptor Potential Channel 
Leads to Melanocyte Loss in Varitint-Waddler Mice. Proc. Natl. Acad. Sci. U. S. A. 104, 
18321–6 (2007). 
16.  X.-P. Dong et al., The type IV mucolipidosis-associated protein TRPML1 is an 
endolysosomal iron release channel. Nature. 455, 992–996 (2008). 




18.  R. Bargal et al., Mucolipidosis Type IV: Novel MCOLN1 Mutations in Jewish and Non-
Jewish Patients and the Frequency of the Disease in the Ashkenazi Jewish population. Hum. 
Mutat. 17, 397–402 (2001). 
19.  D. A. Zeevi, A. Frumkin, G. Bach, TRPML and lysosomal function. Biochim. Biophys. 
Acta. 1772, 851–858 (2007). 
20.  M. Sun et al., Mucolipidosis type IV is caused by mutations in a gene encoding a novel 
transient receptor potential channel. Hum. Mol. Genet. 9, 2471–2478 (2000). 
21.  G. Altarescu et al., The neurogenetics of mucolipidosis type IV. Neurology. 59, 306–313 
(2002). 
22.  J. S. Geer et al., Mucolipidosis Type IV: A Subtle Pediatric Neurodegenerative Disorder. 
Pediatr. Neurol. 42, 223–226 (2010). 
23.  R. Bargal et al., Identification of the gene causing mucolipidosis type IV. Nat. Genet. 26, 
120–23 (2000). 
24.  N. Greenfield, Using circular dichroism spectra to estimate protein secondary structure. Nat. 












Structural Studies of TRPP2 
 
 
3.1  Introduction 
      As described in Chapter I, TRPP2 is a member of the TRP channel family of proteins and 
mutations in this channel lead to autosomal dominant polycystic kidney disease (ADPKD) (1, 2). 
Due to the clinical relevance of this protein, investigations pertaining to TRPP2 are becoming 
increasingly more prevalent. Initially, several structural studies on isolated cytoplasmic domains 
of TRPP2 were published, including the crystal structure of the coiled-coil domain, which was 
solved in our lab (3), as well as the NMR structures of the EF-hand domain (4–6). In order to gain 
insight into the structural effects of ADPKD mutations as well as the mechanisms underlying 
channel regulation, I set out to determine a high-resolution structure of near full-length TRPP2.  
      Prior to this endeavor, no published data on the crystal or cryo-EM structure of a full-length 
TRP channel were reported. Since then, several full-length TRP channel structures were solved 
using cryo-EM, due to recent technological advances in this field. As mentioned in Chapter I, 
major improvements in classification software as well as direct electron detectors have occurred, 
enabling structures of membrane proteins to be solved at atomic resolution. Prominently, this 
recent ‘resolution revolution’(7) was pioneered by the elucidation of the TRPV1 channel (8–10). 
Subsequently, high-resolution cryo-EM structures of other TRP channels including TRPA1 (11), 
and TRPV2 (12, 13) were determined. Additionally, the high-resolution crystal structure of 
TRPV6 was solved (14). 
      Until quite recently, no structures have been solved containing the transmembrane region of 





TRPP2 that included the transmembrane domains (15). Thereafter, Grieben et al. and Wilkes et al. 
published similar TRPP2 structures of closed and open states, respectively (16, 17). These 
structures will be analyzed in detail in Chapter IV. The aim of this chapter is to highlight the 
methods we implemented in order to successfully express and purify the human TRPP2 channel, 
as well as the cryo-EM analysis that we performed. An additional topic of discussion will address 
the comparison of methods utilized in this study as well as those applied by other groups that 
solved TRPP2 structures.  
 
3.2  Screening of TRPP2 constructs using FSEC  
3.2.1  Rationale for cloning truncated constructs 
      Based on my preliminary studies, TRPP2 seemed to be a promising protein for structural 
determination. Since working on a full-length membrane protein was a new endeavor, it was 
important to create and analyze a wide range of constructs to assess which had suitable yield and 
purity for structural studies. Initially, my goal was to identify constructs that could be used for 
crystallographic analysis. Many variables appear to affect the expression level, homogeneity, and 
ability to crystallize membrane proteins. Some of these variables include truncations, detergent 
types (18), lipids (19), homologues used (20), types of affinity tags, as well as the location of tags 
in the construct (21, 22). However, after the emergence of the first high-resolution cryo-EM 
structure of TRPV1 (8, 9), we applied cryo-EM methodology in order to evaluate TRPP2 protein 
samples for structural determination.    
      Before generating truncations within TRPP2, a secondary structure prediction search on human 
TRPP2 using PSIPRED (23) and Jpred (24) was performed in order to get a general sense of where 





on the N- and C-termini of TRPP2 were created, removing flexible and disordered regions of these 
proteins, and cloned into a pEGFP vector (Clontech). Consequently, each construct contained an 
EGFP tag on the N-terminus of the TRPP2 protein. Enhanced green fluorescence protein (EGFP) 
tags were utilized in order to detect the protein expression levels, homogeneity, and aggregation 
of particular constructs through a method known as fluorescence-detection size-exclusion 
chromatography (FSEC) (22). Notably, the S1-S6 transmembrane segments of the protein were 
included in all of the constructs. According to studies performed by Dr. Yong Yu, a previous 
member of our lab, the coiled-coil domain is thought to play a key role in the assembly of 
homomeric TRPP2 (3). Therefore, all of the constructs that I created contained the coiled-coil 
domain at the C-terminus.  
 
3.2.2  Transient HEK cell transfection and FSEC 
      TRPP2 constructs were then transiently transfected into human embryonic kidney 293 (HEK 
293T) cells (ATCC) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's 
instructions. Of note, HEK293T cells were used instead of the glycosylation-deficient GnTI-/- HEK 
cells (HEK293S) used by other groups for FSEC analysis (22). Since the expressed protein had an 
EGFP tag on its N-terminus, the transfection efficiency was able to be examined under the 
fluorescent microscope. Forty-eight hours after transfection, cells were pelleted and resuspended 
in a solution containing 50 mM NaHPO4,, 300 mM NaCl, 2.5% (w/w) glycerol pH 8.0, and Halt 
protease-inhibitor cocktail (Thermo Fisher Scientific). The nonionic detergent n-Dodecyl-β-D-
maltoside (DDM; Anatrace) was added at a final concentration of 10% and lysates were incubated 
at 4°C for 1 hour. The solution was then clarified by centrifugation at 16,000 r.p.m. for 10 min. 





(GE Healthcare), for size-exclusion chromatography (SEC), connected to a spectrofluorometric 
detector RF-10AXL (Shimadzu) which measured the fluorescence. The gel filtration buffer 
contained .05% DDM, 50 mM NaHPO4, 300 mM NaCl, and 2.5% glycerol pH 8.0. 
 
3.2.3  FSEC analysis of human TRPP2 constructs transfected in HEK293 cells 
      FSEC is a valuable screening technique that can assess the monodispersity and expression level 
of a protein tagged with green fluorescent protein (GFP) by analyzing the elution trace of GFP 
fluorescence (20). By subjecting proteins fused to GFP to SEC methods, FSEC can assess in a 
simple manner the stability, approximate molecular size, as well as the yield of membrane proteins, 
without the need for purification (21, 22). When analyzing FSEC traces, it is important to examine 
the extent to which proteins are present in the void volume peak or the included volume peak. 
Proteins that migrate in the void volume are likely misfolded and insoluble, while proteins in the 
included volume peak are presumed to be correctly folded (20, 22). 
      In addition, the shape of the included peak is a way to gauge the quality of the protein. A 
monodispersed sharp included peak is highly preferable for crystallization and other structural 
studies over a polydispersed included peak that contains multiple oligomeric or conformational 
states (20–22). Through this method, I was able to detect which constructs produced a greater 
monodispersed included peak with low levels of aggregation that could be used further for 
structural analysis. The FSEC traces for the most promising human TRPP2 (hTRPP2) constructs 
expressed in HEK293T cells, hTRPP2:181-927 and hTRPP2:191-927, are illustrated in Figure 1. 








Figure 1.  FSEC traces of human TRPP2 constructs after transient transfection in HEK cells. 
(A-B) FSEC traces of human TRPP2:181-927 (A) and TRPP2:199-927 (B). The void, TRPP2-
GFP, and ‘free’ GFP peaks are illustrated.  
 
      Upon FSEC analysis, the traces of both hTRPP2:181-927 and hTRPP2:191-927 were very 
similar. Notably, they exhibited relatively monodispersed peaks with regard to their included 
volume peaks containing GFP-TRPP2, characteristic of well-folded proteins. Therefore, these 
truncations appeared to be relatively soluble in DDM because only a small amount of the proteins 
aggregated and migrated in the void peak. Since these findings were very promising, hereafter, I 
primarily focused on further investigating these two constructs for structural analysis.  
      HEK cells provide near native translocation machinery, post-translational modifications, and 
a lipid environment that can be very important for the production of human membrane proteins 
(22). Although it appeared highly favorable to express human TRPP2 in its native environment of 
human kidney cells, due to limited resources we could not pursue large-scale purification from 





lab was fully equipped with the necessary materials needed to scale-up purification of TRRP2 from 
insect cells. Hence, I started to utilize the baculovirus-based expression system in insect cells to 
test the expression levels of promising constructs including TRPP2:181-927 and TRPP2:199-927.  
 
3.3  Insect cell baculovirus-based expression system 
      The insect cell baculovirus-based expression system has been previously utilized to express 
mammalian membrane proteins since it uses similar protein post-translational modifications and 
sorting machinery to that found in mammalian cells (22). An advantage of using the baculovirus 
system is that the virus can easily be propagated in insect cells to high titers (21, 25). Additionally, 
this system often creates properly folded membrane proteins (21, 25), an essential characteristic 
for structural studies. 
 
3.3.1  Generation of recombinant baculoviruses 
      The Bac-to-Bac® Baculovirus Expression System (Invitrogen) protocol was implemented 
according to manufacturer’s instructions in order to efficiently create recombinant baculoviruses 
for TRPP2 structural studies. The human TRPP2 gene containing various N- and C-terminal 
truncations initially linked to GFP were subsequently cloned into a pFastBac™ vector. After 
confirming the correct truncations through sequencing, the pFastBac™ constructs were 
transformed into DH10Bac™ competent E. coli cells (Invitrogen) to produce recombinant 
bacmids. Since DH10Bac™ cells have a baculovirus shuttle vector (bacmid), upon transformation 
transposition occurs between the pFastBac™ vector and the bacmid resulting in recombinant 
bacmids. After transformation, the DH10Bac™ cells were transferred to LB agar plates containing 





IPTG. Blue/white selection was carried out and white colonies were chosen, which contained the 
recombinant bacmid in a background of blue colonies that carry the non-recombinant bacmid. 
     Subsequently, I purified the recombinant bacmid DNA by performing minipreps. The isolated 
bacmid DNA was then transfected into Spodoptera frugiperda (Sf9) insect cells (Invitrogen) in 
order to create recombinant baculovirus stocks at 27°C. Several days after transfection, I checked 
the fluorescence of the insect cells using a fluorescent microscope to assess the transfection 
efficiency, whereby most of the cells were infected by the virus. Subsequently, I collected the 
media in each well from the transfection plate, which contained the P1 virus. I then amplified this 
virus in Sf9 cells and collected the virus generated, known as the P2 virus. The P2 virus contained 
amplified baculoviral stock that was later utilized to infect Hi5 (Trichoplusia ni) cells (Expression 
Systems) for small and large-scale expression of TRPP2. 
 
3.3.2  FSEC analysis of human TRPP2 constructs transfected into Sf9 cells 
      For FSEC analysis, I then harvested 500μl of infected insect cells by centrifugation. FSEC 
analysis was performed using the same procedure described in section 3.2.2 for HEK293 cells. 
FSEC was performed on a number of samples, and the two most promising constructs yet again 
were human TRPP2:181-927 and TRPP2:199-927. The FSEC profiles of these constructs resulted 
in generally monodispered main protein peaks, suggestive of homogenously folded proteins 





cells. Subsequently, I continued to perform small-scale and large-scale purification of these 
truncated proteins, which will be described in detail in later sections.  
 
Figure 2.  FSEC traces of human TRPP2 constructs after transient transfection in Sf9 cells. 
(A-B) FSEC traces of hTRPP2:181-927 (A) and hTRPP2:199-927 (B) transiently expressed in Sf9 
cells and solubilized in DDM. The TRPP2-GFP and ‘free’ GFP peaks are highlighted. 
 
3.4  FSEC of mouse TRPP2 constructs transfected in HEK293 cells 
      Screening through additional homologues of TRPP2 is a robust approach to determine which 
proteins are the most stable in detergents and have increased expression levels (26). Therefore, we 
made various mouse TRPP2 (mTRPP2) constructs with truncations at the N- and C-termini of the 
protein. Both the six transmembrane segments as well as the coiled-coil domain in mTRPP2 were 
present in the constructs. Dr. Ravi Kalathur, a scientist at the New York Structural Biology Center 
(NYSBC), helped to expedite the cloning and screening of these constructs. The mTRPP2 
truncations were cloned into pTriEx 1.1 vectors modified for ligation independent cloning [LIC] 





GFP-Flag-His10]. The protocols for the solubilization of whole cell lysates in DDM and 
subsequent FSEC analysis were the same as those described for the human TRPP2 constructs. 
Representative FSEC profiles of a subset of samples are indicated in Figure 3.  
 
 
Figure 3.  FSEC traces of mouse TRPP2 constructs after transient transfection in HEK cells. 
(A-D) FSEC traces of mTRPP2:25-916 (A), mTRPP2:35-923 (B), mTRPP2:18-938 (C), and 
mTRPP2:68-938 (D). Of note, (A, C) had GFP linked to the C-terminus of the constructs, while 





      Notably, all of the constructs exhibited quite high levels of aggregation in the void volume 
peaks, indicative of insoluble and misfolded proteins. In addition, despite making various 
truncations and placing the GFP tag on the N- and C-termini, the FSEC traces overall looked very 
similar in all four samples. Therefore, based on these preliminary studies it appeared that the 
truncations and the positions of the tags did not play a major role in the overall expression level 
and homogeneity of the samples. Thus, since the FSEC profiles from the transfected mouse TRPP2 
constructs did not look promisng, I primarily focused my efforts on optimizing purification 
conditions for the human TRPP2 constructs.  
 
3.5  Purification of hTRPP2 in Hi5 cells using DDM and amphipol 
      Since both hTRPP2:199-927 and hTRPP2:181-927 exhibited the most promising FSEC 
profiles in both HEK cells and insect cells, I then proceeded to express and purify these constructs 
at a small-scale from insect cells. It has been shown that Hi5 cell lines demonstrate higher (tenfold) 
susceptibility to baculovirus infection as well as higher protein yield compared to Sf9 cells (27). 
Additionally, since it has been reported that Hi5 cells are more favorable for the expression of 
glycosylated proteins (28, 29), hereafter, Hi5 cells were utilized in all purifications described. 
However, amplification of the P1 virus was carried out in Sf9 cells.   
 
Generation of TRPP2 constructs with C-terminal MBP 
      The human TRPP2 gene containing the truncations 199-927 and 181-927 was cloned into a 
modified pFastBac vector with SbfI and AscI restriction sites. The resulting construct contained 
hTRPP2 followed by a tobacco etch virus (TEV) protease recognition sequence site, a maltose 





were further investigated were derived from the expression of this vector. The TRPP2 baculoviral 
stock was generated according to the manufacturer’s instructions (Invitrogen, Bac-to-Bac), as 
previously mentioned. 
 
3.5.1  Small-scale purification in DDM 
      A 200 ml culture of Hi5 insect cells was infected with the hTRPP2:199-927 virus when the 
cell density reached 2×106 cells/mL at 27 °C. Forty-eight hours after infection, cells were harvested 
by centrifugation at 4°C. Cell pellets were suspended in a buffer containing 250 mM NaCl, 10% 
glycerol, and 20 mM Hepes pH 8.0 (buffer A) in the presence of a protease inhibitor cocktail 
(Roche) and homogenized with a glass dounce homogenizer. The cells were then disrupted by 
sonication, and were subjected to ultracentrifugation at 45,000 r.p.m for 1 hr at 4°C. The resulting 
pelleted cell membrane was resuspended in buffer A containing the Roche protease inhibitor 
cocktail and homogenized once more with a glass dounce homogenizer. The TRPP2 protein was 
then extracted with 1% DDM for 1 hr at 4°C. 
      Subsequently, the solubilized membrane was clarified from cell debris by ultracentrifugation 
at 45,000 r.p.m for 30 min at 4°C. The supernatant was then incubated with amylose resin (NEB) 
with gentle agitation for 1 hr at 4°C. The resin was isolated by centrifugation at 3,000 r.p.m and 
transferred to a gravity column. The resin was subsequently washed with 15 column volumes of 
buffer A containing .05% DDM. TRPP2 was eluted with the same buffer containing .05% DDM 
and 20 mM maltose. The protein was concentrated by ultrafiltration utilizing the Amicon 
Centrifugal Filter Units (EMD Millipore) and concentrations were measured using a NanoDrop 
(Thermo-Scientific). TRPP2 was further purified by size-exclusion chromatography (SEC) with a 





NaCl, and 20 mM Hepes pH 7.4. The peak fractions containing TRPP2 were then collected and 
examined on an SDS-PAGE gel.  
 
3.5.2  Reconstitution into amphipols 
      Apart from detergents, amphipathic polymers (amphipols) are an alternative approach to 
stabilize the transmembrane domains of membrane proteins after solubilization and purification 
with detergent (30). These amphipols are able to mimic the lipid environment of the membrane 
and firmly attach to the transmembrane domains of membrane proteins (31, 32). In fact, amphipols 
have been extensively used in order to determine several other TRP channel cryo-EM structures 
including TRPV1 (8, 9), TRPV2 (13), and TRPA1 (11).  
      The methods described previously were utilized to purify the TRPP2 protein. Upon elution of 
TRPP2 in .05% DDM, TEV protease (40μg per 1mg TRPP2) was added in order to cleave the 
MBP tag. Simultaneously, the protein was then mixed with amphipol A8-35 (Anatrace) at a 1:3 
(w/w) ratio and incubated overnight at 4°C with gentle agitation. Afterwards, the sample was 
incubated with Bio-Beads SM-2 (Bio-Rad) (15mg per 1ml channel/detergent/amphipol mixture) 
for 8 hr in order to remove detergent, according to published methods (9, 11) with modifications. 
Bio-Beads were subsequently removed over a disposable polyprep column. The protein was then 
concentrated and purified by SEC in a buffer containing 150 mM NaCl and 20 mM Hepes pH 7.4.  
      Size-exclusion chromatography (SEC), like FSEC, is a highly effective method for assessing 
the monodispersity and stability of a protein. The presence of a single symmetrical Gaussian peak 
is indicative of a properly folded protein that is monodisperse, while multiple asymmetric peaks 
likely suggest an unfolded and unstable protein that is polydisperse (20, 22). As shown in Figures 





are similar with relatively monodispersed TRPP2 peaks, indicating that the proteins are correctly 
folded and homogenous. However, since the proteins were expressed at a small-scale, the SEC 
profiles demonstrated relatively poor expression. Of note, the critical micelle concentration (CMC) 
of DDM is 0.0087% and the concentration used in the gel filtration buffer was significantly higher 
than the CMC. The critical micelle concentration (CMC) of a detergent is the threshold 
concentration above which micelles are produced. 
      Interestingly, upon exchange of DDM with amphipol A8-35 the protein peaks were no longer 
detected (Figures 4B, D). The protein appeared to have aggregated and visible precipitation was 
present after centrifugation prior to loading onto the gel filtration column. At first, since TEV and 
amphipol A8-35 were added at the same time, it was difficult to determine what caused the 
aggregation. Consistent with this observation, it has been reported that in some cases upon 
amphipol reconstitution, trace amounts of aggregates were identified (32, 33). Presumbaly, the 
Bio-Beads were absorbing DDM too quickly, without allowing amphipol A8-35 to properly 
stabilize the protein, thus leading to protein aggregates. Of significance, it has been demonstrated 
that adding Bio-Beads slowly in steps to the protein-detergent mixture can aid in the reduction of 
aggregated protein (34). Therefore, in subsequent protein preps I added Bio-Beads in a stepwise 
manner to remove DDM.  
      Additionally, I also altered the amphipol reconstitution methods by initially adding TEV 
protease followed by mixing the protein with amphipol A8-35 at a higher ratio, 1:6 or 1:8 (w/w), 
rather than 1:3. Presumably, a higher ratio of amphipol present would aid in the stabilization of 
the protein. As a result, a small protein peak corresponding to TRPP2:181-927 was visible (Figure 
5C). However, this peak was significantly smaller than the correspoding TRPP2 peak in the DDM 





detergent, Lauryl Maltose Neopentyl Glycol (LMNG), and subsequently reconstituted the protein 
in amphipol, I began to obtain a higher protein yield with less aggregation (Figure 8). Therefore, 
by adjusting parameters in the amphipol reconstituion protocol, I was able to solve the amphipol 











Figure 4.  SEC traces from small-scale purification of TRPP2 in DDM and amphipol A8-35. 
(A) SEC trace of human TRPP2:181-927 in a buffer containing .05 % DDM, 150 mM NaCl, and 
20 mM Hepes pH 7.4. The peaks correspond to TRPP2 and MBP, respectively. (B) SEC trace of 
human TRPP2:181-927 after amphipol reconstitution in a buffer containing 150 mM NaCl and 20 
mM Hepes pH 7.4. The TRPP2 peak was not present. (C) SEC trace of human TRPP2:199-927 
purified in the same buffer used in (A). The peaks depict TRPP2 and MBP. (D) SEC trace of 
human TRPP2:199-927 after amphipol reconstitution in the same buffer used in (B). Notably, the 
TRPP2 peak was not exhibited. (E) SDS-PAGE of TRPP2 samples stained with Coomassie Blue 
to visualize the protein bands. The lanes are as indicated: 1, 181-927 eluted from amylose resin; 
2, 181-927 after TEV cutting; 3, 181-927 gel filtration profile peak (A); 4, 199-927 before TEV 
cutting; 5, 199-927 gel filtration profile peak (C); 6, 181-927 eluted from amylose resin; 7, 181-
927 after TEV cutting and amphipol reconstitution; 8, 199-927 before TEV cutting and amphipol 
reconstitution; 9, 199-927 after TEV cutting and amphipol reconstitution; 10, 199-927 profile peak 









3.5.3  Inhibition of N-glycosylation 
      Post-translational modifications such as glycosylation play a role in the proper folding and 
overall stability of membrane proteins. Although modifying these predicted glycosylation sites can 
lead to more homogeneous samples, it could also be deleterious to the expression of the protein 
since some proteins need native glycosylation (35). Initially, I was purifying TRPP2 with the goal 
of obtaining its crystal structure. Since TRPP2 contains five glycosylation sites, (Asn 299, Asn305, 
Asn328, Asn362, and Asn375) (36), the glycosylated protein would presumably lead to 
heterogeneity in the protein sample if used for crystallization. Therefore, I added an antibiotic 
tunicamycin to the insect cells upon viral infection.     
      In theory, tunicamycin should inhibit the addition of glucosamine into N-glycosidically linked 
glycoproteins (37). As indicated in the SDS-PAGE gel in Figure 5, it appears that the TRPP2 
protein was not glycosylated after tunicamycin was introduced, since the band in lane 4 migrated 
at a slightly lower molecular weight than the glycosylated samples (lanes 1-3) (Figure 5D). In 
addition, upon cutting with TEV the TRPP2 band in lane 6 also had a lower molecular weight 
compared to the glycosylated protein in lane 7, indicating that indeed glycosylation was inhibited 
(Figure 5D). However, the protein peak of TRPP2 with tunicamycin seemed broader (Figure 5B) 










Figure 5.  SEC traces from small-scale purification of TRPP2:181-927. (A) SEC trace of 
human TRPP2:181-927 in a buffer containing .05 % DDM, 150 mM NaCl, and 20 mM Hepes pH 
7.4. Peaks corresponding to TRPP2 and MBP+TEV are denoted. (B) SEC trace of human 
TRPP2:181-927 with the addition of tunicamycin purified in the same gel filtration buffer utilized 
in (A). (C) SEC trace of human TRPP2:181-927 after amphipol A8-35 reconstitution in a buffer 
containing 150mM NaCl and 20 mM Hepes pH 7.4. (D) SDS-PAGE of TRPP2 samples stained 
with Coomassie Blue. The lanes are as indicated: 1-3, 181-927 elute from amylose resin (.05% 
DDM); 4, 181-927 elute from amylose resin (tunicamycin sample); 5, 181-927 after TEV cutting 
(.05% DDM sample); 6, 181-927 after TEV cutting (tunicamycin sample); 7, 181-927 after TEV 
cutting (sample reconstituted in amphipol). All of the proteins indicated were initially solubilized 





       Since we later decided to use cryo-EM instead of X-ray crystallography to determine the 
structure of TRPP2, we assumed that glycosylation would not hinder structural determination 
using cryo-EM. As indicated in Figure 6, although protein engineering is often required for protein 
crystallization in order to remove glycosylation and flexible sites, glycosylated membrane proteins 
can be determined by cryo-EM and presumably require less protein engineering (38). Therefore, 
















Figure 6. Role of glycosylation in membrane protein structural determination. Protein 
engineering is often required for successful protein crystallization in order to eliminate 
glycosylation and flexible sites. Alternatively, glycosylated membrane proteins can be determined 
by cryo-EM with less need for modifying regions that will likely cause heterogeneity in the 







3.5.4  Large-scale purification of TRPP2 in DDM 
      Since recent advancements occurred in the field of single-particle cryo-EM, we also wanted to 
utilize this structural approach to obtain a high-resolution structure of TRPP2. Thus, we initiated 
a collaboration with the laboratory of Dr. Reza Khayat (City College of New York) and began 
testing TRPP2 samples that had relatively monodispersed peaks. Dr. Devendra Srivastava, a 
postdoctoral fellow in the Khayat lab, prepared the negative-stain and EM grids and Dr. Khayat 
along with Dr. Srivastava both tested the samples at the Simons Electron Microscopy Center at 
NYSBC.  
      I subsequently started performing large-scale preps with hTRPP2:199-927 to obtain sufficient 
protein yield for cryo-EM analysis. In order to achieve a higher yield, I infected 3-4 L of Hi5 insect 
cells with virus followed by incubation for 72 hr. The purification procedure was the same as 
previously denoted, with slight modifications. Notably, the MBP tag was not cleaved and 2 mM 
TCEP (tris (2-carboxyethyl) phosphine) was added to the buffer at every step of the purification 
procedure. An SDS-PAGE gel was used to evaluate the purity of the protein sample and TRPP2-
MBP appeared to be pure (Figure 7C). 
      The protein yield was significantly higher (Figure 7A) than previously observed, yet the 
sample was slightly heterogeneous. Nonetheless, only fractions within the main peak were 
collected. A few microliters of the TRPP2 protein at 0.84 mg/ml in 0.05% DDM were applied to 
EM protochip C-flat real gold grids and plunge-frozen in liquid ethane cooled by liquid-nitrogen 
to immobilize the protein particles present within the thin layer of vitreous ice. However, detergent 
micelles were apparent and the protein was not easily detectable (Figure 7B). 











Figure 7. TRPP2-MBP and TRPV2 purified in DDM. (A) SEC trace of human TRPP2:199-
927-MBP in a buffer containing .05 % DDM, 150 mM NaCl, 20mM Hepes, and 2 mM TCEP pH 
7.4. (B) Representative electron micrograph of TRPP2 in .05% DDM embedded in vitreous ice. 
(C) SDS-PAGE of TRPP2 samples. The lanes are as indicated: 1, TRPP2 eluted in .05% DDM; 
2, SEC fraction E10; 3, SEC fraction E11; 4, SEC fraction E12; 5, SEC fraction F12; 6, SEC 
fraction F11; 7, SEC fraction F10; 8, SEC fraction F9. (D-E) SEC profiles of TRPP2:199-927-
MBP purified in .05% DDM two days (D) and nine days (E) at 4°C after elution from amylose 
resin. (F) SEC trace of TRPV2 solubilized and purified in DDM (30). (G) Negative-stain EM 
micrograph of TRPV2 in DDM (30). Of note, (F-G) are adapted from (30). 
 
      Similar EM grids were observed using protein from subsequent preps. Aliquots of TRPP2 were 
then tested two and nine days after elution from amylose resin to assess the long-term stability of 
the protein at 4°C (Figures 7D, E). Interestingly, although hTRPP2:199-927 samples appeared to 
be stable at 4°C for more than one week and had relatively monodispersed peaks, the samples did 
not look promising when tested on negative-stain or EM grids. However, my findings suggest that 
small-scale preps yield more monodispersed protein peaks than do larger preps. At smaller yields, 
the main TRPP2 protein peak appeared to be less polydispersed and therefore more homogeneous.    
      Perhaps the intrinsic nature of DDM led to polydispersity in the samples. Notably, as illustrated 
in Figures 7F and 7G, the solubilization and purification of TRPV2 in DDM led to heterogeneity 
in the sample as indicated by the SEC profile and negative-stained EM micrograph (30). 
Interestingly, both the TRPP2 and TRPV2 SEC profiles appear very similar, as do their respective 
cryo and negative-stained micrographs. Moreover, the gel filtration profiles of these proteins 
exhibited shoulders to the left of the main protein peaks. Taken together, these results further 






3.6  Purification of hTRPP2 in Hi5 cells using LMNG 
       I then proceeded to test how well TRPP2 behaves in the maltose-neopentyl glycol (MNG) 
class of detergents, which was used for the structural determination of TRPV2 by cryo-EM (12). 
This class of detergents is relatively new and has been reported to aid in the stabilization of 
membrane proteins for structural studies (30). MNG detergents have been reported to have a milder 
effect when stabilizing membrane proteins compared to DDM (39). Depending on the size of the 
prep, .5-4 liters of Hi5 insect cells were infected with the hTRPP2:199-927 virus when the cell 
density reached 2×106 cells/mL at 27°C. Seventy-two hours after infection, cells were harvested 
by centrifugation at 4°C. Cell pellets were suspended in a buffer containing 200 mM NaCl, 10% 
glycerol, and 50 mM Hepes pH 8.0 (buffer A) in the presence of the SIGMAFAST protease 
inhibitor cocktail (Sigma-Aldrich) and homogenized with a glass dounce homogenizer. The cells 
were then sonicated and clarified by ultracentrifugation at 45,000 r.p.m for 1 hr at 4°C. The 
pelleted cell membrane was resuspended in buffer A containing the SIGMAFAST protease 
inhibitor cocktail and further homogenized. The TRPP2 protein was then extracted with 1% Lauryl 
Maltose Neopentyl Glycol (LMNG, Anatrace) for 1 hr at 4°C. Subsequently, the solubilized 
membrane was subjected to ultracentrifugation at 45,000 r.p.m for 30 min at 4°C. The resulting 
supernatant was then incubated with amylose resin for 1 hr at 4°C. The resin was collected by 
centrifugation at 3,000 r.p.m, transferred to a gravity column, and washed with 15 column volumes 
of buffer A containing .003% LMNG. TRPP2 was eluted with the same buffer containing .003% 
LMNG and 40 mM maltose. The protein was then concentrated and further purified by SEC with 
a Superose 6 column equilibrated with SEC buffer containing .003% LMNG, 150 mM NaCl, and 





3.6.1  Reconstitution of TRPP2 into amphipols   
      Briefly, the eluted hTRPP2 protein was cleaved with TEV protease for 8 hr and the protein 
was then mixed with amphipol A8-35 at a 1:6 (w/w) ratio. After rotating the sample with amphipol 
for 6 hr, I added Bio-Beads sequentially every 1.5 hr using 15 mg per 1 ml channel/ 
detergent/amphipol mixture. After 10 hr, all the Bio-Beads were added and the sample rotated 
overnight at 4°C. The protein was then concentrated and subjected to SEC, utilizing a gel filtration 
buffer containing 150 mM NaCl and 20 mM Hepes pH 7.4 The protein appeared to have existed 
in multiple conformations and/or oligomeric states, resulting in a polydisperse protein peak (Figure 
8A). As seen in the preceding DDM SEC profiles, a prominent shoulder was present to the 
immediate left of the TRPP2 main SEC peak after reconstituion into amphipol (Figure 8A). 
According to an SDS-PAGE gel, the main peak fractions also contained TEV protease. 
      In a subsequent prep, upon cleavage with TEV I tried to separate TEV and MBP from TRPP2 
using cobalt beads. Theoretically, since both TEV and MBP are his-tagged they should bind to the 
cobalt beads after cleavage, and TRPP2 should not. However, TRPP2 also bound to the cobalt 
beads as well and was only eluted from the resin when imidazole was added. Therefore, it appeared 
that a strong interaction with TRPP2 and MBP was present, although they were able to be separated 
by gel filtration. Additionally, since a linker region containing the TEV protease-cleavage site was 
created right after the TRPP2 sequence in the expression vector, it is plausible that TEV protease 
was still able to bind quite tightly to this linker region of TRPP2, thus being present in the protein 
peak and subsequent gel.  
      Thereafter, since TEV could not be easily separated from TRPP2, MBP was not cleaved in the 
majority of subsequent preps. In Figure 8B, TRPP2-MBP was purified in a gel filtration buffer 





is 0.001% and the protein was stable after purification due to the presence of the relatively 
monodispersed peak. Since negative-staining of TRPP2 samples in 0.003% LMNG (3x above the 
CMC) generated bad ice, we subsequently tested how the protein behaved below the CMC of 
LMNG. 
      When TRPP2:199-927-MBP was reconstituted in amphipol A8-35 (Figure 8C), polydispersity 
in the main SEC peak containing TRPP2 was less evident than seen in the cleaved protein sample 
(Figure 8A), although the peak was still quite broad. Evidently, the presence of polydispersity in 
the TRPP2 main peak varied from one prep to another. However, despite the improvements in the 
quality of the protein, when the amphipol A8-35 samples were applied to negative-stain and EM 
grids the protein complex appeared to dissociate, exhibiting broken particles and high levels of 
aggregation. Similar results were seen when TRPP2 was solubilized in DDM and transferred to 























Figure 8. SEC traces of TRPP2 purified in LMNG and amphipol A8-35. (A) SEC trace of 
human TRPP2:199-927 after amphipol reconstitution in a buffer containing 150 mM NaCl and 20 
mM Hepes pH 7.4. TEV was also present in the main TRPP2 peak. (B) TRPP2:199-927-MBP 
purified in .0008% LMNG, 150 mM NaCl, and 20 mM Hepes pH 7.4. (C) SEC trace of human 
TRPP2:199-927-MBP after amphipol reconstitution purified in the same gel filtration buffer used 
in (A). MBP was not cleaved from TRPP2. From the left, the peaks correspond to tetrameric 





3.7  Titan Krios beta-testing phase at NYSBC 
 
      To produce suitable samples for cryo-EM analysis on the newly installed Titan Krios at 
NYSBC, LMNG was utilized during extraction and purification of TRPP2. The purification 
procedure for the TRPP2:199-927 protein was primarily the same as previously denoted, with 
slight modifications. The gel filtration buffer contained .0008% LMNG, 150 mM NaCl, 20 mM 
Hepes pH 7.4, and 2 mM TCEP. The protein peak fractions F11 and F10 were collected, avoiding 
the polydispersed region from E11 and E12 (Figure 9A). The protein eluted from the column at 
.6mg/ml in F10. Based on previous negative-stain experiments, the protein in the F10 fraction 
appeared to be more homogenous than in the F11 fraction.  
      The protein was then brought to our collaborators in the Khayat lab. Dr. Srivastava made 
negative-stain and cryo-EM grids to utilize during the beta-testing phase on the Titan Krios. 
Briefly, several microliters of the human TRPP2 protein (.45mg/ml) were loaded onto Protochip 
c-flat gold grids 1.2/1.3 and blotted for 3.0 s using a blot force of 1 at 100% relative humidity and 
4°C using Vitrobot Mark IV. The grids were then immediately plunged into liquid ethane cooled 
by liquid nitrogen. Micrographs were acquired by a Titan Krios microscope equipped with an FEI 
Falcon 2 direct electron detector. Dr. Khayat along with Dr. Srivastava both collected cryo-EM 
data on the microscope. Figure 9B illustrates a representative micrograph from the Titan Krios 
session.  















Figure 9. Representation of TRPP2 data collected on the Titan Krios. (A) Gel filtration profile 
of purified TRPP2 in .0008% LMNG. (B) Representative EM micrograph of human TRPP2:199-
927. Particles were selected by semi-automatic particle picking and subjected to 2D screening. (C) 
2D class averages of TRPP2 cryo-EM particles. (D) Enlarged 2D class average from (C) with the 






      Additionally, we also set up EM grids with the presumable TRPP2 agonist triptolide, 
mentioned in Chapter I. TRPP2 protein was incubated overnight with 10 µM of triptolide and EM 
grids were subsequently prepared and tested on the Titan Krios. It appeared that the particles with 
and without triptolide (Figures 10A, B) looked very similar, generating 2D class averages 
comparable to those seen in Figure 9. 
Figure 10. Cryo-EM particles of TRPP2 collected on the Titan Krios. (A-B) Illustrative 
micrographs of human TRPP2:199-927 with the presence (A) and absence (B) of triptolide.  
 
 
3.7.1  Analysis of TRPP2 particles 
      Upon analysis of the micrographs, it appeared that the particles exhibited a strongly preferred 
orientation, highlighting the top view of TM domain cross-sections (Figures 9C, D). 2D class 
averages are indicated in Figure 9C, while Figure 9D highlights the 2D class average with the most 
promising attributes. For the first time, 2D class averages revealed a distinct tetrameric structure 
exhibiting four-fold symmetry (Figure 9D). Moreover, subtle structural features within the 





      Routinely, 2D projections can subsequently be combined to generate a 3D reconstruction, only 
if enough particles in various orientations are available (38). Although the data we collected 
resulted in reasonable 2D class averages, 3D class averages and reconstructions were not able to 
be produced due to the lack of additional orientations. One factor that may have led to preferred 
particle orientation is that adsorption of TRPP2 particles to the air-water interface could have 
occurred (40). Within the time between blotting and freezing of the sample, Brownian motion 
could result in the colliding of particles at the air-water interface (40, 41). Since some particles 
tend to attach to the air-water interface in a preferred orientation, this phenomenon may have taken 
place in our samples.  
      The ice thickness may have also contributed to the preferred orientation of TRPP2. Although 
thinner ice is conducive to a better signal-to-noise (SNR) ratio, (42) it may also promote preferred 
orientations. When ice is thin on the EM grid, particles may become compressed between air-water 
interfaces when the layer of water encompassing the particle is too thin (40). Thicker ice, on the 
other hand, would affect the data collection by leading to higher background, limiting the ability 
to reach high-resolution. However, thicker ice could provide a greater range of orientations yet 
lower SNR due to increased ice contrast (42). Additionally, we had trouble seeing particles on EM 
grids that had thicker ice. 
      Furthermore, we primarily used protein in a detergent that was at or below the CMC, not only 
for EM grids used during the Krios session, but in general. Our rationale for staying below the 
CMC of the detergents was to prevent excess detergent particles from interfering with data 
collection. Moreover, the particles appeared to be of better quality when the detergent used was 
below the CMC, and the protein seemed stable after being run through the gel filtration column. 





affected the particles. For instance, the CMC of LMNG is .001% and the EM grids that we tested 
during the Krios session were below the CMC, at 0.0008 %.  
     Although it was a wonderful opportunity to test our samples on the Titan Krios at NYSBC, 
unfortunately the microscope was still in its initial beta-testing phase when we were in need of it 
most. Soon after, we initiated another collaboration with the laboratory of Dr. Xueming Li 
(Tsinghua University) in order to expedite the process of optimizing grid conditions to overcome 
the preferred orientation dilemma. Graduate students Heng Zhou and Xiaoyuan Zhou prepared the 
negative-stain and EM grids as well as collected and analyzed the data. Additionally, Dr. Minghui 
Li then became involved in the project for several months and aided with protein purification.  
 
3.8  Structural studies of the TRPP2 F604P mutant 
      As described in Chapter I, Arif et al. reported that F604P, a point mutation in the S5 
transmembrane domain of TRPP2, resulted in a constitutively open gain-of-function (GOF) 
channel when expressed in Xenopus oocytes (43). This finding was particularly of interest to us 
since we wanted to solve the structure of TRPP2 in an open state. Therefore, if indeed the protein 
was locked in an open state it could aid in the reduction of conformational heterogeneity, possibly 
enabling us to overcome the preferred particle orientation dilemma we were facing.  
      Subsequently, I introduced F604P by mutagenesis into the 199-927 truncation present within 
the pFastBac™ vector. This construct also contained hTRPP2 followed by a TEV protease 
recognition sequence site, an MBP tag, and an octa-histidine tag at the C-terminus. Additionally, 
the TRPP2 F604P protein was expressed and purified using the aforementioned protocol, with 
slight modifications. Initially, the gel filtration buffer used to purify the TRPP2 F604P-MBP 





      Figure 11A displays a similar SEC profile to that of the wild-type TRPP2-MBP protein (Figure 
9). This mutant protein also exhibited a slight shoulder adjacent to the main TRPP2 peak, 
indicating the possible presence of multiple oligomeric protein states. However, upon addition of 
soybean lipids (Avanti polar lipids), the level of polydispersity decreased (Figure 11B). Perhaps 
the soybean lipid aided in stabilizing the protein, yet the SEC profile was still quite broad. Soybean 
lipid was added to the elution buffer at a 1:5 ratio (soybean lipid to detergent) when the protein 
was eluted from the amylose resin. The gel filtration buffer contained .001% soybean lipid, .005% 
LMNG, 150 mM NaCl, and 20 mM Hepes pH 7.4.   
      In order to test the stability of TRPP2 in the presence of soybean lipids, two 500µl aliquots of 
protein were left at 4°C for 5 days after elution from the amylose resin. One of the samples was 
then run on the gel filtration column (Figure 11C) and the other was heated to 37°C to test its 
thermostability before being loaded onto the column (Figure 11D). The gel filtration buffer used 
for both these runs included the same components used to purify the protein illustrated in Figure 
11B. Notably, the proteins maintained their homogenous behavior and displayed monodispersed 
peaks as seen in the larger scale purification of TRPP2 in Figure 11B. Remarkably, the TRPP2 
protein was stable even after being heated to 37°C. Not only did this experiment indicate the 
stabilizing effect soybean lipids had on the TRPP2 F604P-MBP protein, but it also reassured us 












Figure 11. Gel filtration profiles of TRPP2 F604P purified with LMNG and soybean lipids.  
(A) Gel filtration profile of human TRPP2:199-927 F604P-MBP purified in a buffer containing 
.005% LMNG, 150 mM NaCl, and 20 mM Hepes pH 7.4. (B) Gel filtration profile of human 
TRPP2:199-927 F604P-MBP purified in a buffer containing .005% LMNG, 150 mM NaCl, and 
20 mM Hepes pH 7.4, with the addition of .001% soybean lipids. (C) Gel filtration profile of 
human TRPP2:199-927 F604P-MBP purified in the buffer indicated in (B). After elution from the 
amylose resin, the sample was stored at 4°C for 5 days before being run on the gel filtration 
column. (D) Same procedure utilized in (C), however, the protein was heated to 37°C before being 





      Therefore, since the SEC profiles looked promising for TRPP2:199-927 F604P-MBP in 
LMNG, especially in the presence of soybean lipids, I purified another batch of this protein and 
sent it to our collaborators at Tsinghua University. Of note, all negative-stain and grid preparations 
that will be discussed in the rest of this chapter were performed by the Li group at Tsinghua 
University. Additionally, the Li group ran the shipped protein samples through the gel filtration 
column so that the grids could be made with fresh protein. The samples were run on the size-
exclusion column in a buffer containing .0008% LMNG, 150 mM NaCl, and 20 mM Hepes pH 
7.4, with the addition of .0002% soybean lipids. However, although the SEC profiles of 
TRPP2:199-927 F604P-MBP in LMNG looked promising, the negative-stain and EM grids did 
not. These grids exhibited a fair amount of protein aggregates and the protein was not detectable 
in the EM grids (Figure 12), presumably due in part to the dissociation of the protein.  
 
 
Figure 12. Negative-stain and EM grids of the hTRPP2:199-927 F604P-MBP in LMNG (A-






      Similarly, upon analysis of the TRPP2 F604P-MBP protein reconstituted in amphipol A8-35, 
both the negative-stained and EM grids exhibited a large amount of broken or aggregated particles 
(Figures 13A, B). Within some grids, the ice appeared to be too thin, which may have exacerbated 
the particles, causing them to dissociate to a greater extent. However, although the protein 
displayed relatively monodispersed SEC profiles when reconstituted in amphipol, it appeared that 
the TRPP2 truncated proteins could not form stable tetramers and thus were not able to be used 
for structural analysis. We previously observed similar results from grids containing wild-type 
TRPP2 reconstituted in amphipol after being solubilized in DDM or LMNG.  It remains to be seen 
why our samples reconstituted in amphipol appeared to have exhibited dissociated particles when 
both negative-stain and EM grids were made. Interestingly, prior to setting up grids, the addition 
of detergent to the amphipol sample resulted in the re-association of the channel and the quality of 
particles present in the grids increased considerably. Therefore, for the 199-927 TRPP2 truncation, 









Figure 13. Negative-stain and cryo-EM grids of hTRPP2 F604P in amphipol A8-35. (A-B) 
Illustrative negative-stain EM (A) and cryo-EM image (B) of hTRPP2 F604P-MBP after 





      Nonetheless, it is important to consider that analysis of proteins by size-exclusion 
chromatography and SDS-PAGE does not necessarily predict how samples will behave when 
subjected to EM analysis. Therefore, the most effective way to assess the quality of a protein 
sample is to test it on negative-stain grids (42). Since images of particles are averaged together in 
order to obtain a 3D reconstruction, it is important for protein samples to be homogenous, 
especially to attain high-resolution. Yet preparing homogeneous samples for cryo-EM analysis 
remains challenging (41). 
3.9  Titan Krios data collected at Tsinghua University 
      Our collaborators at Tsinghua University next tested hTRPP2:199-927 samples purified in 
0.0008% LMNG, 150 mM NaCl, and 20 mM Hepes pH 7.4. Our goal was to try to obtain sharper 
2D class averages as well as to solve the particle orientation dilemma that we previously 
encountered. Just prior to making the grids, .2% glycerol was added to the purified protein sample 
in order to minimize particle aggregation. For creating EM grids, 4µl of the human TRPP2 protein 
(.5mg/ml) were loaded onto glow-discharged Quantifoil R1.2/1.3 holey carbon 400 mesh copper 
grids. The Vitrobot (FEI) was set at 100% humidity at 8°C and blotted for 3.5 s, blot force 0. The 
grids were then plunged into liquid ethane cooled by liquid nitrogen. Micrographs were 
subsequently acquired by a Titan Krios TEM equipped with a K2 Summit direct electron detector 
(Gatan). 
      2D classification of the particles was then carried out and 2D class averages (Figure 14C) 
highlighted common features of the particles. Based on these results, it was evident that the 
preferred orientation dilemma was still present, since we could not see any apparent side views. 





previously observed (Figure 9D), yet this view of TRPP2 demonstrated an improvement in overall 
particle quality. Notably, we were able to discern prominent features including the S1-S4 helices 
of the voltage sensing domain (outer periphery) as well as the central pore within TRPP2 (Figure 
14C). Collectively, our 2D class averages represent the TM domain cross-sections of TRPP2 in 
great detail and are very similar to a view seen in the solved TRPP2 structure as reported by 
Grieben et al. (16). 
      Besides adding glycerol to the samples, we used other additives upon grid preparation in order 
to overcome the preferred particle orientation dilemma. Of note, in a previous study reporting the 
ryanodine receptor (RyR1) in its closed state 0.2% of fluorinated octyl-maltoside, a non-
solubilizing detergent, was applied to the protein buffer prior to setting up the EM grids (44). 
Fluorinated octyl-maltoside can presumably enhance protein distribution within vitreous ice (44). 
Therefore, we also used this detergent to assess whether it too could improve the distribution of 
TRPP2 particles. However, this did not ameliorate the quality of the particles to a great extent. 














Figure 14. Cryo-EM analysis of hTRPP2:199-927 in LMNG. (A-B) Representative negative- 
stain image (A) and electron micrograph (B) of human TRPP2:199-927 in .0008% LMNG. Ice 
particles were also present within the EM grids. Protein particles were selected and subjected to 
2D screening. (C) Enlarged views of representative TRPP2 2D class averages, highlighting 
detailed features of the tetrameric channel. (D) Ribbon representation of the TRPP2 tetramer as 
reported by Grieben et al. (16). Voltage sensing domain S1-S4 helices are depicted in light blue, 
and the pore domains (S5, pore helix 1, pore helix 2, S6) are denoted in dark blue. The linker 
domain between S1 and S2 is displayed in orange and yellow. Glycosylation sites are indicated by 
sticks. Notably the S1-S4 helices are clearly visible within (C), resembling the architecture of the 





3.10  Comparison of methods used for TRPP2 structural studies 
      Initially, Shen et al. (15) reported the first TRPP2 cryo-EM structures at 3Å resolution in a 
closed conformational state from three N- and C-terminally truncated constructs reconstituted into 
amphipols and nanodiscs (Figure 15). Thereafter, Grieben et al. (16) also published a closed state 
TRPP2 cryo-EM structure at 4.2 Å of a truncated construct (Figure 15). Of note, Grieben et al. 
(16) also collected X-ray crystallography data of TRPP2, yet at a lower resolution, 5.5 Å. 
Additionally, Wilkes et al. also reported TRPP2 cryo-EM structures at 4.2 Å and 4.3 Å, purportedly 
displaying open conformational states of the full-length channel. Thus, this section serves to 
analyze the differences in methods implemented by these three independent research groups as 
well as our group for structural determination of TRPP2.  
 
3.10.1  Constructs and protein purification methods   
Cytoplasmic domains of TRPP2 are not necessary for structural stability  
      After analysis of these publications, what we found to be most striking is that the human 
TRPP2 structures remained stable without their C-terminal cytoplasmic domains, especially the 
coiled-coil domain, and the structures were solved without their presence. Like all other TRP 
channels, TRPP2 formed a tetrameric structure (15–17). Yet, as previously mentioned, TRPP2 has 
been found to form trimers when expressed in Xenopus oocytes in HEK293 cells (3). Additionally, 
the coiled-coil domain was shown to be necessary for the homomeric assembly of TRPP2 (3). 
Therefore, I always created truncations that included this domain in order to presumably stabilize 






      As indicated in Figure 15, Shen et al. made use of a hTRPP2:198-703 construct, which did not 
include the EF-hand domain as well as two other constructs TRPP2:198-792 and TRPP2:53-792, 
which did contain these domains. Interestingly, all three of the reported TRPP2 structures 
determined by Shen et al. (15) were superimposable and very similar with no additional densities 
present for the EF-hands in any of the structures. These findings suggest that the intracellular 






        








Figure 15. Schematic diagram displaying constructs utilized in TRPP2 structural studies. 
hTRPP2:1-968 was used by Wilkes et al. (17); hTRPP2:53-792, 198-792, and 198-703 were used 
by Shen et al. (15); hTRPP2:185-723 was utilized by Grieben et al. (16); and hTRPP2:199-927 
was used in the Yang lab. Diagram modified from (15). 
 
      Notably, the densities of the termini within the structures reported by all three groups could 
not be elucidated. Of note, the hTRPP2:199-927 construct that I utilized included the coiled-coil 
domain. Thus, this region was likely to be flexible as well, since Wilkes et al. utilized the full-





(17). Additionally, the hTRPP2:199-927 truncation that I utilized was very similar at the N-
terminus to the other truncations used for structural determination.       
      Furthermore, it has been reported that conformational changes within NMR structures of the 
EF-hand domain occurred upon binding of calcium (4). Taken together, although the C-terminal 
domains were not able to be resolved in the various TRPP2 structures due to their flexibility, it 
remains to be seen what role the N- and C-terminal domains play in the overall TRPP2 channel. 
Moreover, it is apparent that the presence of these domains did not produce significant 
heterogeneity in the protein samples to hinder structural analysis. 
      Table 1 indicates the methods implemented in various TRPP2 studies to express, purify, and 
analyze protein samples using cryo-EM. However, it is important to note that many parameters 














Table 1.  Protein purification procedures for structural studies of TRPP2 







Table 1 (continued) 
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Expression systems and glycosylation 
      It appears that in the case of purifying TRPP2, HEK293S GnTI-/- and HEK293S GnTI- cells 
are the most preferable expression systems, followed by Sf9 cells, and Hi5 cells. In agreement 
with our findings, Grieben et al. (16) also demonstrated that it is not necessary to purify TRPP2 in 
HEK cells, yet, since this system provides a more native environment for the protein, it appears to 
be beneficial. However, we did not have the capability or resources to perform large-scale 
purification from HEK cells in our lab. Interestingly, Grieben et al. (16) purified protein from 24 
liters of Sf9 cells instead of Hi5 cells, even though Hi5 cells have been shown to produce protein 
at a higher yield (27). Thus, I primarily used Hi5 cells for protein expression and could obtain 
good protein yield from a few liters of culture.  
      It has been reported that glycosylation of TRPP2 is key for its stability and trafficking (36). As 
previously mentioned, five N-glycosylation sites are present within TRPP2 (Asn299, Asn305, 
Asn328, Asn362, and Asn375) which reside within the linker domain present between the first two 
transmembrane segments of the channel (36). The structural implications of the presence of 
glycosylation sites in TRPP2 will be further elucidated in Chapter IV. While Shen et al. (15) and 
Wilkes et al. (17) expressed TRPP2 in HEK293S GnTI-/- and HEK293S GnTI-  cells, respectively, 
Grieben et al. (16) performed extensive enzymatic deglycosylation using α-L-fucosidase and 
PNGase. However, residual oligosaccharides were present within the structures (15–17). Of note, 









Detergents and lipids 
      The choice and use of detergents during protein purification and EM sample preparation 
appeared to have played an important role in the overall success of this project. Since the MNG 
family of detergents are relatively new, the use of LMNG for cryo-EM analysis has not been 
extensively studied. Although Wilkes et al. solubilized TRPP2 in LMNG, the protein was later 
reconstituted in amphipol and EM grids were not made with LMNG (17). Alternatively, Grieben 
et al. solubilized TRPP2 in DDM, yet set up EM grids using the UDM (n-Undecyl-β-D-
maltopyranoside) detergent (16). Of note, UDM has one less carbon than DDM in its chemical 
structure. Presumably, Grieben et al. screened through various detergents to find the most 
promising one for structural studies.  
      Most of our efforts were geared towards optimizing the detergent concentration conditions 
used during protein purification as well as grid preparation. Since samples solubilized in DDM 
and LMNG had promising SEC profiles, we primarily focused on testing these two detergents. 
Although we conducted additional experiments to determine the stability of TRPP2 when 
solubilized in additional detergents including OG, CHAPS, and DMNG, cryo-EM analysis of these 
samples were not extensively tested. However, our findings indicated that DDM in general was 
not a suitable detergent for cryo-EM analysis and LMNG may not be conducive to the proper 
distribution of particles. Therefore, these findings may demonstrate why DDM and LMNG 
detergents were not used during EM grid preparation by other groups. Thus, these observations 
underscore the need to test a wide variety of detergents in order to asses which are most suitable 







      Notably, lipids were visible in the TRPP2 structures described by Shen et al. (15) and Wilkes 
et al. (17). I recently started incorporating soybean lipids into my purification protocols, which 
presumably helped to stabilize the channel. Upon the addition of soybean lipids, although the gel 
filtration profiles of both the wild-type and mutant (F604P) TRPP2 constructs demonstrated 
greater monodispersity than without the presence of lipids, the protein particles seemed to be 
similar when tested on cryo grids.  
 
Gel filtration profiles of TRPP2 
      Upon observation of the gel filtration profiles of TRPP2 reported by Shen et al. (15), Wilkes 
et al. (17), and our research group, several patterns are apparent (Figure 16). Notably, the gel 
filtration profile from the TRPP2:199-927 protein reconstituted in amphipol A8-35 that I purified 
(Figure 16E) is similar to the profiles reported by the other groups (Figures 16A, D). However, the 
amphipol A8-35 profiles displayed by Shen et al. and Wilkes et al. had peaks that appeared to be 
more monodispersed, indicating samples with greater homogeneity. Additionally, the gel filtration 
profile for the TRPP2:199-927 protein in .0008% LMNG (Figure 16F), our most promising sample 
for structural analysis, seemed to be broader than when reconstituted in amphipol A8-35 (Figure 
16E) and had the broadest peak overall. Furthermore, it appears that the hTRPP2 proteins 
reconstituted in lipid nanodiscs (Figures 16B, C) resulted in a larger amount of aggregated protein 
compared to hTRPP2 samples reconstituted in amphipol A8-35 (Figures 16A, D).  















Figure 16. Comparison of gel filtration profiles of hTRPP2. (A-C) Gel filtration profiles 
reported by Shen et al. (15) of hTRPP2:53-792 in amphipol A8-35 (A), hTRPP2:198-792 in lipid 
nanodiscs (B), and hTRPP2:198-703 in lipid nanodiscs (C). (D) Gel filtration profile of full-length 
hTRPP2:1-968 in amphipol A8-35 shown by Wilkes et al. (17). (E) Gel filtration profile of 
hTRPP2:199-927 in amphipol A8-35 purified in our lab. (F) Gel filtration profile of hTRPP2:199-







3.10.2  Parameters for cryo-EM analysis  
Table 2.  Sample preparation and cryo-EM data acquisition parameters for TRPP2 studies 








                    





          References             (15)                   (16)                     (17)     
     
      Table 2 illustrates the parameters used for sample preparation and cryo-EM data acquisition, 
after the proteins were purified using size-exclusion chromatography. Of note, the Yang and Li 
group column refers to the parameters used by our collaborator at Tsinghua University. Markedly, 





than the concentrations used by other groups. This may have played a role in the overall quality of 
the grids that we observed.  
      Representative EM micrographs from the various research groups are illustrated in Figure 17. 
Notably, our micrograph denoted in Figure 17D contains particles that look similar to those present 






Figure 17. Representative micrographs of human TRPP2. (A-D) Representative EM 
micrographs of TRPP2 samples from various research groups. (A) hTRPP2:198-703 in lipid 
nanodiscs reported by Shen et al. (15). (B) hTRPP2:1-968 in amphipol revealed by Wilkes et al. 
(17). (C) hTRPP2:185-723 in 0.035% UDM depicted by Grieben et al. (16). (D) hTRPP2:199-927 






      After data collection from the micrographs, TRPP2 particles were subjected to analysis and 
2D class averages were generated (Figure 18). Although other groups obtained 2D class averages 
exhibiting particles in multiple random orientations (Figures 18A-E) as previously mentioned, the 

























Figure 18. 2D class averages of human TRPP2 cryo-EM particles. (A-C) 2D class averages 
reported by Shen et al. (15) of hTRPP2:198-703 in lipid nanodiscs (A), hTRPP2:198-792 in lipid 
nanodiscs (B), and hTRPP2:53-792 in amphipol A8-35 (C). (D) Representative 2D class averages 
of  hTRPP2:185-723 in 0.035% UDM reported by Grieben et al. (16). (E) 2D class averages of 
hTRPP2:1-968 in amphipol A8-35 revealed by Wilkes et al. (17). (F) Representative 2D class 
averages of hTRPP2:199-927 in .0008% LMNG, purified in our lab, illustrating detailed features 





      Essentially, the top view seen in our sample (Figure 18F) seemed to have the highest quality 
features for this particular orientation, while the other 2D class averages with the same view 
appeared blurry. Notably, the four-fold symmetrical axis in the tetramer is clearly visible from the 
2D class averages of hTRPP2:199-927, highlighted by distinctive S1-S4 helices and the central 
pore.  
 
3.11 Analysis of new constructs reconstituted into nanodiscs and amphipols 
      I was still optimizing methods in order to overcome the preferred orientation dilemma for the 
TRPP2 F604P protein when the first TRPP2 structure was published. I then made additional 
truncations removing the C-terminal coiled-coil domain, yet keeping the EF-hand domain. The 
TRPP2 F604P-MBP:181-787 construct was expressed and purified in DDM as previously 
described, with modifications. Consequently, the protocols for the reconstitution of TRPP2 in 
nanodiscs were adapted from Shen et al. and Gao et al. (10, 15). In brief, soybean polar lipid extract 
was rehydrated by sonication in the buffer utilized to elute the protein, producing a clear lipid stock 
at 10 mM concentration. The MSP2N2 membrane scaffold protein was expressed and purified 
from E. coli as previously reported (45). Purified TRPP2 channel (1 mg/ml) solubilized in 0.5 mM 
DDM was then combined with MSP2N2 (170 - 250 mM) and the soybean lipid stock at a 1:1:200 
molar ratio. This mixture was then incubated on ice for 30 min. Subsequently, Bio-Beads were 
added to remove DDM at 1 hr time intervals for a total of four batches. The sample was gently 
rotated at 4°C.  
      TEV protease was then added in combination with the final batch of Bio-Beads followed by 
sample incubation overnight at 4°C. Bio-Beads were then removed and the nanodisc reconstitution 





containing 150 mM NaCl, 10 mM HEPES, and 2 mM CaCl2 pH 7.4. Of note, calcium chloride 
was added in all buffers during purification, adapted from Shen et al. (15), since it was suggested 
that calcium can stabilize the EF-hand domain (4, 6).  
      However, upon SEC analysis of the nanodisc sample, the main included peak corresponding 
to tetrameric TRPP2 was quite broad and not monodispersed, suggestive of heterogeneity in the 
sample (Figure 19A). Nonetheless, this peak was further assessed by preparing and testing 
negative-stain and cryo-EM grids (Figures 19B, C). The cryo grids were generated with 1.9 mg/ml 
of TRPP2 sample. Yet, there appeared to be a fair amount of aggregation in the EM grids (Figure 
19C). Therefore, the parameters we used to purify and analyze the sample needed to be further 





Figure 19. Analysis of TRPP2 reconstituted in nanodiscs. (A) Gel filtration profile of hTRPP2 
F604P:181-787 after reconstitution in lipid nanodiscs indicates a heterogeneous sample. 
Demonstrative negative-stain (B) and cryo-EM (C) micrographs of TRPP2 illustrating aggregated 





      Additionally, the hTRPP2 F604P:185-723 construct was also generated based on the truncation 
used by Grieben et al. (16). This protein was purified in parallel with either DDM or LMNG as 
previously mentioned. The hTRPP2 F604P:185-723 truncation contained the EF-hand domain but 
lacked the coiled-coil domain. The eluted TRPP2 protein was mixed with amphipol A8-35 at a 1:6 
(w/w) ratio and subsequently incubated overnight with gentle agitation at 4 °C. To enable the 
substitution from detergent to amphipol to occur, the sample was incubated with Bio-Beads for 
8 hr. After removal of Bio-Beads, TEV protease was added to the protein sample and incubated at 
4°C overnight. TRPP2 proteins were then concentrated by centrifugation prior to loading onto the 
Superose 6 gel filtration column. This method for reconstitution of TRPP2 in amphipols was 
adapted from Shen et al.(15).  
      The hTRPP2 F604P:185-723 samples that were solubilized in LMNG and reconstituted in 
amphipol appeared to have had greater monodispersity in their gel filtration profiles (Figures 20D, 
G) rather than when TRPP2 was first purified in DDM and then transferred to amphipol (Figure 
20A). The presence or removal of the MBP tag did not appear to play a major role with regard to 
the monodispersity of the samples (Figures 20D, G). However, removal of the MBP tag (Figures 
20G-I) in samples that were solubilized in LMNG and transferred to amphipol led to protein 
particles that were less aggregated and dissociated (Figure 20I), compared to samples when the tag 
was not removed (Figure 20F). Nonetheless, the cryo-EM samples in amphipol were not as suitable 
for analysis as were those in LMNG, despite the greater level of monodispersity in the amphipol 
samples.  










Figure 20. Assessment of the homogeneity of TRPP2 F604P. (A) Gel filtration profile of 
hTRPP2 F604P:185-723 after being purified in DDM, reconstituted in amphipol, and cleaved with 
TEV. Negative-stain (B) and EM micrographs (C) of hTRPP2 F604P:185-723 purified in (A) are 
indicated. The protein concentration used to make the EM grids was .96 mg/ml. (D) Gel filtration 
profile of hTRPP2 F604P-MBP:185-723 after being purified in LMNG and reconstituted in 
amphipol, without being cleaved with TEV. Notably, the TRPP2 tetrameric peak is monodisperse 
and therefore homogeneous. Negative-stain (E) and cryo-EM images (F) of hTRPP2 F604P-MBP: 
185-723 purified in (D). 1mg/ml of protein was used to generate the EM grids. (G) Gel filtration 
profile of purified hTRPP2 F604P:185-723 after exchange from LMNG to amphipol, and being 
cleaved with TEV. The TRPP2 protein peak is monodisperse and purified to homogeneity. 
Negative-stain (H) and electron micrographs (I) of hTRPP2 F604P-MBP:185-723 purified in (G). 
2mg/ml of protein sample was used to make cryo-EM grids for data collection.  
 
      Interestingly, less aggregation was present in the negative-stain micrographs of purified 
hTRPP2 F604P:185-723 in amphipol (Figures 20B, E, H) compared to the negative-stain images 
of purified hTRPP2 F604P-MBP:199-927 in amphipol (Figure 13A). The 185-723 truncation may 
have played a role in stabilizing the protein in amphipol and creating greater homogeneity in the 
sample, as seen in both the gel filtration profiles and the negative-stain grids (Figure 20). However, 












3.12  Summary  
      Structural determination of membrane proteins has and remains to be inherently challenging 
(46). Due to the intrinsic nature of membrane proteins, various barriers exist including obtaining 
a sufficient amount of protein as well as finding conditions that stabilize the protein in a correctly 
folded state. Although we were able to overcome these barriers, the preferred orientation exhibited 
by the TRPP2 particles was by far the greatest obstacle we had to surmount in the TRPP2 project.    
      Heterogeneity is a main problem that all structural biologists must overcome with their 
samples. It became apparent to us that heterogeneity may not only significantly hinder the 
crystallization of a protein, but also cryo-EM analysis of a sample as well. Therefore, it is important 
to have homogeneity in the sample, although some heterogeneity can prove to be beneficial to 
provide alternative conformational states. The homogeneity of the TRPP2 protein samples varied 
from one protein prep to another and was assessed by a variety of techniques including FSEC, 
SEC, and SDS-PAGE prior to preparing negative-stain and EM grids. Hence, we pursued 
structural analysis with the samples that looked most promising.  
      Our most significant finding was obtaining a view of hTRPP2-MBP:199-927 that contained 
highly detailed structural features. Remarkably, looking down the four-fold symmetrical axis in 
the 2D class averages, we were able to clearly see the central pore as well as the S1-S4 helices 
within the tetramer. However, the distribution of the particles appeared to be too homogeneous in 
our case. Hence, the particles exhibited a strongly preferred orientation impeding us from moving 
forward to create a reasonable 3D reconstruction due to the lack of particles in additional 
orientations. 
      Since protein purification and sample preparation requires a series of steps and includes many 





orientation dilemma that we had to overcome. Over time, the protein preps were optimized by 
altering a number of parameters including the protein truncations, detergents, buffer solutions, and 
lipid concentrations. One of the primary factors that likely contributed to the presence of the 
preferred particle orientation was the type of detergent utilized during protein purification and 
sample preparation, primarily DDM and LMNG. Of note, during small-scale preps with DDM or 
LMNG, the SEC TRPP2 peaks appeared more monodispersed compared to protein purified in 
large-scale preps. Therefore, an increase in protein concentration led to greater heterogeneity of 
the samples. Hence, although TRPP2 was stable below the CMC of the detergents, upon SEC 
analysis, it appeared that DDM or LMNG detergents were not very suitable for cryo-EM analysis. 
EM grids that contained DDM did not exhibit good particles, while EM grids containing LMNG 
displayed particles with a particular particle orientation. Studies to further investigate how to 
address the preferred orientation conundrum in the TRPP2 F604P samples are currently underway.  
      Moreover, additional factors may have resulted in the heterogeneous samples we were 
obtaining. Protein truncations, glycosylation, and the expression systems implemented could also 
play a role in the proper folding of TRPP2 and may have contributed to the heterogeneity of the 
sample. Of note, the amphipol dilemma I originally encountered during purification, whereby 
TRPP2 was precipitating out of solution upon amphipol reconstitution, was resolved. The 
amphipol reconstitution protocol was optimized by altering the concentration of amphipol utilized 
and adding Bio-Beads in batches to stabilize the protein during reconstitution. However, TRPP2 








3.13  Conclusion 
      New technological advances in the field of single-particle cryo-EM provide an excellent 
opportunity for high-resolution structural determination of membrane proteins. Overall, the 
structural investigations described in this chapter provide valuable insights into the optimization 
of the TRPP2 protein purification and sample preparation procedures necessary to obtain a high-
resolution cryo-EM structure. However, although we made great strides towards producing human 
TRPP2 protein with suitable yield and purity for cryo-EM analysis, a major obstacle that we 
needed to overcome in order to obtain a 3D model of the protein was the preferred orientation that 
TRPP2 was fixed in. It remains to be determined what factors specifically caused the preferred 
particle orientation. Despite my ambitious efforts to obtain a cryo-EM structure of human TRPP2, 
additional research groups published high-resolution structures of the same protein. A detailed 
understanding of the solved TRPP2 channel structures will be described in Chapter IV. These 
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Chapter IV  
Analysis of TRPP2 Structures 
 
4.1  Introduction 
      As aforementioned, three research groups recently solved cryo-EM structures of TRPP2. The 
methods utilized to purify these proteins were discussed in Chapter III. The aim of this chapter is 
to provide a detailed understanding of the structural features of TRPP2. Furthermore, comparisons 
between the solved TRPP2 structures as well as their respective ion-permeation pathways will be 
elucidated.    
 
4.2  General architecture of the TRPP2 structures 
      Like other TRP channel structures (1–3), the structure of TRPP2 (4–6) is tetrameric and 
contains six transmembrane helices (Figures 1A, C). The transmembrane region of each TRPP2 
monomer contains a voltage-sensing domain (VSD) which includes the S1 to S4 helices, and a 
pore domain consisting of the S5 and S6 helices (Figure 1B) (4). In addition, the S4-S5 linker joins 
the VSD and pore domains (4). Moreover, a P-loop structure exists between S5 and S6, which 
comprises pore helix 1, a pore filter (Leu641-Gly642) (Figure 8B), and pore helix 2 (5). Within 
the tetramer, each VSD domain in one monomer participates in ‘domain swapping’ with the pore 
domain of the adjacent monomer (4). Although all three determined TRPP2 structures share 







Figure 1. Cryo-EM structure of human TRPP2 in lipid nanodiscs. (A) View of TRPP2 in a 
closed state conformation from the side (left) or bottom (right). Each monomeric subunit within 
the tetramer is color coded. Densities of the nanodisc (gray) and of lipids (purple) are also 
indicated. (B-C) Ribbon representations of the TRPP2 monomeric (B) and tetrameric structures 






4.3  Extracellular polycystin-mucolipin domain in TRPP2 
      Notably, an extracellular linker is present within TRPP2, which is also a characteristic feature 
of TRPML channels (7). Shen et al. erroneously mentioned that this domain is limited to the 
PKD2s, PKD1, and PKD1-like proteins (4, 8). In fact, all three research groups that solved the 
TRPP2 structures (4–6) failed to acknowledge that the TRPML subfamily exhibits this domain. 
The research groups referred to this linker as the polycystin domain (4) or the tetragonal opening 
for polycystin (TOP) domain (5, 6). Instead, we hereby propose that the I–II linker domain in 
TRPP2 be regarded as the ‘polycystin–mucolipin domain’ (9) due to its structural similarity in 
both TRPP2 and TRPML1 (Figures 4, 5). Henceforth, the I-II linker domain in TRPP2 and 
TRPML1 will be referred to as the polycystin–mucolipin domain in this chapter. 
 
4.3.1  Structural features of the polycystin-mucolipin domain 
      The polycystin-mucolipin domain in TRPP2 comprises 219 amino acid residues (Ser244-
Leu462) positioned in three α helices (α1–α3) and a central five-stranded anti-parallel β-sheet (4, 
5). Of significance, the polycystin-mucolipin domain in TRPP2 is a tetramer, similar to that of the 
corresponding domain in TRPML1 (9). Additionally, three β-hairpins are situated at ~ 90° intervals 
(Figures 2A, B) (5). Since these structural elements are reminiscent of a three-leaf clover (TLC), 
these β-hairpins can be referred to as TLC 1-3 (Figures 2A, B) (5). Furthermore, TLC 1-3 interacts 
with adjacent polycystin-mucolipin domains, the S3–S4 extension, and the pore, enabling 




Figure 2.  Polycystin–mucolipin domain structure of TRPP2. (A) Schematic demonstrating the 
VSLD (voltage-sensor-like domain) in light blue, PD (pore domains) in dark blue, and polycystin–
mucolipin domain (orange and yellow). The helices, β-strands, and glycosylation sites in the 
polycystin–mucolipin domain are depicted by cylinders, arrows, and hexagons, respectively. (B) 
Perpendicular orientations of the polycystin–mucolipin domain. The five-stranded β-sheet, β1-5, 
is indicated in yellow while the three α-helices (α1–3) are denoted in orange. The TLC extension 
(dark red) includes a long loop between β1 and β2 generating three β-hairpins (TLC1–3). 
Glycosylation sites, NAG 3–5, are indicated in pink. Figure adapted from (5). 
 
      Moreover, extensive inter- and intra- subunit interactions are established within the polycystin-
mucolipin domain that aid in stabilizing the structure. For instance, TLC 1 and the β4-β5 turn of 
one subunit interacts with the β3-β4 turn and the α1 helix from the polycystin-mucolipin domain 
of an adjacent subunit (Figure 3A) (4). Furthermore, the β4-β5 turn also interacts with α1 of an 
adjoining domain through hydrogen bonding between Thr448 and Tyr248 (Figure 3A). Evidently, 
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the polycystin-mucolipin domain appears to play a role in channel assembly, due to the presence 
of extensive associations with the polycystin-mucolipin domain in adjacent subunits (4). In 
addition, the polycystin-mucolipin domain associates with the TRPP2 transmembrane core at the 















Figure 3. Interactions in the polycystin–mucolipin domain affecting tetrameric assembly. (A) 
Left, TLC 1 and the β4-β5 turn of one subunit (blue surface representation) interacts with the β3-
β4 turn and the H1 helix (α1), indicated in yellow, from the polycystin-mucolipin domain of an 
adjacent subunit (ribbon). Right, enlarged view of interactions. (B) The polycystin–mucolipin 
domain (blue surface representation) associates with transmembrane segments (ribbons) at the pre-
S6 loop and the helix turn indicated by the magenta boxes. Figure adapted from (4). 
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4.3.2  Comparison of polycystin–mucolipin domains  
      The structure of the polycystin-mucolipin domain in TRPP2 is similar to the overall 
architecture of the TRPML1 I-II linker (Figure 5A) (9), as detailed in Chapter II. Although the 
polycystin–mucolipin domains of TRPML1 and TRPP2 include varying primary sequences 
(Figure 4), in general, they exhibit very similar tetrameric structures (Figure 5A). Notably, in 
TRPML1, the luminal pore loop projects downward toward the ion-selectivity filter, while this 
loop in TRPP2 is positioned upward in the vicinity of the luminal/extracellular environment 
(Figure 5C) (9). When the TRPML1 I-II linker was docked onto the full-length TRPP2 structure 
(Figure 5E), it appeared that a continuous α-helix was created from α1 of TRPML1 and S1 of 
TRPP2. In addition, both polycystin-mucolipin domains in TRPML1 and TRPP2 contain several 
N-linked glycosylation sites. These sites are present in TRPML1 at residues 159, 179, 220, and 





















Figure 4. Sequence alignment of the TRPML1 and TRPP2 polycystin-mucolipin domains. 
The amino acid sequences of the TRPML1 and TRPP2 polycystin-mucolipin domains are 
illustrated. Secondary structural elements are indicated in orange and green corresponding to 
TRPML1 and TRPP2, respectively. Red residues highlight luminal pore-loop aspartates. Identical 






Figure 5. Structural comparisons of the polycystin–mucolipin domains. (A-C) Overlay of the 
tetrameric polycystin–mucolipin domain structures of human TRPML1 at pH 6.0 (orange) and 
human TRPP2 (green) illustrated from above (A) or parallel (B-C) to the membrane surface. The 
α1 helix is prominently displayed in (B) and (C). (C) Superimposed peripheral regions from the 
tetrameric structures in (B) indicating varying orientations of the luminal pore-loop. Structures 
viewed from the membrane surface contain a luminal pore-loop directed upward (in TRPP2) or 
downward (in TRPML1). (D) Overlay of the monomeric structures of the polycystin–mucolipin 
domain in TRPML1 and TRPP2, denoting the alignment of α-helices and β-sheets. (E) Docking 
of the TRPML1 polycystin–mucolipin domain (PDB code:5TJA) onto the TRPP2 structure (PDB 
code:5T4D). Ribbon representations highlight the side views parallel to the surface of the 
membrane. (A-D) were produced using PyMOL and reported by Li et al. (9) and (E) was generated 




4.4  Structural features of TRPP2CL, TRPP2MI, and TRPP2SI 
      The structures of the closed conformational state of TRPP2, determined by Shen et al. (4) and 
Grieben et al. (6) will hereafter be referred to as TRPP2CL. The cryo-EM structure of the closed 
state is indicated in Figures 1 and 6. Additionally, the full-length human TRPP2 open state 
structures, solved by Wilkes et al. (6) will be regarded as TRPP2SI (single-ion state) and TRPP2MI 
(multi-ion state). As indicated by Figure 6, conformational differences exist between the TRPP2CL 













Figure 6. Comparison of the closed and open conformational states of TRPP2. (A-B) Ribbon 
representations illustrating the superposition of the TRPP2CL (4) (pink) and TRPP2SI (6) (purple) 
tetrameric structures. Orientations of the structures are illustrated parallel to the membrane surface 
(A) as well as from the extracellular side of the membrane looking down the luminal pore (B). 
Cations positioned along the translocation pathway are specified by green spheres. Illustrative 
representations of the structures were generated using Chimera (12) with PDB codes:5T4D 
(TRPP2CL) and  5MKE (TRPP2SI).        
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      Moreover, both the open TRPP2MI and TRPP2SI structures (6) are in complex with cations and 
are distinctly different from each other as well as from the closed state TRPP2CL structure, 
particularly in the S4-S5 linker (4–6). Notably, the structures of TRPP2MI  and TRPP2SI differ from 
one another in various sections including the polycystin–mucolipin domain, in a loop between S2 
and S3, and in a linker between S4 and S5 (Figure 7) (6). The S4-S5 linker within TRPP2SI likely 
associates with α4 residues located in the EF-hand, consequently leading to a conformational 

















Figure 7. Cryo-EM structures of human TRPP2 in open conformational states. (A) Ribbon 
representations demonstrating the tetrameric structures of TRPP2SI  (6) (A) and TRPP2MI (6) (B). 
The TRPP2SI structure is denoted in light blue and the TRPP2MI structure is indicated in orange. 
The structures are oriented parallel to the membrane surface. (C) Overlay of TRPP2SI and TRPP2MI 
structures. Cations located along the translocation pathway are illustrated by green spheres. 
Structural representations were created utilizing Chimera (12) with PDB codes 5MKE and 5MKF 




4.5  Characteristics of the ion-translocation pathway in TRPP2CL 
      In both the TRPP2CL structures, it is apparent that the two gates,  present at the selectivity filter 
and the S6 region, are captured in a closed non-conductive state (Figures 1, 6) (4, 5). Primarily, 
cations present in the ER lumen or extracellular environment are able to flow into the upper 
vestibule of TRPP2 through the 9 Å wide opening at the center of the polycystin-mucolipin domain 
(5). Moreover, four lateral openings serve as additional entry points for cations (Figure 8A) (5). 
Furthermore, eight acidic residues from each monomer are present in this vestibule rendering this 
region highly negatively charged (Figure 8D) (4, 5). These negatively charged side chains likely 
aid in repelling anions while attracting and accumulating cations to improve ion conduction 
(Figure 8D) (4, 5). 
      The selectivity filter between pore helices 1 and 2, which encompasses Leu641, Gly642, and 
Asp643, is one gate that impedes the movement of hydrated cations in the closed state (Figures 
8B, C) (4).  Notably, Leu677 and Asn681 establish the narrowest region of the lower gate (Figures 
8B, C), obstructing the conduction of hydrated cations (4). Interestingly, the upper gate at the 
selectivity filter as well as the lower gate are presumably allosterically regulated by a network of 
interactions (Figure 8E) (4). As indicated in Figure 8E, these associations are likely to be formed 
by residues of one monomer at the selectivity filter and pore helix 1 (Leu641 and Arg638, 
respectively) and residues from an adjacent monomer in pore helix 2 and the S6 helix (Phe661 and 














Figure 8. Configuration of the TRPP2CL pore. (A) Views of sliced molecular surfaces colored 
by electrostatic potential from the membrane surface (left) and down the four-fold symmetry axis. 
Pore openings, vestibules, and gates are indicated by numbers 1-6. Yellow dashed lines highlight 
the openings leading to the pore (5). (B) Ion permeation pathway within the pore. Notable residues 
at the selectivity filter and lower gate are depicted as sticks. (C) Calculations of the pore radius. 
(D) Presence of negatively charged residues colored by surface electrostatic potential at the outer 
pore region (left). Negatively charged aspartate and glutamate residues are displayed as sticks 
(right). (E) Interactions coupling the selectivity filter and pore helix 1 of one monomer with S6 
and pore helix 2 of an adjacent monomer. Figure adapted from Grieben et al. (A) (5) and Shen et 
al. (B-E) (4).  
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4.6  Ion-translocation pathways in TRPP2MI and TRPP2SI  
 
      TRPP2MI contains a restricted entrance gate from the extracellular surface of the membrane at 
Thr265 and Lys267 within the Cat0 site (Figures 9C, 10A, 10C). In TRPP2MI, the entrance gate 
has a radius of 3.0 Å compared to the wider gates in TRPP2CL (4.4 Å) (5) and TRPP2SI (4.7 Å) 
(Figure 9C) (5, 6). Figures 10A and 10B further illustrate the differences between TRPP2MI and 
TRPP2SI at the entrance gate. Due to its narrow entrance gate, TRPP2MI appears to function as a 
preselectivity filter, limiting the access of hydrated ions yet allowing dehydrated ions to enter the 
gate (6). In addition, TRPP2MI and TRPP2SI are significantly broader than TRPP2CL at the 
selectivity filter and the lower gates (Figure 9C) (6). Intriguingly, a number of Ca2+ and Na+ ions 
exist in the ion transit pathways of TRPP2MI and TRPP2SI (Figures 9D,E and 10A, B) (6). Of note, 
both Ca2+ and Na+ were incorporated into the protein purification procedure. 
      With a pore radius of 1.7 Å at Leu641, TRPP2SI has the widest selectivity filter compared to 
that of TRPP2MI (1.4 Å) and TRPP2CL (1.0 Å) (Figure 9C). Wilkes et al. identified alterations in 
the conformation of Asp643, and its interaction with Arg638 is changed, impacting the 
arrangement of the pore radius (6). In TRPP2MI  (Figure 10C), the carbonyl oxygens of Leu641 at 
the Ca2 site are capable of coordinating  Ca2+ or Na+, while in TRPP2SI (Figure 10D), the Cat2* 
site can contain two cations (6). Further along the translocation pathway, Phe 669, located midway 
between the Cat3 and Cat4 sites, constricts the channel (Figure 10C) (6). Lastly, Asn681 and 
Ser685 associate with a density at the Cat5 site in TRPP2MI (Figure 10C) and TRPP2SI (Figure 











Figure 9. Representation of the ion permeation pathways of TRPP2MI and TRPP2SI. (A-B) 
Solvent-accessible pathways along the pores in structures TRPP2MI (A) and TRPP2SI (B). Two 
diagonally opposed subunits are illustrated. A number of residues along the ion permeation 
pathway are depicted as sticks. (C) Radius of the pore in different regions along the translocation 
pathway in the open states, TRPP2MI and TRPP2SI  (6), and closed state TRPP2CL (5). (D, E) Sliced 
molecular surface representation of TRPP2MI (D) and TRPP2SI (E). Left, viewed down the pore 
axis of the tetramer. Right, viewed parallel to the membrane. Representations are colored by 
electrostatic potential, red indicating highly negatively charged regions. Ca2+ (green spheres) and 
additional cations (blue spheres) are depicted. Yellow arrows denote exit pathways for ions. Figure 
adapted from (6). 





Figure 10. Cation-binding sites along the ion permeation pore of TRPP2MI and TRPP2SI. (A-
B) View looking down the four-fold symmetry axis of TRPP2MI (A) and TRPP2SI (B). Each 
monomer is illustrated in a separate color. (C-D) Movement of cations Ca1 and Cat2-5 in TRPP2MI 
(C) or Cat2* and Cat5* in TRPP2SI (D). Densities along the transit pathway are represented by 






4.7  Role of glycosylation in TRPP2 
      As mentioned previously, TRPP2 contains five potential N-glycosylation sites (11) (Asn299, 
Asn305, Asn328, Asn362, and Asn375) situated in TLC2 or TLC3 within the polycystin–
mucolipin domain. It has been found that glycosylation of this domain is key for trafficking and 
stability of TRPP2 (11). However, all three of the research groups attempted to reduce the 
glycosylation levels present in the protein during expression and purification prior to solving the 
TRPP2 structures (4–6). Yet, in the TRPP2 structure solved by Grieben et al. NAG, N-
acetylglucosamine, components at three N-glycosylation sites (Asn328, Asn362, and Asn375) 
were determined (Figure 2B, Table 1) (5). Two additional N-glycosylation sites, Asn299 and 
Asn305, were unable to be resolved due to a disordered region, Ser298–Ala303 (5).  
      Furthermore, TRPP2MI contains four N-glycosylated residues (Asn299 in TLC2; Asn328, 
Asn362, and Asn375 in TLC3), while TRPP2SI exhibits three sites (Asn305, Asn362 and Asn375) 
that are N-glycosylated (Table 1) (6). However, it appears that the large glycan group at Asn305 
in TRPP2SI would inhibit the intrasubunit interactions that exist in TRPP2MI. Notably, either 
Asn305 or Asn328 can be glycosylated at any given time. If one residue is glycosylated, the other 
site would not be available for glycosylation to occur (6). Intriguingly, all of the reported TRPP2CL 
structures have N-glycosylation sites at Asn328, Asn362, and Asn375, as observed in the TRPP2MI 
structure, with the exception of Asn299 (4, 5). Perhaps Asn299 is playing a critical role in the open 
state TRPP2MI structure. Additionally, Asn328 (which is not glycosylated in TRPP2SI) interacts 






Table 1. Glycosylated residues present in the published TRPP2 structures 
 






TRPP2:53–792 Asn328, Asn362, and Asn375 closed Shen et al. (4) 
TRPP2:185–723 Asn328, Asn362, and Asn375 closed Grieben et al. (5) 
TRPP2:1-968 
full-length 
Asn299, Asn328, Asn362, and 
Asn375 
open (TRPP2MI)   Wilkes et al. (6) 
TRPP2:1-968 
full-length 




      It remains to be seen whether N-glycosylation induces conformational changes in TRPP2SI and 
TRPP2MI or if the structures themselves direct the arrangement of N-glycosylation (6). 
Furthermore, due to glycosylation, the two structures differ with regard to the interactions between 
the polycystin-mucolipin domain in one subunit and the P loop of the adjacent subunit (Figure 11) 
(6). Notably, the variability in N-glycosylation present within TRPP2SI or TRPP2MI affect the 
conformational changes in β5 and α1 (Figure 11) (6). In TRPP2MI, Gln456 associates with Gln622 
of pore helix 1 and Glu651 interacts with Trp455 in β5 (Figure 11A) (6). However, in TRPP2SI, 
Glu651 in pore helix 2 associates with the polycystin-mucolipin domain through Lys271, while 
Gln622 interacts with Ser254 within α1 (Figure 11B). Interestingly, pore helix 1 and pore helix 2 
















Figure 11. Presence of N-glycosylation within TRPP2MI and TRPP2SI. (A-B) Enlarged views 
of alterations in the structural conformations among β5 and α1 of the polycystin-mucolipin domain 
in one subunit and the P loop (pore helix 1 and 2) of the adjacent subunit. Detailed interactions are 
demonstrated within TRPP2MI (A) and TRPP2SI (B). Pore helix 1 and 2, part of the P loop between 
S5 and S6, are indicated in blue. β5 and α1 are highlighted in yellow. Notable residues are 
displayed as sticks and density maps are represented by mesh. Black lines illustrate interactions. 






4.8 Discussion of ADPKD-associated missense mutations in TRPP2 
      As described in Chapter I, mutations in TRPP2 account for 15% of all autosomal dominant 
polycystic kidney disease (ADPKD) cases (13). Although 278 variations in TRPP2 have been 
identified in patients with ADPKD, according to the ADPKD database at the Mayo Clinic 
(http://pkdb.mayo.edu/), not all of these variants have been documented to be pathogenic (5). It is 
presumed that 26 germline missense mutations, situated within the main architecture of the 
channel, appear to play a role in the development of ADPKD (4, 5).  
      The structures of TRPP2 now provide us with a framework from which to consider the roles 
that these ADPKD-associated mutations play in channel formation (5). ADPKD missense 
mutations were mapped onto these structures and their relative locations are indicated in Table 2 
and Figure 12. Notably, many ADPKD missense mutations create extensive interactions with one 
another due to their close proximity, especially within the polycystin-mucolipin domain. 
Intriguingly, the TRPP2 polycystin-mucolipin domain contains approximately 60% of the 
pathogenic missense mutations in this channel (6). The structural implications of various 
pathogenic mutations present in the polycystin-mucolipin, VSD, and PD domains will 








Table 2.  ADPKD-causing missense mutations in TRPP2                 
              
Table modified from Grieben et al. (5) 
 
ADPKD  Mutation       Domain   Structural Location 
W280R polycystin-mucolipin α2 helix 
Y292C polycystin-mucolipin α2 helix 
R306Q polycystin-mucolipin polycystin-mucolipin interface 
L314V polycystin-mucolipin β1 strand 
R322W polycystin-mucolipin β1 strand 
R325P polycystin-mucolipin β1 strand 
R325Q polycystin-mucolipin β1 strand 
C331S polycystin-mucolipin TLC1 hairpin 
Y345C polycystin-mucolipin TLC1 hairpin 
S349P polycystin-mucolipin TLC1/2 hairpin interface 
A356P polycystin-mucolipin TLC2 hairpin 
A384P polycystin-mucolipin TLC3 hairpin 
G390S polycystin-mucolipin β2 strand 
W414G polycystin-mucolipin α3 helix 
G418V polycystin-mucolipin α3- β3 loop 
R420G polycystin-mucolipin β3 strand 
R440S polycystin-mucolipin β4 strand 
T448K polycystin-mucolipin β4- β5 loop 
D511V VSD (voltage-sensing domain) S3 helix 
L517R VSD (voltage-sensing domain) S3 helix 
N580K PD (pore domain) S4-S5 loop 
A615T PD (pore domain) S5 
F629S PD (pore domain) Pore helix 1 
C632R PD (pore domain) Pore helix 1 
R638C PD (pore domain) Pore helix 1 






Figure 12. Locations of pathogenic ADPKD missense mutations in TRPP2. (A) ADPKD-
causing missense mutations, indicated in red, are mapped onto the monomeric TRPP2 structure. 
(B) Orientation of tetrameric TRPP2 viewed from above the polycystin-mucolipin domain. (C) 
Sliced pore domain/VSD view of the tetramer. (B-D) ADPKD-causing missense mutations are 
illustrated as circles of varying color denoting the structural implications of these mutants, ranging 
from pink (severe) to yellow (mild). (D) Cartoon and molecular surface representation of the 
monomeric TRPP2 structure mapped with ADPKD-causing missense mutations, depicted as 
circles. Missense mutations displayed on the surface of the protein are indicated. Figure adapted 





Proposed interactions of several ADPKD mutations in the polycystin-mucolipin domain 
 
T448K and C331S 
    Thr448 is located in the β4-β5 loop (Figures 12A, B, D) and interacts with the α1 helix of an 
adjoining polycystin-mucolipin domain through a hydrogen bond with Tyr248 on the β3-β4 loop 
(5). Hence, the T448K ADPKD mutation would presumably perturb channel assembly (4). Cys331 
resides in TLC1 (Figures 12A, B, D)  and forms a disulfide bond with Cys344, which appears to 
restrict the β-hairpin into a rigid conformation (5). Notably, in TRPP2MI, a disulfide bridge is 
formed between Cys331 and Cys344 which provides stability to TLC3 (6). Interestingly, this 
disulfide bridge is not observed in TRPP2SI (6) or the TRPP2CL structure reported by Grieben et 
al. (5), but is discerned in the TRPP2CL structure determined by Shen et al. (4). Therefore, the 
ADPKD mutation C331S would likely disrupt this critical inter-subunit interface within the 
tetrameric polycystin-mucolipin domain. 
 
Gly418 interacts with Tyr345, Arg 325, and Arg 420 
      Gly418 is situated in the α3-β3 loop (Figure 12A) and interacts with several residues that can 
harbor an ADPKD mutation, including Tyr345 (5). Tyr345 resides in the TLC1 β-hairpin at the 
junction of TLC1-3, situated near the β3 strand (Figures 12A, D) (5). However, when Gly418 is 
mutated, the sidechain of Tyr345 would most likely be altered (5). Gly418 also interacts with two 
additional residues, Arg325 and Arg420, which are pathogenic upon mutation. Arg325 is located 
in β1 (Figures 12A, B), adjacent to the TLC2 and the α3-β3 loop, which forms a π-stacking 
interaction with Phe358 (5). Of note, two separate missense mutations in Arg325, R325P and 
R325Q, can lead to ADPKD (5). Arg420 is situated in the β3 strand between the polycystin-
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mucolipin subunits (Figure 12A). Collectively, Gly418 and its respective interactions with Arg420 
and Tyr345 presumably aid in the stabilization of the junction between TLC1-3 and the adjacent 
polycystin-mucolipin subunits (5). Thus, ADPKD-causing mutations G418V, R420G, and Y345C 
would likely disrupt the assembly of the polycystin-mucolipin domain (5). 
 
Arg306 and Leu314 
      Arg306 is situated at the interface of the polycystin-mucolipin subunits and associates with 
TLC1 of the adjacent subunit as well as the S3-S4 extension (5). Of note, Arg306 is located next 
to one of the glycosylation sites, Asn305 (5). Therefore, disruption of this region by the pathogenic 
R306Q mutation may have an effect on the glycosylation state of Asn305 (5). Additionally, 
Leu314 is situated in β1 at a junction between the central beta-sheet and the extension between 
S3-S4 (5). Since both Arg306 and Leu314 are positioned at interfaces within the polycystin-
mucolipin domain (Figure 12D), mutations in these residues would likely lead to the 
destabilization of this region (5). 
 
Examples of proposed interactions of ADPKD missense mutations in the VSD 
D511V and L517R 
       D511V is a well-characterized and common disease-causing missense mutation in ADPKD 
patients (13, 14) which is shown to lead to channel-inactivation (15). Notably, the D511V 
pathogenic mutation is situated on S3 and its side chain expands into the space amid the S1–S4 
helices (Figure 12C) (5). Therefore, the side chain position of Asp511 is key to forming a 
hydrogen-bonding network incorporating Lys572 and Lys575 on S4, in addition to Tyr487, 
Glu491, and Asn508 (4, 5). In TRPP2SI, Asp511 interacts with Lys575, while it associates with 
Lys572 in TRPP2MI once conformational changes occur in S4 (6). Therefore, this interaction 
148 
 
between Asp511 in S3 and Lys572 or Lys575 in S4 may contribute to the stabilization of the open 
conformation within the lower gates (6). Hence, this D511V mutation is predicted to alter the VSD 
structure through conformational changes (5, 6).  
      Leu517 is situated midway up S3, exhibiting a sidechain that packs against S4 and projects 
into the lipid bilayer (Figure 12C) (5). Therefore, the pathogenic L517R mutation would introduce 
a destabilizing charged residue within the center of the membrane (5). 
 
 
Examples of proposed interactions of ADPKD missense mutations in the pore domain  
 
R638C and C632R 
      As noted earlier, Arg638 is located on pore helix 1 and its side chain protrudes into the upper 
region of the pore (Figure 12C) (4, 5). At the selectivity filter, Asp643 appears to form a cation-π 
interaction with Phe646 (4, 5). The ADPKD mutation R638C alters the charge and presumably 
eliminates this interaction, disrupting the association between the pore helices of two adjacent 
subunits (4). Similarly, Cys632 also resides in pore helix 1, containing a side chain that is situated 
between pore helix 1 and S5 (5). Like R638C, C632R leads to a change in charge which likely 










4.9    Conclusion  
      This chapter has provided a detailed summary of the published TRPP2 channel structures, 
which reveal several interesting features. Like other TRP channels, TRPP2 forms a tetrameric 
structure and its polycystin-mucolipin domain is very similar to that seen in the TRPML subfamily. 
Comparison of TRPP2 in its closed (TRPP2CL) and open (TRPP2MI and TRPP2SI) states illustrated 
not only notable structural differences but also variations with regard to their respective ion-
permeation pathways and glycosylation patterns. Since these structures lack resolved N- and C-
terminal domains, it remains to be seen how these termini affect the overall structure of the full-
length channel. Nonetheless, these structures have opened an entirely new avenue for structural 
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      The studies that we conducted on TRPML1 and TRPP2 provide significant insights into the 
structural characterization of these channels. The aim of this section is to summarize our findings 
as well as discuss future investigations that can be conducted on these proteins. 
      The TRPML1 I-II linker structures that we obtained were the first high-resolution crystal 
structures of a TRPML channel domain. Despite the changes in pH, the I-II linker structures at pH 
4.5, 6.0, and 7.5 did not undergo significant conformational changes, indicating that these 
structures were in highly stable states. However, protein structures alone cannot demonstrate how 
proteins behave within the cell. Thus, functional studies enabled us to assess the dynamic qualities 
of these static TRPML1 I-II linker structures. Our findings demonstrate that the dual Ca2+/pH 
regulatory mechanism of TRPML1 involves the complex interplay between the protonation of 
aspartates in the luminal pore and the blockade of Ca2+. Additionally, we characterized three 
MLIV-causing missense mutations, L106P, T232P, and C166F, which are present within the 
TRPML1 I-II linker. Our confocal imaging analyses as well as our structural and biochemical 
results comprehensively reveal that these missense mutations affect the structural integrity of the 
tetrameric I-II linker alone as well as within the greater context of the full-length TRPML1 
channel.  
      Ultimately, our goal is to determine a high-resolution structure of full-length TRPML1 using 
cryo-EM. Our cryo-EM studies thus far have identified density for the extracellular domain, but 
not for the transmembrane segments. Therefore, further studies are needed in order to optimize our 
cryo-EM sample conditions. If indeed we are able to solve a full-length structure, it will be the 
first high-resolution cryo-EM structure of a channel in the TRPML subfamily.  
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      An additional area of investigation that I focused on was to obtain a high-resolution cryo-EM 
structure of TRPP2. We have made great strides in optimizing TRPP2 protein purification and 
sample preparation procedures in order to pursue structural studies. As mentioned previously, 
many factors play a role in creating the proper conditions to generate protein particles of suitable 
quality for cryo-EM analysis. Every factor is a piece of the overall structural puzzle, and all of the 
pieces must align in order for the sample to yield a high-resolution structure. Using cryo-EM, we 
were able to obtain a very detailed view of human TRPP2 that exhibited the four-fold symmetrical 
axis, the central pore, as well as the S1-S4 helices within the tetramer. However, we had to 
overcome a significant preferred particle orientation dilemma. We presume that the preferred 
orientation of particles was due to a combination of factors including the presence of detergent, 
glycosylation of the protein, truncations, expression systems utilized, as well as grid preparation 
conditions. Although speculations can be made why our samples behaved differently compared to 
those of other groups, it is currently not possible to definitively conclude what exactly was 
impeding us from obtaining additional orientations. With the knowledge gained from the solved 
TRPP2 structures, we intend to try to resolve this dilemma in order to solve TRPP2 structures in 
different states.  
      It is important to keep in mind that the solved TRPP2 structures display only snapshots of the 
wild-type protein in a few states. Although the structural implications of ADPKD-causing 
missense mutations have been proposed based on the TRPP2 structures, additional studies are 
needed in order to determine whether these hypotheses are indeed correct. Thus, we intend to 
investigate various TRPP2 proteins harboring ADPKD-causing missense mutations using FSEC 
to ascertain if any of these proteins look promising for structural analysis. However, one limitation 
of structurally investigating these ADPKD-associated missense mutations is that the proteins may 
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misfold and aggregate due to inherent instability. Nonetheless, pathogenic missense mutations that 
do not extensively disrupt the structural integrity of TRPP2 can be further examined. 
      Moreover, we plan to characterize these ADPKD-causing missense mutations by determining 
their subcellular localization patterns using confocal fluorescence microscopy. Since TRPP2 
normally localizes to the ER, it would be interesting to determine if pathogenic missense mutations 
result in mislocalization of the channels. Together with our structural findings, these studies would 
enable us to gain a better understanding of the mechanism of disease of ADPKD.  
      It is apparent that the wild-type TRPP2 solved structures are only part of the overall story of 
TRPP2 and the role that it plays in ADPKD. Taken together, although progress has been made in 
the TRPP2 field, many uncertainties and controversies exist, from the biophysical properties of 
TRPP2 to the role this protein plays in the pathogenesis of ADPKD. Therefore, further studies are 
necessary in order to better understand the function of this channel. Significantly, the structural 
determination of the PKD1/TRPP2 complex would provide valuable information that would 
significantly improve our knowledge of ADPKD. Due to continuous advancements being made in 
the cryo-EM field, this complex will undoubtedly be determined in the future. Hence, TRPP2 and 
PKD1 structures can be potential targets for the development of new therapeutic drugs for the 
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Many types of ion channels are present in the membranes of intracel-
lular organelles, such as the endoplasmic reticulum, Golgi apparatus, 
mitochondria, endosomes and lysosomes1–6. These channels help to 
establish and maintain ionic-concentration gradients across organel-
lar membranes, and/or serve as release channels for key signaling ions, 
including Ca2+ and H+. Many organelles have high concentrations 
of Ca2+ and H+ in their lumens1,3–5,7. These ions in turn regulate 
the activities of numerous organellar ion channels8–12. Elucidating 
the molecular mechanisms underlying this universal regulation is 
instrumental in understanding the physiological and pathophysio-
logical functions of organellar ion channels.
TRPML1 is a member of the transient receptor potential mucolipin 
(TRPML) channel subfamily, which was first identified as a genetic 
determinant of mucolipidosis type IV (MLIV)13–15, one of ~50 lyso-
somal storage disorders. Young children with MLIV often show cog-
nitive, linguistic and motor deficits and are sometimes blind6,16–18. 
TRPML1 is located primarily in lysosomes, where its main role is to 
conduct Ca2+ from the lysosome lumen to the cytoplasm5,6,19–23. This 
Ca2+-release step is important in many lysosome-dependent cellular 
events, including exocytosis5,6,21,24,25, membrane trafficking5,6,25–27 
and autophagy5,6,24,25,28–30. TRPML1 activity is regulated by luminal 
and extracellular Ca2+ and H+ (refs. 6,19–23,31,32). In the presence 
of divalent ions, TRPML1 currents are greatly potentiated by H+, via 
unknown mechanisms6,19–23,31,32. The dual regulation by Ca2+ and 
H+ has clear physiological relevance: TRPML1 exists primarily in 
lysosomes, and during biogenesis and lysosomal exocytosis, it may 
also be present in other organelles, including late endosomes and the 
plasma membrane23–25,33. These distinct subcellular compartments 
have different pH levels and Ca2+ concentrations1,5,6,23. The extracel-
lular side of the plasma membrane has 1.8–2 mM Ca2+ and a near-
neutral pH of 7.2–7.4, whereas late endosomes have 0.5 mM Ca2+ 
and an acidic pH of 5.5–6.0. Lysosomes have 0.5–0.6 mM Ca2+ and 
an even more acidic pH of 4.5–5.0, a condition crucial for the activity 
of their native hydrolases23,34. Thus, depending on its subcellular 
location, TRPML1 may be regulated to different extents by Ca2+ and 
pH and may consequently exhibit different activities. The molecular 
mechanism of this dual regulation is unknown.
The crucial role of TRPML1 in cellular processes is further dem-
onstrated by the existence of >20 mutations in the TRPML1 gene that 
have been linked to MLIV6,18,35. Among these mutations, some (such 
as frameshift or nonsense mutations) completely abolish TRPML1 
expression, but many (>12) are single–amino acid missense mutations6. 
How these missense mutations alter the structure and function of 
TRPML1 is largely unclear.
We used a structural approach to investigate the molecular mecha-
nism of dual Ca2+/pH regulation of TRPML1 and MLIV pathogenesis, 
focusing on the linker between the first two transmembrane segments 
(S1 and S2) of TRPML1, which we refer to as the I–II linker. Like other 
TRP-channel subunits, TRPML1 contains six transmembrane seg-
ments (S1–S6; Supplementary Fig. 1a). The I–II linker accounts for 
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more than one-third of the channel’s length (Supplementary Fig. 1b). 
In lysosomes and endosomes, this linker faces the lumen (and is there-
fore also referred to as the ‘luminal linker’); on the plasma mem-
brane, it faces the extracellular solution (Supplementary Fig. 1a). 
Moreover, it is the site of three single–amino acid missense mutations 
that cause MLIV6,17,18,36,37 (Supplementary Fig. 1b). We solved the 
crystal structures of the luminal linker at three different pH condi-
tions (corresponding to the pH in lysosomes, endosomes and the 
extracellular milieu) and elucidated its role in the dual regulation of 




To obtain human TRPML1 currents, we followed a well-established 
method by expressing a constitutively active mutant channel desig-
nated TRPML1VP (tagged with EGFP on its N terminus) in HEK 293T 
cells20,38. TRPML1VP contains the V432P mutation, which mimics a 
spontaneous gain-of-function mutation (A419P) in mouse TRPML3 
that causes the varitint-waddler (Va) phenotype39–41. The V432P 
mutation enables TRPML1 to traffic to the plasma membrane and to 
become spontaneously active20,38. In whole-cell patch-clamp record-
ings, TRPML1VP produced a strong inward-rectifying current in a 
nominal divalent-ion-free (NDF) extracellular/luminal solution at pH 
7.4 (Fig. 1a,b). Addition of Ca2+ to the extracellular/luminal solution 
inhibited the current in a dose-dependent manner. A dose–response 
curve yielded an apparent half-maximal inhibitory concentration 
(IC50) of 0.27 mM, with a Hill coefficient of 1 (Fig. 1c), thus suggest-
ing a one-to-one blocking mechanism.
Ca2+ inhibition of TRPML1 was strongly dependent on 
extracellular/luminal pH, and became much weaker when the pH 
of the extracellular/luminal solution was lowered from 7.4 to 4.6, the 
pH of the lysosome lumen. The dose–response curve was shifted to 
the right at pH 4.6 (Fig. 1c), thereby increasing the apparent IC50 by 
14-fold, to 3.8 mM. Intriguingly, the shape of the dose–response curve 
was different, and the Hill coefficient was changed from 1 to 0.5 (Fig. 1c), 
thus suggesting negative cooperativity between extracellular/luminal 
Ca2+ and H+. Owing to attenuated Ca2+ inhibition at pH 4.6, 
TRPML1VP currents were augmented when the extracellular/luminal 
pH was lowered from 7.4 to 4.6 (Fig. 1d).
It should be mentioned that the dual regulation by luminal Ca2+ 
and pH described above was observed in a gain-of-function mutant 
rather than the wild-type (WT) channel. Because the V432P mutation 
enables the channel to open constitutively, any effects of luminal Ca2+ 
and H+ on gating might not be revealed.
Crystal structure of the luminal linker
Because the TRPML1 luminal linker faces the endolysosomal lumen 
and constitutes a large part (>1/3) of the channel, we investigated its 
role in the Ca2+/pH regulation of TRPML1. We first determined the 
X-ray crystal structure of the luminal linker (G84–S296) of human 
TRPML1 at a 2.3-Å resolution at pH 6.0 (Fig. 2 and Table 1). The 
structure shows that the linker forms a tetramer with four-fold rota-
tional symmetry (Fig. 2a). The structure is ~90 Å wide (outer diam-
eter) and ~30 Å tall. At the center of the tetramer exists a highly 
electronegative pore, termed the luminal pore (Fig. 2b). Each pro-
tomer has a structural fold consisting of two long α-helices (α1 and 
α2, with 22 and 17 residues, respectively), two short α-helices (α3 and 
α4), eight β-strands and three loops with >15 residues (between α1 
and α2, α3 and β1, and β4 and β5, respectively) (Fig. 2c). The four 
α-helices are packed tightly against a five-stranded β-sheet formed 
by β1, β4, β5, β6 and β7. One side of this β-sheet faces the luminal 
pore, and the other side faces the outside of the tetramer (Fig. 2a,c). 
Two intrasubunit disulfide bonds are present, one between C166 in 
β1 and C192 in β4, and another between C253 in β6 and C284 in the 
short loop between β7 and β8. The structure of E199–K219 (which 
constitutes part of the loop between β4 and β5) was unresolved, 
presumably because of its flexibility.
The TRPML1 I–II linker structure has a number of unique and 
notable features. (i) The luminal pore is lined by a novel 16–amino 
acid, reentrant luminal pore loop (L106–T121) that connects to heli-
ces α1 and α2 (Fig. 2a,d). The narrowest region of the luminal pore 
is 14 Å, a diameter wide enough to allow fully hydrated Na+, K+ and 
Ca2+ ions to pass through. (ii) The luminal pore contains 12 aspartate 
residues (D111, D114 and D115 in each linker) (Fig. 2a,d), thus mak-
ing this region highly electronegative at neutral pH (Fig. 2b). (iii) The 
first 22 amino acids of the luminal linker (G84–F105) form an α-helix 
(α1) that may be of strategic importance for allosteric modulation: 
it connects directly to S1 at the N terminus and to the luminal pore 
loop at the C terminus (Fig. 2a). When the TRPML1 I–II linker is 
placed on top of the transmembrane segments of the TRPV1 struc-
ture42, α1 aligns reasonably well with S1 (Supplementary Fig. 2). 
Indeed, α1 appears to form a continuous α-helix with S1, thereby 
anchoring the I–II linker to the rest of the channel. We speculate that 
in the full-length channel, sequential movements of cytoplasmic and 





























































IC50 = 3.8 mM
IC50 = 0.27 mM
pH 7.4 (n = 7)










Figure 1 Dual regulation of TRPML1 by Ca2+ and pH. (a) Families of 
TRPML1VP currents at pH 7.4 and the indicated concentrations of 
extracellular Ca2+. (b) Current–voltage (I–V) relationship of the currents 
in a at the indicated Ca2+ concentrations. NDF, nominal divalent-cation 
free. (c) Dose–response relationships of Ca2+ inhibition of TRPML1VP at 
pH 7.4 and 4.6, at a potential of −80 mV. Error bars, s.e.m. Numbers of 
recordings (n) are shown in parentheses. Solid curves are fits to the Hill 
equation. (d) Time course of TRPML1VP currents at the indicated pH, with 
1 mM Ca2+ and either Na+ or NMDG+ as the charge carrier. Source data 
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(iv) Another α-helix (α2, R122–A138), whose N terminus is con-
nected to the luminal pore loop, forms a flat perimeter on the top of 
the luminal pore (Fig. 2a).
Confirming the luminal-linker structure in full-length TRPML1
The structure described above was obtained from an isolated chan-
nel domain. Is this tetrameric structure preserved in the full-length 
channel? We used two approaches to address this question. First, the 
crystal structure shows that each luminal linker interacts with two 
neighboring linkers (Fig. 2a); therefore, we performed biochemical 
experiments to examine cross-linking among them. In this experi-
ment, we used Caenorhabditis elegans instead of human TRPML1 
because, for unknown reasons, the human TRPML1 protein remained 
tetrameric even in reducing SDS–PAGE (data not shown). On the 
basis of the intersubunit interface of the human TRPML1 I–II linker, 
























































Figure 2 Crystal structure of the TRPML1 I–II linker. (a,b) Ribbon representation (a) and electrostatic-potential surface representation (b) of the I–II 
linker structure at pH 6.0. Top panels, top-down views from the extracellular/luminal side of the membrane. Bottom panels, side views parallel to the 
membrane. (c) Stereo top-down view of a protomer. (d) Stereo side view of the luminal pore loop. The front subunit was removed for clarity.
Table 1 Data collection and refinement statistics
TRPML1 I–II linker, pH 6.0  
(PDB 5TJA)
TRPML1 I–II linker, pH 6.0, 
K2Pt(CN)4 derivative
TRPML1 I–II linker, pH 4.5  
(PDB 5TJB)
TRPML1 I–II linker, pH 7.5  
(PDB 5TJC)
Data collection
Space group I422 I422 P4212 F432
Cell dimensions
 a, b, c (Å) 125.3, 125.3, 76.7 125.3, 125.3, 76.5 94.4, 94.4, 50.7 182.8, 182.8, 182.8
 α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Wavelength 1.5418 1.5418 1.5418 1.0750
Resolution (Å) 20.0–2.3 (2.38–2.30)a 20.0–2.6 (2.69–2.60)a 20.0–2.4 (2.49–2.40)a 20.0–2.4 (2.49–2.40)a
Rsym (%) 9.9 (37.7) 13.8 (64.4) 6.8 (43.4) 5.9 (34.0)
I / σ(I ) 20.0 (4.6) 14.6 (2.8) 19.0 (2.8) 22.3 (3.7)
CC1/2 0.982 (0.944) 0.961 (0.866) 0.968 (0.872) 0.969 (0.882)
Completeness (%) 99.9 (99.6) 99.9 (99.8) 99.3 (98.3) 98.0 (98.6)
Redundancy 7.2 (6.1) 6.9 (6.4) 4.7 (3.8) 4.2 (4.1)
Refinement
Resolution (Å) 20–2.3 20–2.4 20–2.4
No. reflections 13,298 (1,337) 8,777 (927) 9,088 (1,033)
Rwork / Rfree 0.228 / 0.253 0.212 / 0.252 0.216 / 0.253
No. atoms
 Protein 1,518 1,268 1,426
 Water 111 104 66
B factors
 Protein 33.0 42.1 50.3
 Water 37.2 45.5 47.6
R.m.s. deviations
 Bond lengths (Å) 0.010 0.007 0.006
 Bond angles (°) 1.7 1.5 1.4
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C. elegans TRPML1 that were predicted to form intersubunit disulfide 
bonds; these included D104C in linker A and T293C in linker B; 
H111C in linker A and Y136C in linker B; and D158C in linker A and 
D137C in linker B (Fig. 3a). We also engineered six noncomplemen-
tary pairs of cysteines in two neighboring linkers that were predicted 
not to form intersubunit disulfide bonds: D104C and Y136C; D104C 
and D137C; H111C and T293C; H111C and D137C; D158C and 
T293C; and D158C and Y136C. The results were as predicted: under 
nonreducing conditions (i.e., without DTT), purified full-length 
TRPML1 proteins containing complementary cysteine mutations 
formed oligomeric bands in SDS–PAGE at the expense of the mono-
meric bands (Fig. 3b, top, lanes 2, 6 and 10; uncropped images shown 
in Supplementary Data Set 1). However, those proteins containing 
noncomplementary cysteine mutations remained monomeric (Fig. 3b, 
top, lanes 1, 3, 4, 5, 7 and 8). (The D158C Y136C protein in lane 9 
appeared to have been degraded or precipitated and did not yield a 
band.) Under reducing conditions (i.e., with DTT), all proteins existed 
as monomers (Fig. 3b, bottom). The existence of the oligomer bands 
only in the complementary cysteine pairs and only under nonreduc-
ing conditions was consistent with disulfide-bond formation between 
the engineered cysteines, even though the molecular weight of the 
oligomer bands was larger than that of a predicted tetramer, possibly 
because of tetramer aggregation.
Second, we carried out single-particle cryo-EM analysis of the 
purified full-length WT C. elegans TRPML1 protein (Supplementary 
Fig. 3). The cryo-EM density of the extracellular domain (ED) was 
clear and robust, but that of the transmembrane domain (TMD) was 
unclear and heterogeneous (Supplementary Fig. 3c,d). The ED and 
TMD were distinguishable and recognizable on the basis of their 
dimensions and the gross similarity of the TRPML1 and TRPV1 
TMDs. We therefore used a masking procedure that allowed us to 
segregate the ED from the TMD during subsequent cryo-EM analy-
sis (Supplementary Fig. 3c). A cryo-EM density map of the ED was 
obtained at an overall resolution of 5.28 Å with C4 symmetry imposed 
(Fig. 3c and Supplementary Fig. 3c). Even at this limited resolution, 
the ED, ~79% of which is made up of the luminal linker, is visible as a 
tetramer with a large pore in the center (Fig. 3c), thus confirming two 
of the most salient hallmarks of the crystal structure of the luminal 
linker. Given the limited resolution, we did not build an atomic model 
or identify secondary structures on this density map; however, the 
crystal structure of the luminal linker could be fitted with a correla-
tion coefficient of 0.75, thus indicating a reasonably good fit (Fig. 3d). 
The extra density not covered by the luminal-linker crystal struc-
ture in the composite may come from the E199–K219 loop (which is 
unresolved in the crystal structure), other extracellular loops and/or 
glycosylation.
Together, the above biochemical and cryo-EM studies suggest that 
the TRPML1 luminal linker has the same structure in the full-length 
channel as in the isolated domain: it forms a tetramer and contains 
a large central pore. This conclusion was further supported by 
structure-guided mutagenesis studies described directly below.
The luminal-linker tetramer is crucial in TRPML1 assembly
The crystal structure of the luminal linker shows that it forms a tight 
tetramer through extensive intersubunit interactions. These interac-
tions include hydrogen-bonding, formation of ion pairs, hydropho-
bic interactions and formation of an antiparallel, domain-swapped, 
three-stranded β-sheet between two neighboring subunits (Fig. 4a 
and Supplementary Fig. 1b). The interface between two adjacent 
linkers has a buried surface area of 1,430 Å2. To examine whether the 
tetrameric assembly of the luminal linker is important in the tetra-
meric assembly of full-length TRPML1, we mutated L144 and R146, 
two residues that engage in intersubunit interactions (Fig. 4a), to 
lysine and serine, respectively, in both the isolated luminal linker 
and full-length human TRPML1. We then examined the oligomeric 
states of WT and mutant linker domains or full-length proteins 
by native gel electrophoresis. In a nondenaturing gel, the isolated 
luminal linker containing the L144K R146S mutation (Fig. 4b, 
top, lane 2) migrated at a much lower molecular weight than did 
the WT linker (Fig. 4b, top, lane 1), thus suggesting their being a 
monomer and a tetramer, respectively, and indicating that the double 
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Figure 3 Verification of the I–II linker structure in the full-length protein. (a) Location of three pairs of amino acids in the I–II linker structure, with 
distances between the Cβ atoms indicated. Residues without or with parentheses correspond to human and C. elegans amino acids, respectively.  
(b) SDS–PAGE of full-length WT and mutant TRPML1 proteins under nonreducing (top) and reducing (bottom) conditions. The lanes are: 1, WT;  
2, D104C T293C; 3, D104C Y136C; 4, D104C D137C; 5, H111C T293C; 6, H111C Y136C; 7, H111C D137C; 8, D158C T293C; 9, D158C Y136C;  
10, D158C D137C. Uncropped images are shown in Supplementary Data Set 1. (c,d) Cryo-EM structure of the I–II linker in full-length TRPML1, 
without (c) or with (d) superposition of the I–II linker crystal structure. Top panels, top-down views from the extracellular/luminal side of the membrane. 
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In a blue native gel, full-length WT TRPML1 showed a distinct 
band, which presumably corresponded to tetramers (Fig. 4b, bottom, 
lane 1). This band was absent for mutant full-length TRPML1, 
which migrated as aggregated oligomers (Fig. 4b, bottom, lane 2), 
thus suggesting that the L144K R146S mutation disrupted the 
tetrameric assembly of full-length TRPML1.
In agreement with the above biochemical observations, a mutant 
TRPML1VP channel containing the L144K R146S mutation (termed 
TRPML1VP-LR) produced low whole-cell currents when it was 
expressed in HEK 293T cells, in an NDF solution at either pH 7.4 
or 4.6 (Fig. 4c). We then examined the subcellular localization of 
TRPML1-LR, containing the L144K R146S mutation, by using con-
focal fluorescence microscopy. The WT and mutant channels tagged 
with EGFP were expressed in live HeLa cells, which were labeled 
with the lysosomal marker LysoTracker to identify lysosomes. WT 
TRPML1 had a punctuate distribution and localized to lysosomes, as 
previously observed43–46; TRPML1-LR, however, had a diffuse distri-
bution throughout the cell and did not localize to lysosomes (Fig. 4d). 
Altogether, these results indicate that proper formation of the lumi-
nal-linker tetramer is critical for the proper assembly and proper 
subcellular organelle targeting of TRPML1.
MLIV mutations in the luminal linker disrupt TRPML1 assembly 
and localization
Three MLIV-causing single–amino acid missense mutations (L106P, 
C166F and T232P) are present in the TRPML1 luminal linker (Fig. 5a). 
These mutations produce milder MLIV symptoms than do trun-
cation or frame-shift mutations18,47,48, which generally result in a 
complete loss of the TRPML1 protein. The pathogenic mechanisms 
of these missense mutations at the channel level are unknown. The 
crystal structure of the luminal linker provides a structural context to 
investigate how these mutations affect TRPML1 structure, assembly, 
localization and activity.
In the structure, L106 is at the junction of the anchoring α-helix (α1) 
and the luminal pore loop, C166 forms a disulfide bond with C192, and 
T232 is located on β5 of a core β-sheet (Fig. 5a and Supplementary 
Figs. 1b and 4a). The luminal-linker protein containing any one of 
the three pathogenic mutations was expressed but with low yields. CD 
measurements of the purified proteins revealed marked changes in the 
secondary structures of all three mutant linkers (Fig. 5b). In a blue native 
gel, the full-length WT protein migrated as a distinct putative tetramer 
band (Fig. 5c, lane 1), whereas the full-length mutant proteins migrated 
as aggregated oligomers (Fig. 5c, lanes 2, 3 and 4). Size-exclusion 
chromatography further confirmed increased aggregation of the mutant 
proteins (Fig. 5d). These results indicated that all three mutations dis-
rupt the structure of the luminal pore and the tetrameric assembly of the 
full-length channel. These detrimental effects were expected, because 
two of the mutations (L106P and T232P) introduce a proline, and one 
of the mutations (C166F) disrupts an intrasubunit disulfide bond and 
replaces a small amino acid with a larger hydrophobic one.
In agreement with the biochemical characterizations, confocal 
imaging showed that the mutant channels expressed in HeLa cells 
were diffusely distributed in the cells and did not localize to lyso-
somes, where the WT channels were primarily found (Fig. 5e and 
Supplementary Fig. 4b). As expected, because of abnormal assembly, 
the mutant channels produced little or no current in HEK 293T cells 
when the mutations were introduced in TRPML1VP (Fig. 5f).
The luminal pore is critical for Ca2+ and pH regulation of TRPML1
The existence of a luminal pore is a distinct feature of TRPML1. The 
manual docking model (Supplementary Fig. 2) suggests that the 
luminal pore is a part of the ion-conduction pathway. To test this 
hypothesis, we simultaneously mutated three amino acids with rela-
tively small side chains (S110, G112 and A113) in the luminal pore 























































Figure 4 Intersubunit interactions of the I–II linker contribute to TRPML1 
assembly. (a) The intersubunit interface of the I–II linker. L144 and  
R146 are boxed in red, and their interacting partners are indicated.  
(b) Native gel electrophoresis of WT and mutant I–II linker proteins  
(top) or full-length proteins (bottom). Uncropped images are shown  
in Supplementary Data Set 1. (c) Left, families of currents of the 
indicated channels at pH 7.4 or pH 4.6. Right, average current amplitude 
at −80 mV of the indicated channels at pH 7.4 or pH 4.6. Numbers of 
recordings are shown in parentheses. Error bars, s.e.m. Source data  
are available in Supplementary Data Set 2. (d) Confocal images of live 
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(a sulfhydryl-specific modifying reagent with a head group 5.8 Å wide) 
on ion conduction in the mutant channel (termed TRPML1VP-3C). 
The whole-cell current of TRPML1VP did not change significantly 
after extracellular application of 5 mM MTSET, but the current of 
TRPML1VP-3C was quickly and irreversibly inhibited (Supplementary 
Fig. 5), thus supporting the hypothesis above. In agreement with the 
structural revelation of a wide luminal pore, the current reduction after 
MTSET modification was only partial (Supplementary Fig. 5b–d). 
Further supporting the notion of a wide luminal pore and the spe-
cificity of thiol modification, the currents of TRPML1VP channels 
carrying a S110C G112C or a G112C A113C double mutation were 
not inhibited by 5 mM extracellular MTSET (data not shown).
The presence of 12 aspartate residues in proximity within the luminal 
pore (Fig. 2a,d) strongly suggests that this pore region plays a role in Ca2+ 
and pH regulation. We tested this possibility by simultaneously mutat-
ing all 12 aspartate residues (D111, D114 and D115 in each subunit) 
to glutamine in TRPML1VP, thus generating a mutant channel termed 
TRPML1VP-3DQ. These mutations greatly decreased Ca2+ inhibition at 
pH 7.4, increasing the apparent IC50 by 20-fold, from 0.27 mM to 5.5 mM, 
while keeping the Hill coefficient at 1 (Fig. 6a). Decreasing the pH 
from 7.4 to 4.6 attenuated Ca2+ inhibition of TRPML1VP (Fig. 1c). 
The aspartate→glutamine mutations further decreased Ca2+ inhibition 
at pH 4.6, thereby increasing the apparent IC50 from 3.8 mM to >10 mM 
(Fig. 6b). These results indicated that the luminal-pore aspartate resi-
dues are important for Ca2+ and pH regulation of TRPML1.
The high electronegativity of the luminal pore is also expected 
to enhance Ca2+ conduction by attracting and concentrating Ca2+. 
However, the effect on Ca2+ conduction is likely to be complex and 
pH dependent. On the one hand, the luminal-pore aspartates attract 
and concentrate Ca2+ and hence increase Ca2+ conduction; on the 
other hand, they bind Ca2+, thereby blocking the luminal pore and 
decreasing Ca2+ conduction. Thus, the end result on Ca2+ conduction 
is a balance between these two opposite effects, depending on the 
protonation state of the luminal-pore aspartates.
To examine the importance of the luminal pore on Ca2+ conduction, 
we used Ca2+ imaging to measure Ca2+ influx into HEK 293T cells 
expressing TRPML1VP after switching from an extracellular solution 
without Ca2+ to one with 3 mM Ca2+. We chose this concentration to 
achieve a balance between a sufficiently strong Ca2+ signal and physi-
ological relevance. Intracellular Ca2+ increased gradually over time 
after the concentration was switched from 0 to 3 mM Ca2+ (Fig. 6c). 
The slow rise time was not due to a slow solution exchange, which 
was complete in 100–300 ms, but it might have been due to a slow 
accumulation of Ca2+ inside the cells. Nonetheless, the rise time was 
significantly faster at pH 4.6 than at pH 7.4, thus presumably reflect-
ing a faster Ca2+ conduction at pH 4.6. This outcome was probably 
mostly due to a weaker inhibition of the channel by Ca2+, even though 
the Ca2+-concentrating effect was also attenuated at this acidic pH.
We next examined the effect of the aspartate→glutamine mutations 
on Ca2+ conduction. These mutations are expected to produce two 
opposite effects: (i) less Ca2+ inhibition and hence increased Ca2+ 
conduction and (ii) less of a Ca2+-concentrating effect and hence 
decreased Ca2+ conduction. The initial rise time of the Ca2+ increase 
was similar at pH 4.6 and 7.4 for TRPML1VP-3DQ, in agreement with 
the expected effect of the aspartate→glutamine substitutions (Fig. 6d). 
At pH 7.4, the time course of Ca2+ increase of TRPML1VP-3DQ was 
similar to that of TRPML1VP (Fig. 6e), which was strongly inhibited by 
Ca2+ at that pH. However, at pH 4.6, the aspartate→glutamine muta-
tions significantly slowed the time course of Ca2+ increase (Fig. 6f). 
This result can probably be attributed to a markedly decreased Ca2+-
concentrating effect in the mutant channel. Altogether, these results 
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Figure 5 Effects of MLIV-causing mutations. (a) Locations of three MLIV-causing missense mutations in the structure of the I–II linker. (b) CD spectra 
of WT and mutant I–II linker proteins. [θ]MRE, Mean residue ellipticity. (c) Native gel electrophoresis of WT and mutant full-length proteins. Uncropped 
images are shown in Supplementary Data Set 1. (d) Fluorescence-detection size-exclusion chromatography profiles of the indicated GFP-tagged 
proteins. (e) Confocal images of live HeLa cells expressing the indicated GFP-tagged channels. Red indicates LysoTracker-labeled lysosomes.  
Scale bar, 5 µm. (f) Average current density at −80 mV of the indicated channels at pH 7.4. Numbers of recordings are indicated in above the bars. 
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conduction through TRPML1. However, the TRPML1VP-3DQ channel 
currents clearly still exhibited strong inward rectification, thus indi-
cating that this property is not controlled by the luminal-pore aspar-
tate residues (Supplementary Fig. 6).
The luminal-pore structure is not substantially altered by pH
There are two possibilities for how acidic pH attenuates Ca2+ inhibition 
of TRPML1. First, low pH changes the structure of the luminal pore, 
either globally or locally. Second, low pH simply protonates the lumi-
nal-pore aspartates without causing substantial structural changes.
To distinguish between these possibilities, we obtained crystal struc-
tures of the TRPML1 luminal linker at pH 4.5, mimicking its native 
physiological state, and at pH 7.5, mimicking the pH at the plasma 
membrane. Both structures were determined at a 2.4-Å resolution 
(Fig. 7a and Table 1). Because residues E199–K219 were unresolved 
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Figure 6 Effect of luminal-pore aspartate mutations. (a,b) Dose–response relationships of Ca2+ inhibition of the indicated channels at pH 7.4  
(a) and pH 4.6 (b) at a potential of −80 mV. Error bars, s.e.m. Numbers of recordings are shown in parentheses. Solid curves are fits to the Hill 
equation. Source data are available in Supplementary Data Set 2. (c–f) Time course of intracellular Ca2+ increase at pH 7.4 or pH 4.6, after a step 
increase in extracellular Ca2+ from 0 to 3 mM in cells expressing the indicated channels. Ratios of fluorescence intensities at 340/380 nm are shown. 
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Figure 7 Structures of the TRPML1 I–II linker at different pH levels and model of Ca2+/pH regulation. (a) Superposition of the crystal structure of  
the I–II linker obtained at pH 4.5, 6.0 and 7.5, viewed from the extracellular/luminal side of the membrane. (b) Side view of the superimposed  
luminal-pore-loop structures obtained at pH 4.5, 6.0 and 7.5. (c) Model of Ca2+/pH dual regulation of TRPML1. Two of the four subunits are schematized,  
with yellow representing the ED and green representing the TMD. The luminal-pore aspartates are red or pink, depending on luminal pH, and yellow 
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in the pH 4.5 and pH 7.5 structures. The different structures show 
some differences in the periphery; for example, at pH 4.5, the first 
nine amino acids of α1 became unstructured, and several β-strands 
(β2, β3 and β8′) could not be resolved. These differences might have 
been caused by different crystal packing in different pH conditions.
Remarkably, the structures are almost identical in most regions, 
including the luminal pore loop (Fig. 7a,b). Even the side chain 
orientation of the luminal-pore aspartates is virtually the same 
(Fig. 7b), although the crystals at different pH are in completely dif-
ferent crystal forms (Table 1). These structures indicate that the I–II 
linker exists in a highly stable state. Thus, the attenuated Ca2+ inhibi-
tion at the acidic pH (Fig. 1) is probably due to protonation of the 
luminal-pore aspartates rather than to large conformational changes 
in the luminal pore.
DISCUSSION
The long luminal/extracellular linker between the first two trans-
membrane segments is a unique but shared feature of the TRPML 
and TRPP subfamilies of TRP channels. Our crystal structure of the 
TRPML1 I–II linker is, to our knowledge, the first high-resolution 
structure of a TRPML channel. Because the I–II linkers of TRPML2 
and TRPML3 share high amino acid sequence homology with 
TRPML1 (Supplementary Fig. 1b), they probably have the same 
or similar structures. Recently, a 3.0-Å-resolution cryo-EM struc-
ture of a human TRPP2 construct containing the ED and TMD has 
been obtained49. Comparisons of the structures of the TRPML1 and 
TRPP2 I–II linkers show that despite divergent primary sequences 
(Supplementary Fig. 7a), the two linkers have a very similar over-
all structural fold (Supplementary Fig. 7b) and form tightly bound 
tetramers (Supplementary Fig. 7c,d). We suggest that, given its 
unique presence in both TRPP and TRPML channels, the I–II linker 
domain be named the ‘polycystin–mucolipin domain’ instead of the 
‘polycystin domain’, as has been proposed recently49. However, struc-
tural comparisons also reveal that the highly electronegative luminal 
pore loop is a unique hallmark of TRPML1 (Supplementary Fig. 7e). 
In TRPML1, this loop extends downward toward the ion-selectivity 
filter, whereas in TRPP2 it bends upward toward the luminal/
extracellular entryway.
Our studies show that the novel luminal pore of TRPML1 has an 
important physiological function. Because of TRPML1’s crucial role in 
numerous cellular processes, especially lysosome-dependent events, 
the subcellular localization and activity of TRPML1 must be tightly 
regulated. Although TRPML1 localizes mainly to lysosomes, it can be 
inserted into the plasma membrane under certain circumstances, such 
as during lysosomal exocytosis23–25,33. Cells appear to use multiple 
regulatory mechanisms to ensure proper levels of TRPML1 activity 
in different subcellular compartments—high activity in lysosomes 
and low activity in the plasma membrane. One mechanism is sub-
cellular-compartment-dependent regulation by phosphoinositides. 
Thus, TRPML1 is activated by phosphatidylinositol 3,5-bisphos-
phate (PI(3,5)P2) (ref. 22), which is enriched on the lysosome mem-
brane23,50. However, TRPML1 is inhibited by PI(4,5)P2 (ref. 33), which 
is abundant on the plasma membrane. The Ca2+/pH dual regulation is 
another subcellular compartmentalized regulatory mechanism. The 
acidic environment of the lysosome ensures high TRPML1 conduct-
ance in lysosomes by diminishing TRPML1 inhibition by luminal 
Ca2+. In contrast, the neutral extracellular pH ensures low TRPML1 
conductance on the cell surface by enhancing TRPML1 inhibition by 
extracellular Ca2+.
Notably, the dual regulation by luminal Ca2+ and pH described here 
was observed in a gain-of-function mutant rather than the WT channel. 
Because the V432P mutation enables the channel to open constitu-
tively, any allosteric effect of luminal Ca2+ and H+ on channel gating 
might not have been revealed. Our studies suggest, however, that the 
dual Ca2+/pH regulation is due to Ca2+ block of the luminal pore 
and modulation of this block by protonation. This dual regulation is 
largely conferred by the luminal-pore aspartate residues, which either 
form a low-affinity Ca2+-binding site or attract extracellular/luminal 
Ca2+ through electrostatic interactions, thus resulting in Ca2+ binding 
at a site in the transmembrane pore. From our structural and func-
tional studies, we propose a molecular model for the dual regulation 
of TRPML1 by extracellular/luminal Ca2+ and pH. At pH 7.4, virtu-
ally all luminal-pore aspartates carry negative charges (Fig. 7c, top 
left). These negative charges attract and bind extracellular/luminal 
Ca2+, thereby blocking Ca2+ as well as monovalent-cation conduction 
(Fig. 7c, top right). Lowering the pH to 4.6, which is close to the pKa 
of the aspartate side chain, results in protonation of the aspartates, 
thereby decreasing the net negative charges and attenuating the Ca2+ 
block (Fig. 7c, bottom right). There is residual Ca2+ block at pH 4.6, 
because some of the aspartates are unprotonated and can attract and 
bind Ca2+. The negative cooperativity observed at pH 4.6 between 
H+ and Ca2+ (Fig. 1c) is in good agreement with the protonation 
hypothesis. Mutating the aspartates to glutamines removes all the 
negative charges in the luminal pore and markedly further decreases 
Ca2+ block (Fig. 7c, bottom left).
A docking model (Supplementary Fig. 2) suggests that the 
TRPML1 I–II linker constitutes virtually all of the exposed surface 
of TRPML1 in the endolysosomal lumen and thus may contain all 
the interaction sites between TRPML1 and the lipids and proteins in 
the lumen. Notably, the structure of E199–K219 in the TRPML1 I–II 
linker was unresolved (Fig. 2 and Supplementary Fig. 1b), probably 
because of its flexibility. This 21–amino acid loop may protrude into 
the endolysosomal lumen, beyond an otherwise rigid structure, and 
is thus a candidate interaction site with endolysosomal lumen mol-
ecules. Finally, the architecture and strong electronegativity of the 
luminal pore suggest that it may be a suitable site for structure-based 
design of TRPML1-specific blockers.
METHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the online 
version of the paper.
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ONLINE METHODS
Mutagenesis and cloning. The human TRPML1 clone (GenBank BC005149) 
was purchased from OpenBiosystems. The C. elegans TRPML1 (CUP-5) was 
cloned from a cDNA library. Site-directed mutagenesis was carried out with 
overlapping PCR or a QuikChange Site-Directed Mutagenesis Kit (TransGen 
Biotech) to produce all the mutations. The DNA sequences of all constructs 
were verified by DNA sequencing. Depending on the experiment, WT and 
mutant constructs were cloned into different expression vectors, as detailed 
in the respective sections.
Expression and purification of the TRPML1 I–II linker protein. A DNA frag-
ment encoding the I–II linker (residues 84–296) of human TRPML1 was obtained 
by PCR and cloned into a modified pET26b(+) vector. A maltose-binding protein 
(MBP) tag was added to the N terminus of the I–II linker, and a DNA fragment 
encoding the recognition site of thrombin was inserted between the MBP tag and 
I–II linker. The resulting construct thus encoded a fusion protein consisting of an 
N-terminal MBP tag followed by the thrombin-recognition site, the I–II linker 
and a C-terminal hexahistidine tag.
Rosetta-gami 2 (DE3) cells were used to express the I–II linker to allow 
proper disulfide-bond formation. Transformed cells were selected and grown 
at 37 °C in 10 l of LB medium containing 50 mg/ml kanamycin and 34 mg/ml 
chloramphenicol in an incubator shaker at 250 r.p.m. When the optical density at 
600 nm reached 1.0, the culture was cooled to 22 °C, and 0.1 mM isopropyl 
β-d-1-thiogalactopyranoside (IPTG) was added. The bacterial cells were incu-
bated for another 12 h in the shaker at 22 °C before they were harvested by centrif-
ugation at 3,000g for 15 min. The cells were resuspended in a solution containing 
50 mM sodium phosphate, pH 8.0, 300 mM NaCl and 2.5% (w/w) glycerol (solu-
tion A). Then 5 mM imidazole, 0.5 mg/ml lysozyme, 25 mg/ml DNase and 2 mM 
PMSF were added, and the cells were disrupted by sonication. Insoluble cell debris 
was removed by centrifugation at 17,000g for 30 min. The supernatant was incu-
bated with Ni–NTA His-Bind resin (Novagen) with gentle agitation at 4 °C for 1 h. 
The beads were spun down at 800g for 1 min and transferred to a gravity-flow 
chromatography column. After the resin was washed with ten volumes of 
solution A containing 5 mM imidazole, the bound protein was eluted with 
500 mM imidazole in solution A. The eluted protein was incubated with amylose 
resin (NEB) at 4 °C for 2.5 h. The resin was collected by centrifugation at 800g for 
1 min, transferred to a column, and washed with solution A. The MBP-tagged 
protein was eluted with 20 mM maltose in solution A. Thrombin (Sigma-Aldrich) 
was added at 4 U per milligram protein to cleave the MBP tag. After incubation 
at 16 °C overnight, the protein was concentrated and purified on a Superdex 
200 column (GE Healthcare) to remove the MBP. The gel-filtration solution 
contained 10 mM HEPES and 150 mM NaCl, pH 7.5. The peak fractions cor-
responding to the tetrameric I–II linker protein were collected and concentrated 
to 4 mg/ml for crystallization.
Crystallization, data collection, structure determination and refinement. 
Crystallization of the TRPML1 I–II linker was carried out by using the hanging-
drop vapor-diffusion method at 16 °C (for pH 6.0) or 20 °C (for pH 4.5 and 7.5). 
For the pH 6.0 crystal, the protein solution was mixed with reservoir solution at 
a 1:1 ratio. The reservoir solution contained 1.38 M sodium phosphate mono-
basic monohydrate and 0.42 M potassium phosphate dibasic, pH 6.0, and 5% 
pentaerythritol ethoxylate (3/4 EO/OH) (Hampton Research). The best crystals 
grew from drops formed with 4 mg/ml protein. For the pH 4.5 crystal, the pro-
tein concentration was 4 mg/ml, and the reservoir solution contained 200 mM 
magnesium sulfate, 5.3% PEG 3350 and 100 mM acetate, pH 4.5. Crystals at pH 
7.5 were obtained by macroseeding in a reservoir solution of 100 mM magnesium 
sulfate, 4% PEG 3350 and 100 mM HEPES, pH 7.5, with a protein concentration 
of 4 mg/ml. Heavy atom–derivative crystals were prepared by soaking crystals 
in a solution containing 1.53 M sodium phosphate monobasic monohydrate and 
0.47 M potassium phosphate dibasic, pH 6.0 and 1 mM K2Pt(CN)4 for 24 h.
Single crystals were flash-cooled in liquid nitrogen with Paratone-N (Hampton 
Research) (for pH 4.5 and 6.0 crystals) or 30% glycerol as a cryoprotectant 
(for pH 7.5 crystals). X-ray diffraction data for native and derivative crystals 
(at pH 4.5 and 6.0) were collected at 100 K on a RAXIS-IV detector with Cu K 
radiation (λ = 1.5418 Å) from a Rigaku RuH3R X-ray generator. X-ray diffraction 
data at pH 7.5 were collected at the National Synchrotron Light Source (NSLS) 
beamline X29 at Brookhaven National Laboratory.
The diffraction images were processed and scaled with the HKL package51. 
The structure of the I–II linker at pH 6.0 was solved with the single isomor-
phous replacement with anomalous scattering (SIRAS) method with native and 
platinum-derivative data sets. Two platinum sites were found with Shake and 
Bake52, and were input into SOLVE53 for calculating the initial phases. Density 
modification was done with RESOLVE53 to improve phase accuracy. The quality 
of the density map from RESOLVE was sufficiently good to locate most residues. 
The presence of two intrasubunit disulfide bonds aided in the tracing. The initial 
model was built with COOT54. Refinement with CNS55 and manual rebuilding 
were done iteratively. Structures of the I–II linker at pH 4.5 and 7.5 were solved 
by molecular replacement with PHASER56, with the structure at pH 6 used as the 
search model. Cycles of refinement with CNS and manual model correction with 
COOT were carried out. Crystallographic statistics are summarized in Table 1.
Expression and purification of the TRPML1 I–II linker for circular dichroism. 
TRPML1 I–II linkers were expressed through viral infection in Hi5 insect cells 
(Expression Systems, not tested for mycoplasma). The linkers were cloned in 
the pFastBac1 vector, which was modified by the insertion of a honeybee melit-
tin secretion signal peptide coding region followed by BamHI/XhoI restric-
tion sites and a hexahistidine-tag coding region. DNA fragments encoding the 
WT or mutant I–II linkers were inserted into the BamHI/XhoI sites of the 
modified vector.
Recombinant baculovirus was generated with the Bac-to-Bac method 
(Invitrogen). The virus was amplified in Sf9 cells (Invitrogen, not tested for 
mycoplasma) and was used to infect Hi5 cells in ESF920 medium (Expression 
Systems). The expressed protein containing a hexahistidine tag on its C termi-
nus was secreted into the extracellular medium, where the honeybee melittin 
secretion signal peptide was cleaved. Forty-eight hours after transfection, cells 
were removed by centrifugation, and the medium containing the desired pro-
tein was collected. The medium was concentrated, dialyzed against solution A 
containing 5 mM imidazole and incubated with TALON metal-affinity resin 
(Clontech) at 4 °C for 1 h. The resin was collected and washed with solution 
A containing 10 mM imidazole. The histidine-tagged protein was eluted with 
300 mM imidazole in solution A. The protein was concentrated and changed 
to a solution containing 10 mM sodium phosphate, 150 mM NaCl, pH 7.0, 
by dialysis for CD analysis.
Circular dichroism spectroscopy. CD was performed with a J-815 CD spec-
trometer (Jasco). All proteins were adjusted to a concentration of 1 mg/ml and 
loaded into a quartz cuvette with a path length of 0.01 cm for measurement. 
A buffer containing no protein was used for subtraction of the baseline signal. 
Measurements were performed from 185 to 250 nm with a 0.1-nm interval, 1-nm 
bandwidth and scanning speed of 50 nm/min. For each protein, three samples 
were measured, and three accumulations were measured for each sample and 
averaged. The MRE was calculated from the raw CD signal, θ, with the equation 
[θ]MRE = θ/(10 × Cr × l), where Cr is the protein concentration (M × residue 
number), and l is the cuvette path length (cm).
Cross-linking. The DNA fragment encoding C. elegans full-length TRPML1 
was cloned into a modified pFastBac1 vector. An MBP tag was added before the 
N terminus of TRPML1, and a hexahistidine tag was added before the N termi-
nus of MBP. A linker region containing a TEV protease–recognition sequence 
(underlined; NNNNNNENLYFQGGGGS) was inserted between the MBP tag 
and TRPML1. Cysteine substitutions were subsequently introduced into this 
background construct.
The baculovirus of TRPML1 was generated in Sf9 cells with the standard Bac-
to-Bac method and was used to infect Hi5 insect cells. Forty-eight hours after 
infection, cells were harvested by centrifugation at 4 °C and suspended in a buffer 
containing 50 mM HEPES-NaOH, pH 7.4, 500 mM NaCl and 5% glycerol, in the 
presence of a protease-inhibitor cocktail (Pierce). After cell disruption by sonica-
tion, the cell debris was removed by centrifugation at 4,000 r.p.m for 10 min at 4 °C, 
and membranes were pelleted by ultracentrifugation at 45,000 r.p.m at 4 °C for 
1 h. The membranes were suspended in buffer A containing protease-inhibitor 
cocktail and homogenized with a glass Dounce homogenizer. TRPML1 proteins 
were extracted with 1% lauryl maltose neopentyl glycol (LMNG, Anatrace) for 1 h 
at 4 °C. The solubilized membranes were clarified by ultracentrifugation for 30 min 
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The resin was collected by low-speed centrifugation at 2,000 r.p.m., transferred 
into a gravity column, and washed with buffer A containing 0.5 mM LMNG and 
0.1 mg/ml soybean lipids (Avanti Polar Lipids). This wash buffer with 20 mM 
maltose was used to elute the MBP-tagged TRPML1 proteins. TEV protease was 
added to the eluted proteins and incubated overnight at 4 °C to cleave the MBP 
tag. The proteins were mixed with 3× SDS loading buffer with or without DTT 
and analyzed with 10% SDS–PAGE.
Native gel electrophoresis and fluorescence-detection size-exclusion chroma-
tography. The WT and L144K R146S mutant I–II linker proteins were obtained as 
described above in the CD experiment. The proteins were loaded on a 6% native 
acrylamide gel. After electrophoresis, the proteins were transferred onto a PVDF 
membrane for western blot analysis. HisTag monoclonal antibody (EMD Millipore, 
cat. no. 70796) was used as the primary antibody. Alexa Fluor 680 goat anti-mouse 
IgG (Invitrogen, cat. no. A-21058) was used as the secondary antibody. Images were 
scanned and analyzed with an Odyssey Infrared Imaging System (Li-COR).
For native gel electrophoresis and fluorescence-detection size-exclusion 
chromatography (FSEC), full-length C. elegans TRPML1 was cloned in the 
pEGFP-C1 vector (Clontech), which was modified by replacing the multiple 
cloning site with a TEV protease–recognition-site coding region and SbfI/AscI 
restriction sites. The DNA fragment encoding the full-length TRPML1 was 
inserted into the SbfI/AscI site. The expressed protein thus had an EGFP tag on 
its N terminus and a TEV protease–recognition site in between the EGFP tag 
and the channel.
HEK 293T (ATCC) cells were transfected with the TRPML1 plasmid with 
Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells were 
washed and resuspended in solution A containing Halt protease-inhibitor cocktail 
(Thermo). DDM was added to a final concentration of 2%, and lysates were incu-
bated at 4 °C for 1 h. The solution was clarified by centrifugation at 16,000 r.p.m. 
for 10 min. This cell lysate was used for blue native PAGE and FSEC57.
Blue native PAGE was performed with a NativePAGE Bis-Tris Gel System 
(Invitrogen). The solubilized cell lysate in DDM was mixed with NativePAGE 
sample buffer and Coomassie blue G-250. Electrophoresis was carried out on 
3–12% Bis-Tris gel at 4 °C. The proteins were transferred to PVDF membranes 
for western blotting. Anti-GFP monoclonal antibody (Santa Cruz, cat. no. 9996) 
and Alexa Fluor 680 goat anti-mouse IgG (Invitrogen, cat. no. A-21058) were 
used for detecting the GFP-tagged TRPML1 protein. Images were scanned and 
analyzed with an Odyssey Infrared Imaging System (Li-COR). All primary anti-
bodies have been validated for their species and applications, per information 
provided by the manufacturers.
FSEC was performed with a spectrofluorometric detector RF-10AXL 
(Shimadzu) for fluorescence detection and a Superose 6 10/300 column (GE 
Healthcare) for size-exclusion chromatography.
Electrophysiology. All electrophysiology source data are presented in 
Supplementary Data Set 2.
Constructs. Human TRPML1 tagged with GFP on the N terminus and contain-
ing the V432P point mutation (TRPML1VP) was cloned in the pEGFP-C1 vector. 
TRPML1VP-3DQ, TRPML1VP-3C and TRPML1VP-LR were also cloned in this 
vector. TRPML1VP was also cloned in pcDNA3.1, in which TRPML1VP-L106P, 
TRPML1VP-C166F and TRPML1VP-T232P were cloned.
Cell culture and transfection. HEK 293T cells were grown in DMEM (30-2002, 
ATCC) supplemented with 0.5% penicillin/streptomycin (Sigma, P-0781) and 
10% FBS (Standard quality, PAA laboratory, 95025-534) with standard proce-
dures. Transfections were performed with LipoD293 (SignaGen Laboratories), 
per the manufacturer’s instructions.
Whole-cell recording and data analysis. All experiments were performed at 
room temperature (22–23 °C). Pipettes were fabricated from borosilicate glass 
(World Precision Instruments) and were fire-polished to resistances of 2–5 MΩ. 
Whole-cell currents were elicited by 150-ms voltage steps from −120 to +100 mV 
with 20-mV increments, with a holding potential of −30 or 0 mV. Currents were 
amplified with an Axopatch 200B and digitized with a Digidata 1440A system 
(Molecular Devices). Currents were low-pass filtered at 1 kHz and sampled at 
10 kHz. pCLAMP software (Molecular Devices) was used for data acquisition 
and analysis. The pipette solution contained 120 mM cesium methanesulfonate, 
4 mM NaCl, 10 mM EGTA, 2 mM MgCl2, 20 mM HEPES and 2 mM Na2-ATP, 
pH 7.2 with CsOH. The pH 7.4 NDF (nominal divalent ion-free) bath solution 
contained 160 mM NaCl, 5 mM KCl, 10 mM glucose and 20 mM HEPES, pH 7.4 
with NaOH. The pH 4.6 NDF bath solution contained 160 mM Na-gluconate, 
5 mM KCl, 10 mM MES, 10 mM glucose and 10 mM HEPES, pH 4.6 with HCl. 
To obtain different Ca2+ concentrations, an appropriate amount of 1 M CaCl2 
stock solution was added to the NDF solutions to achieve a desired final concen-
tration. In the cysteine-modification experiment, MTSET was freshly added to 
the pH 7.4 NDF solution and kept in the dark for <30 min before use.
Data points represent mean ± s.e.m. Dose–response relationships for calcium 
inhibition of TRPML1 channels were fitted to the Hill equation in the form 
of I(X) = Imax – Xn/(Xn + IC50n), where Imax is the current in the absence of 
calcium, I(X) is the normalized current in the presence of calcium, X is the 
calcium concentration, n is the Hill coefficient, and IC50 is the calcium concentra-
tion producing half maximal inhibition. Statistical differences were determined 
with Student’s t test.
Intracellular Ca2+ imaging. TRPML1VP and TRPML1VP-3DQ cloned in 
pEGFP-C1 were transfected into HEK 293T cells. Forty-eight hours after trans-
fection, cells were loaded with Fura-2-AM (10 µM) and Pluronic F-127 (0.02%) 
(Molecular Probes) at 37 °C for 1 h in a Ca2+-free solution. The fluorescence 
ratios of F340/F380 were measured with a fluorescence microscopic system. The 
Ca2+-free solution contained 150 mM NaCl, 1 mM MgCl2 and 10 mM HEPES, 
pH 7.4 with NaOH. In the Ca2+-containing solution, 3 mM CaCl2 was added to 
the solution above.
Confocal imaging. HeLa cells (gift of R. Prywes, Columbia University) were 
maintained in DMEM (Gibco) containing 10% FBS (Atlanta Biologicals) and 100 
µg/mL of penicillin/streptomycin (Invitrogen). Cells were cultured and plated 
onto poly-d-lysine hydrobromide (Sigma)-coated coverslips 18 to 24 h before 
transfection and grown on the coverslips in DMEM plus 10% FBS supplemented 
with 100 µg/mL of penicillin/streptomycin at 37 °C until cells became ~80% 
confluent. Cells were transfected with WT or mutant full-length TRPML1, all 
tagged with EGFP on the N terminus and cloned in the pcDNA3.1 vector, with 
LipoD293 In vitro DNA Transfection Reagent Ver II (SignaGen Laboratories). 
Seventeen hours after transfection, the cells were loaded with 100 nM of the 
lysosomal marker LysoTracker Red DND-99 (Invitrogen) for 50 min at 37 °C. 
Cells were gently and briefly washed three times with PBS (Gibco), and live-
cell images were acquired in PBS at 20 °C. Images were acquired from random 
cells in an unbiased manner with a Nikon Eclipse TE2000-S microscope with a 
60× oil-immersion objective with a spinning-disc confocal system, a Hamamatsu 
C9100-13 back-thinned EM-CCD digital camera (Hamamatsu), and a spinning-
disc head (Yokogawa). z-stacks were acquired at an optical slice thickness of 0.3 μm 
with a Piezo Focus Drive (Ludl). Images were analyzed with Volocity software 
(PerkinElmer). All z-stacks were deconvolved with the iterative restoration func-
tion in Volocity, with the confidence limit set to 99% and the iteration limit set to 
40. All images displayed in the paper are derived from deconvolved z planes.
Cryo-EM sample preparation, data acquisition and image processing.  
C. elegans TRPML1 was expressed in Hi5 insect cells and purified with amylose 
resin with the same procedures as described above in the cross-linking experi-
ment. Eluted TRPML1 protein from amylose resin was mixed with amphipol 
A8-35 (Anatrace) at 1:6 (w/w), and TEV protease was added at 1:20 (w/w) to 
cleave the MBP tag. The mixture was incubated with gentle agitation at 4 °C 
overnight, and detergent was removed with Bio-Beads SM-2 (Bio-Rad) at 4 °C. 
After Bio-Beads removal, the TRPML1 protein was concentrated and further 
purified on a Superose 6 10/300 column in a buffer composed of 20 mM HEPES-
NaOH, 150 mM NaCl, pH 7.4. The peak corresponding to the tetrameric TRPML1 
protein was collected for cryo-EM analysis.
A drop of 4 µl of the amphipol-solubilized protein at 0.6 mg/ml concentra-
tion was loaded onto a glow-discharged Quantifoil R1.2/1.3 holey carbon grid, 
incubated for 3 s, blotted and then plunged into liquid ethane cooled with liq-
uid nitrogen by using a Vitrobot device (FEI Company) at 100% humidity and 
8 °C. The grids were imaged with a Titan Krios microscope operated at 300 kV 
and equipped with a K2 Summit electron-counting camera (Gatan Company). 
UCSFImage4 (ref. 58) was used for data collection with nominal magnification 
of 22,500×, corresponding to an image pixel size of 0.66 Å under super-resolu-
tion counting mode. Images were recorded with a defocus range from 2.1 to 
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plane. The total exposure time was 8 s, thus resulting in a total accumulated 
dose of ~50 e–/Å2. Each micrograph was fractionated into 32 frames, each with 
an exposure time of 0.25 s.
All micrographs were first 2 × 2 binned, thus generating a pixel size of 1.32 Å. 
Motion correction was performed with MotionCorr59. The aligned frames were 
integrated and used for further processing. Defocus for all images was deter-
mined with CTFFIND3 (ref. 60). Particle-picking and all 2D and 3D classification 
and refinement steps were performed with RELION61. Approximately 200,000 
autopicked particles were screened with several rounds of 2D classifications to 
remove most of the ‘junk’ and bad particles. The particles were 4 × 4 binned 
to a pixel size of 2.64 Å for further image analysis. A star-shaped density map 
with C4 symmetry was made and used as an initial reference for 3D classifica-
tion. 71,052 good particles were selected by 3D classification and subjected to 
first-round 3D refinement with C4 symmetry imposed, thus yielding a recon-
struction at a resolution of 8.12 Å. The transmembrane region showed much 
poorer quality than the soluble region, in agreement with the asymmetric features 
shown in 2D class averages. To improve the resolution of the soluble region, 
we applied a soft-edged mask to remove the possible transmembrane region. 
Further 3D refinement of the soluble region generated a reconstruction at a reso-
lution of 5.28 Å. The resolutions were estimated on the basis of the gold-standard 
FSC = 0.143 criterion. ResMap62 was used to calculate the local resolution map. 
The crystal structure of the human I–II linker at pH 6.0 was fit into this cryo-EM 
density map with Chimera63.
Data availability. 3D cryo-EM density maps of full-length C. elegans TRPML1 
or the I–II linker, without and with low-pass filtering and amplitude modifi-
cation, have been deposited in the Electron Microscopy Data Bank under 
accession numbers EMD-6669 and EMD-6670, respectively. The coordi-
nates of the atomic model of the human TRPML1 I–II linker at different 
pH values have been deposited in the Protein Data Bank under accession 
numbers PDB 5TJB (pH 4.5), PDB 5TJA (pH 6.0) and PDB 5TJC (pH 7.5). 
Data for electrophysiology experiments in Figures 1, 3, 4, 5 and 6 and for 
Supplementary Figs. 5 and 6 are provided as Supplementary Data Set 2. 
Other data supporting the findings of this study are available from the corre-
sponding author upon reasonable request.
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Supplementary Figure 1 
Amino acid sequence alignment of TRPML subunits. 
(a) Subcellular localization and transmembrane topology of TRPML1. (b) Amino acid sequence alignment of TRPML subunits. Green 
and yellow mark identical and similar amino acids, respectively. Putative S1-S6 segments are indicated in gray. Secondary structures of 
TRPML1 I-II linker are colored in the same scheme as in Fig. 2c. Bold black residues boxed in red are involved in intersubunit 
interactions. Red triangles mark the luminal pore-loop aspartates. Stars mark the amino acids whose point mutation causes MLIV.   




Supplementary Figure 2 
A docking model of the TRPML1 I–II linker. 
The TRPML1 I-II linker structure is visually and manually docked onto the transmembrane domain (TMD) of the TRPV1 structure (PDB 
code: 3J5P). (a,c) and (b,d) show the ribbon and surface representations, respectively, of the docked structures. Upper panels, top 
down views from the extracellular/luminal side of the membrane. Lower panels, side views parallel to the membrane. The 1 helix of 
the TRPML1 I-II linker and S1 of TRPV1 are highlighted in red and gold, respectively, in (a,c). 




Supplementary Figure 3 
Single-particle cryo-EM analysis of TRPML1. 
(a) A representative micrograph. Typical particles are marked with yellow boxes. (b) Fourier power spectrum of the micrograph shown 
in a with the Thon ring extending to 3Ǻ. (c) Outline of image processing. After multiple rounds of 2D and 3D classification to remove 
unwanted particles, 71,052 particles were selected from 201,010 autopicked particles and subjected to refinement with C4 symmetry 
imposed, yielding a reconstruction at a resolution of 8.12 Å. Due to the possible flexibility of the transmembrane domain (TMD), a soft 
mask surrounding the more rigid extracellular domain (shown in green) was applied for further refinement, resulting in a reconstruction 
at a resolution of 5.28 Å. The angular distribution of the final structure is also shown. (d) Enlarged views of representative 2D classes. 
Orange and green arrows point to TMD regions with different densities, a phenomenon suggestive of flexibility in the TMD. (e) FSC 
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curves of the final TRPML1 reconstruction with (blue) or without (black) mask. The pixel size used was 2.64 Å; thus, the blue curve 
crossing the Nyquist frequency yields a 5.28 Å resolution.  




Supplementary Figure 4 
MLIV-causing mutations cause TRPML1 mislocalization. 
(a) Location of three MLIV-causing missense mutations in the I-II linker structure, marked in red. (b) Confocal images of live HeLa cells 
expressing the indicated GFP-tagged channels. Red indicates LysoTracker-labeled lysosomes. 




Supplementary Figure 5 
Cysteine modification in the luminal pore reduces ion conduction.  
(a, b) Time course of whole-cell currents of the indicated channels in response to 5 mM extracellular MTSET. NDF: nominal divalent 
cation free. (c) Current-voltage curves taken at the time points indicated in b. (d) Normalized and averaged current amplitude of 
TRPML1
vp
-3C at -80 mV of at pH 7.4. Number of recordings is indicated inside the bar. Error bars represent SEM. * p<0.05 with 
Student’s t-test. 




Supplementary Figure 6 
The luminal-pore aspartate mutations do not affect inward rectification.  
(a) Families of TRPML1
vp
-3DQ currents at the indicated pH 7.4 and extracellular Ca
2+
 concentrations. (b) Current-voltage relationship 
of the currents in a. 




Supplementary Figure 7 
Comparison of the structures of the I–II linkers of TRPML1 and TRPP2.  
(a) Amino acid sequence alignment of the TRPML1 and TRPP2 I-II linkers. Secondary structures are indicated. Bold black residues are 
identical residues in both sequences. Bold red residues are the luminal pore-loop aspartates. (b) Superposition of the I-II linker 
protomer structures of TRPML1 (pH 6.0) and TRPP2 (PDB code: 5T4D), aligned by the β strands. (c, d) Superposition of the TRPML1 
and TRPP2 I-II linker tetramer structures, aligned by the β strands and viewed from above (c) or parallel (d) to the membrane. e, Same 
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view as in (d) but showing only two diagonally opposed subunits, highlighting the different orientations of the luminal pore-loop of 
TRPML1 and its counterpart in TRPP2. 
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